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If you know exactly 
what you are going to do, 
what is the point of doing it? 
 
Pablo Picasso 
 
 
 
 
 
 
 
 
 
 
 
To Simon 
IN MEMORIAM 
 
and all the other children who left this world too early due to incurable diseases 
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ABSTRACT 
The four serotypes of dengue virus (DENV) belong to the genus flavivirus, and have a 
positive sense, single-stranded RNA genome of ~11 kb. The DENVs cause the most 
common arthropod-borne viral disease in man with ~100 million infections per year. The 
sole measure of control is limiting the mosquito vectors Aedes aegypti and Ae. albopictus, 
and there is an urgent need for an effective vaccine and potent anti-viral drugs. 
 
DENV infection can be asymptomatic or a self-limited, acute febrile disease ranging in 
severity. The classical form, dengue fever (DF), is characterized by high fever, headache, 
stomach ache, rash, myalgia and arthralgia. Severe dengue, dengue hemorrhagic fever 
(DHF) and dengue shock syndrome (DSS) are accompanied by thrombocytopenia, 
vascular leakage and hypotension. The fatal condition DSS is characterized by systemic 
shock. 
 
Dengue research has been hampered by a lack of appropriate animal models of infection 
and disease. Furthermore, fundamental knowledge such as host cell tropism and virulence 
markers are still not established. This thesis focuses on the characterization of clinical 
DENV isolates from all four serotypes and clinical conditions (DF, DHF, and DSS) aimed 
at identifying viral features involved in pathogenesis. 
 
Attempts to develop a strand-specific qRT-PCR to identify primary target cells for DENV 
replication, failed due to the self-priming phenomenon of the DENV genome. Self-
priming was not restricted to any particular regions of the viral genome, nor to 
contaminating cellular nucleic acids, nor the lack of a poly(A)-tail at the 3‟ end. First-
strand synthesis in situ of the DENV genome is believed to arise due to spontaneous loop-
back structures functioning as transient primers for the reverse transcriptase. 
 
In vitro studies in mammalian Vero cells revealed a decreased level of replication for all 
DENV isolates from DSS patients compared to DENV isolates from DF patients. The 
replication patterns of the DHF isolates resembled either the DF- or DSS-derived DENV 
isolates depending on serotype. The DSS isolates were further distinguished from milder 
case DENV isolates by induction of apoptosis in mosquito C6/36 cells. 
 
Three DENV-1 isolates representing a DF, DHF, and a DSS case, were further 
characterized in vivo in BALB/c mice. Infection with the DF and DHF isolates peaked 
during the first week with viral RNA found primarily in lungs, liver, and to a certain 
extent in brain. In contrast, the DSS isolate was primarily neurotropic and persisted longer 
compared to the DF and DHF isolates.  
 
Genomic sequencing revealed a preference for amino acid substitutions in the viral 
envelope protein and the non-structural (NS) protein NS1 and NS5. Thus, these viral 
proteins may influence pathogenesis either by immunomodulation, and/or host cells 
tropism and replication. 
 
In conclusion, these results based on clinical DENV isolates indicate that DENVs within 
the same serotype and genotype may have both different phenotypes and genotypes. 
These intrinsic viral features could influence virus virulence and disease pathogenesis in 
humans. 
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SAMMANFATTNING 
Denguevirus (DENV) är ett flavivirus, som i sin tur omfattar fyra serotyper, och har ett c:a 11 
kb stort enkelsträngat RNA-genom av positiv polaritet. DENV är myggburna, och infekterar 
årligen 100 millioner människor. För närvarande kan spridningen av DENV endast minimeras 
genom bekämpning av vektorerna Aedes aegypti och Ae. albopictus. Behovet av antivirala 
läkemedel och ett effektivt vaccin är därför akut. 
 
Infektioner orsakade av DENV är i de flesta fall asymptomatiska, men ger i många fall hög 
feber och andra symtom av olika svårighetsgrad. Klassisk denguefeber (DF) karaktäriseras av 
hög feber, huvudvärk, utslag, samt muskel- och ledvärk. I allvarligare fall, såsom vid dengue 
hemorragisk feber (DHF) och dengue chock-syndrom (DSS), ses dessutom blödningar 
orsakade av trombocytopeni, och ökad vaskulär permeabilitet. DSS är ett livshotande 
tillstånd. 
 
Bristen på lämpliga djurmodeller har försvårat dengueforskningen och mekanismerna bakom 
sjukdomsförloppet är fortfarande inte kartlagda. Det är fortfarande oklart i vilka celler DENV 
primärt replikerar och vilka faktorer som bidrar till virus virulens. Denna avhandling bygger 
på karaktärisering av kliniska DENV-isolat omfattande samtliga fyra serotyper från patienter 
med klassisk DF, DHF, eller DSS. Syftet var att få en bättre förståelse för de virusegenskaper 
som bidrar till de olika sjukdomsförloppen. 
 
Försök att utveckla en sträng-specifik qRT-PCR för identifiering av de celltyper som är 
nödvändiga för DENV-replikation var ej möjlig pga “självpriming” av virusgenomet. 
Fenomenet visade sig inte vara begränsat till någon specifik del av genomet, och inte heller 
bero på DNA/RNA från värdcellen. Avsaknaden av poly-A-svans hos virusgenomet var inte 
heller orsaken. Troligtvis uppstår självpriming genom att RNA-genomet hybridiserar med sig 
själv genom en bakåtloop som uppkommer spontant och därmed möjliggör initiering av 
enzymet omvänt transkriptas. 
 
Studier utförda i Vero-celler påvisade en nedsatt virusreplikation för alla isolat från DSS-
patienter, jämfört med isolat från DF-patienter. Virusisolat från DHF-patienter liknade 
antingen dem från DSS-patienter eller DF-patienter beroende på serotyp. Isolaten från DSS-
patienter skiljde sig ytterligare genom att inducera programmerad celldöd i myggceller. 
 
Tre isolat av DENV serotyp 1 från patienter med DF, DHF, eller DSS, studerades i BALB/c 
möss. Viralt RNA hos mössen som hade infekterats med DF- eller DHF-isolaten påvisades 
främst under första veckan efter infektion. Viralt RNA påvisades framförallt i lungor, lever, 
och i några fall i hjärnan. I motsats till dessa fynd påvisades viralt RNA främst i hjärnan hos 
de möss som infekterats med DSS-isolatet. I dessa möss kunde viral RNA dessutom påvisas 
under upp till två veckor.  
 
Sekvensering av samtliga virus visade att majoriteten av mutationerna förekom i E-proteinet, 
samt i NS1- och NS5-proteinerna. Dessa proteiner skulle kunna inverka på sjukdomsförloppet 
genom att interagera med immunförsvaret, och/eller genom virusets replikation, samt vilka 
celler som infekteras. 
 
Tillsammans visar dessa resultat att DENV inom samma serotyp och genotyp kan skilja sig 
både fenotypiskt och genotypiskt. Dessa egenskaper hos virus kan i sin tur inverka på 
virulensen och sjukdomsförloppet hos människa. 
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1 INTRODUCTION 
 
1.1 AN ANCIENT VIRUS WITH CURRENT GLOBAL PUBLIC HEALTH 
REPERCUSSIONS 
Dengue is an acute febrile disease caused by the mosquito-borne dengue viruses (DENVs) 
that are members of the flaviviridae family, genus flavivirus (Westaway et al., 1985). The 
four DENV serotypes (DENV-1 to 4) have emerged from sylvatic strains in the forests of 
South-East Asia (Wang et al., 2000). It is not known when dengue first appeared in 
human populations, but the first described epidemic of a dengue-like illness occurred in 
Philadelphia in the United States in 1780 (Carey, 1971). However, an ancient Chinese 
medical encyclopedia dating to 992 A.D. is believed to refer to dengue fever (DF) when 
describing a disease called water poison. The name was thought to be derived from the 
belief that the disease was connected to flying insects associated with water (Nobuchi, 
1979). The name dengue itself is believed to be derived from “ki-dinga-pepo”, which 
means “strut, swagger” in Swahili (Johnson, 1939). 
 
Epidemics of dengue are thought to have occurred relatively infrequently from 1780 to 
1940, when World War II generated ideal conditions for increased transmission of 
mosquito-borne diseases (Halstead, 1966). Ecological change and destruction, combined 
with the migration of human resources created new endemic patterns of disease. In the 
last decades, both DENVs and the mosquito vectors have escalated in geographic 
distribution causing an increased frequency and magnitude of epidemic DF as well as the 
emergence of dengue hemorrhagic fever (DHF) (Gubler, 2002). 
 
1.1.1 Epidemiology 
DENV is today the most common cause of arboviral disease in the world and all four 
serotypes can be found worldwide. More than 100 countries are endemic, primarily 
affecting tropical and subtropical regions containing over 2.5 billion inhabitants (figure 1) 
(Guzman and Kouri, 2002). The WHO estimates an annual incidence of 100 million 
infections, with approximately 500.000 people with DHF requiring hospitalization, a 
large proportion being children. DHF may develop into dengue shock syndrome (DSS) 
whereof the mortality rate is approximately 2.5 %, although, without proper treatment, 
fatality rates may exceed 20 % (WHO, 1997). 
 
The number of reported dengue cases has increased dramatically since the 1980‟s due to 
several complex reasons (Thomas et al., 2003, Gubler, 2002). The primary driving forces 
include rapid, unplanned urbanization combined with substandard living conditions, lack 
of vector control and surveillance, poor public health programs, international travel, and 
virus and vector evolution (Rigau-Perez et al., 1994, WHO, 1997, Guzman and Kouri, 
2002). The contribution of climatic change is controversial, and it is not known to what 
extent this enhances the spread of mosquitoes, and indirectly the DENVs (Guzman and 
Kouri, 2002, Thomas et al., 2003, Focks et al., 1995, Tun-Lin et al., 2000). 
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Figure 1. Dark-grey shading indicates countries/areas at risk of DENV transmission, 2008. The contour lines 
indicate the potential geographical limits of the northern and southern hemispheres for year-round survival 
of Ae. aegypti, the principal mosquito vector of DENVs. Reprinted by permission from WHO, Dengue: 
guidelines for diagnosis, treatment, prevention and control - New edition (2009), © 2009. 
 
1.1.2 Disease burden 
With approximately 2.5 billion people living in endemic areas, and with roughly 120 
million travelers per year to these regions, the majority of the world‟s population is at risk 
of DENV infection. Successful treatment of patients with DHF and DSS is labor intensive 
and expensive. The dengue disease burden (DDB) in Puerto Rico for the period 1984-
1994 was estimated to be an average loss of 658 disability-adjusted life years (DALYs) 
per million people per year (Meltzer et al., 1998). That is comparable to meningitis, 
hepatitis, malaria, tuberculosis, intestinal helminthiasis, and the childhood cluster of 
diseases (polio, measles, pertussis, diphtheria, and tetanus) combined (Torres and Castro, 
2007, Hanley, 2010). 
 
In South-East Asia, the estimated loss of 420 DALYs per million people per year 
corresponds to twice the burden of hepatitis, and one-third of the burden caused by HIV-
AIDS in the region (Cho Min, 2000, Halstead et al., 2007, Suaya et al., 2007). Thailand 
had a calculated DDB at a loss of 427 DALYs per million people per year for 2001 (Clark 
et al., 2005). Furthermore, the WHO reports that every household of hospitalized dengue 
patients in Cambodia needs to borrow money in order to compensate for the loss of 
income to afford hospitalization costs. Out of these household, 88 % reports „Quite a lot 
to substantial‟ economic impact on the household economy due to dengue illness (WHO, 
1998). 
 
1.1.3 The vector 
Transmission of DENVs is dependent on the vector mosquito Aedes aegypti, and to a 
lesser extent Ae. albopictus (figure 2). The spread of DENVs mirrors the vectors‟ 
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geographical distribution underlining why mosquito density is an important parameter for 
predicting DENV epidemics (WHO, 1997).  
 
The Ae. aegypti mosquito is well adapted to an urban environment and is a highly 
competitive vector due to its anthropophilic nature. It thrives in close proximity to 
humans, and is an intermittent feeder implying a high frequency of multiple host contacts 
during a single gonotrophic cycle. Thus, the female mosquito can infect multiple persons 
in order to complete a single blood meal (Harrington et al., 2001). Protective clothing and 
mosquito-repellent sprays are essential since the Aedes mosquitoes are day-active, 
minimizing the use of bed nets. 
 
The female mosquitoes lay their eggs in artificial water containers such as tires, cans, and 
jars (Gubler, 1987, Gubler, 2004). Due to water requirements for breeding, mosquito 
densities peak during wet season, with the direct consequence of rising numbers of 
dengue cases. 
 
 
Figure 2. DENV circulates in human and sylvatic cycles. Sylvatic strains are both ecologically and 
evolutionarily distinct from endemic viruses, although endemic DENVs are hypothesized to have evolved 
from sylvatic DENV strains. Because of the high level of viraemia resulting from DENV infection of 
humans, the viruses are efficiently transmitted between mosquitoes and humans without the need for an 
enzootic amplification host. DENV is spread principally by the Ae. aegypti mosquito, which breeds in 
domestic and peridomestic water containers, increasing the frequency of contact between mosquitoes and 
humans. In addition, a sylvatic cycle for DENV transmission has been documented in Western Africa 
(Diallo et al., 2003) and South-East Asia (Wolfe et al., 2001). The contribution of the observed sylvatic 
cycle of DENV transmission to human infection is unknown, but appears to be minimal. Reprinted by 
permission from Nature Publishing Group Ltd, Nature Reviews Microbiology, Stephen, et al.,2007 July; 
5:518-528, © 2007. 
 
1.1.4 Dengue virus – mosquito interactions 
In general, Ae. aegypti is less susceptible to infection by DENV than Ae. albopictus, 
which could act as a selection mechanism for more virulent strains of DENV; the lower 
susceptibility would require a higher viral load in the human host in order to infect the 
mosquito (Gubler, 1987). High viral titers in humans have been seen to be correlated to 
severe DHF/DSS (Gubler et al., 1978, Gubler et al., 1981, Vaughn et al., 2000, Wang et 
al., 2003, Tanner et al., 2008). On the contrary, the secondary vector Ae. albopictus could 
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transmit DENV strains that do not replicate to such high titers resulting in less clinically 
overt or severe disease. This scenario proposes that Ae. albopictus could function as a 
maintenance vector involved in the silent transmission of DENV during inter-epidemic 
periods (Gubler, 1987, Gubler, 1998a). The susceptibility of the mosquito vector and 
transmission dynamics, however, are also dependent on DENV strains (Gubler and 
Rosen, 1977, Anderson and Rico-Hesse, 2006, Hanley et al., 2008), but the mechanisms 
underlying the inter-specific and inter-strain differences in vector susceptibility to DENV 
infection remains to be determined.  
 
Once ingested by the mosquito, the DENV establishes a productive infection in the 
mosquito midgut, wherefrom the virus disseminates and replicates in other tissues. In 
order to be transmitted to a human (or non-human primate (NHP)) host during the next 
blood meal, the DENV must ultimately infect the salivary glands and be shed in the 
saliva. Vector competence is genetically determined and genetic traits influencing both 
midgut infection and escape barriers have been mapped to various loci on the Ae. aegypti 
chromosomes (Bosio et al., 2000, Gomez-Machorro et al., 2004, Bennett et al., 2005a, 
Bennett et al., 2005b). 
 
Mosquito cell lines have been generated for studies of mosquito-borne viruses and can be 
used for field isolation of such viruses. Ae. albopictus cells have been used for isolation 
and identification of DENVs from patient‟s blood (Singh and Paul, 1969, Pavri and 
Ghosh, 1969). Arboviral infection of mosquito cell culture yields high concentrations of 
virus and is characterized by a persistent infection as most mosquito cells are not killed by 
the infection (Stalder, 1981). 
 
1.1.5 Prevention and control 
In the continuing search for an effective vaccine and anti-dengue drugs; two measures to 
prevent DENV transmission are to reduce the vector population and to educate people in 
affected areas about basic protection measures (figure 3). Anti-vector control programs 
include rigorous surveillance, spraying pesticides, minimizing potential breeding sites, 
and promoting decent housing and infrastructure. Personal protection includes protective 
clothing and anti-insecticide sprays. 
 
Rapid, unplanned growth of urban centers in South-East Asian and South American 
countries combined with inadequate water supply and sewerage systems have dramatic 
consequences on the transmission of DENV (McCall, 2006, McCall and Lenhart, 2008).  
 
 
Figure 3. Pedagogic material and anti-mosquito campaigns are 
common and widely used in countries where DENV is endemic. 
This  illustration is from a leaflet for childen in Thailand about 
dengue; symptoms of the disease, clinical management, and what 
to do in order to prevent dengue and spread of the disease. Anti-
dengue campaigns are often adjusted to a specific target group 
and illustrative posters are distributed at work places. Households 
receive information on how to protect their family-members at 
home. These efforts to limit the spread of the DENV-transmitting 
mosquitoes are required due to the lack of an effective vaccine. 
Courtesy: Krisana Pengsaa, et. al. (2008). Dengue: A Global 
Health Threat. Thailand Chapter of International Society of 
Tropical Pediatrics, First Edition, © 2008. 
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2 DENGUE VIRUS 
 
2.1 FLAVIVIRUS 
The four serotypes (1 to 4) of DENVs are members of the family Flaviviridae, genus 
flaviviruses. The flaviviruses consist of viruses transmitted by mosquitoes or ticks, and 
viruses without any known arthropod vector. Several of the flaviviruses are known human 
pathogens, such as Japanese encephalitis virus (JEV), West Nile virus (WNV), tick-borne 
encephalitis virus (TBEV), and yellow fever virus (YFV), which is the family prototype 
(Westaway et al., 1985) (figure 4). The flaviviruses are similar in their morphology, 
genomic organization, and antigenic determinants. The latter have implied complications 
by classical serological techniques due to cross-reactivity between antigenic epitopes 
(Casals, 1954, Henchal et al., 1982). 
 
 
 
Figure 4. Phylogenetic tree based on the complete coding region of 20 flaviviruses by the neighbour-joining 
method. Bootstrap statistical analysis was applied with 1000 bootstrap samples (only bootstrap values below 
100% are marked). The main vectors or hosts from which viruses were isolated are indicated. Abbreviations 
not found in the text: Saint Louis encephalitis virus (SLEV), Kunjin virus (KUNV), Murray Valley 
encephalitis virus (MVEV), Powassan virus (POWV), Langat virus (LGTV), strain Vasilchenko (VAS), 
strain Neudoerfl (NEU), strain Hypr (HYPR), Rio Bravo virus (RBV), Montana myotis leukoencephalitis 
virus (MMLV), Modoc virus (MODV), Apoi virus (APOIV). Reprinted by permission from Society for 
General Microbiology, JGV, Charlie et al. 2002; 83: 1875–1885, © 2002. 
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2.2 REPLICATION CYCLE 
 
2.2.1 The genome 
DENV is an enveloped, single-stranded positive-sense RNA virus. The RNA genome is 
approximately 10,700 nucleotides and encodes a 3,411 amino acids long precursor 
polyprotein containing three structural proteins (capsid (C), precursor membrane (prM), 
and envelope (E)) and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, and NS5) (figure 5). The structural proteins are components of the mature 
virus particle whereas the NS proteins are expressed only in the infected cell, and are not 
packaged to detectable levels into mature particles. The structural proteins are not 
involved in replication of the viral genome (Pang et al., 2001a, Pang et al., 2001b, Alvarez 
et al., 2006a). 
 
The open reading frame is flanked by two untranslated regions (5‟ and 3‟ UTR) of 
approximately 95-135 and 114-650 nucleotides, respectively (Rice et al., 1985, Chambers 
et al., 1990) (figure 5). The 5‟-end contains a type I cap, similar to cellular messenger 
RNA (mRNA), and the viral RNA (vRNA) is translated by a cap-dependent initiation 
scanning the 5‟-UTR (Cleaves and Dubin, 1979, Wengler and Gross, 1978). The 3‟-end 
lacks a poly(A) tail, but ends in a conserved stem-loop (SL) structure. Both the 5‟- and 3‟-
UTRs are required for efficient translation and replication (Edgil et al., 2006, Lo et al., 
2003, Romero et al., 2006, Khromykh et al., 2003, Yu and Markoff, 2005). The UTRs 
have characteristic secondary structures that confer distinct functions and show high 
sequence conservation among different DENV serotypes. The 5‟-UTR contains a large 
stem-loop (SLA) that is proposed to act as the promoter for the viral RNA-dependent 
RNA polymerase (RdRp) NS5 (Filomatori et al., 2006, Yu et al., 2008). Both the 5‟- and 
the 3‟-UTRs contain complementary UAR and cyclization sequences (CS) that hybridize 
in order to mediate genome cyclization and RNA synthesis (Alvarez et al., 2008, Alvarez 
et al., 2005, Filomatori et al., 2006, Khromykh et al., 2001). 
 
 
 
 
Figure 5. The single open reading frame encodes three structural proteins (C, (pr)M, and E glycoprotein) and 
seven NS proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and N55). Each end of the genome is flanked by 
a UTR that has characteristic secondary structures.  Reprinted by permission from Nature Publishing Group 
Ltd, Nature Reviews Microbiology, Guzman, et al., 2010 Dec; 8:S7-S16, © WHO, on behalf of TDR 
(WHO/TDR) 2010. 
 
2.2.2 Virus entry 
Viral entry into the host cell is mediated by receptor-mediated endocytosis through an as 
yet unidentified cell-surface receptor. Candidate cellular receptors required for viral entry 
are various glycoproteins (i.e., heparin sulfates), dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN), or a mannose receptor (Chen et 
al., 1997, Tassaneetrithep et al., 2003, Miller et al., 2008). The human C-type lectin-like 
molecule CLEC5A has been suggested to act as a critical macrophage receptor for 
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DENV, and has been described as a proinflammatory receptor for DENV that contributes 
to lethal disease in mice (Chen et al., 2008, Watson et al., 2011). 
 
Upon internalization, the acidic pH in the endosome triggers a conformational change in 
the E protein mediating membrane fusion. The viral nucleocapsid is released into the 
cytoplasm whereupon the virus uncoats and releases the genome (Heinz et al., 1994). 
 
2.2.3 Polyprotein processing 
DENV infection induces intracellular membrane alterations in the cytosol forming vesicle 
packets (VPs) or smooth membrane structures (SMS) where the viral replication complex 
(RC) accumulates (Mackenzie et al., 1996, Miller et al., 2006). The induction of 
membrane structures may serve as a scaffold for anchoring the viral RC. 
 
The input positive-strand vRNA is translated into a single polyprotein, which is cleaved 
into the individual structural and NS proteins. The input strand translation is followed by 
a switch from translation to synthesis of a negative-strand intermediate, which serves as a 
template for new positive-strand vRNA. Multiple rounds of translation produce high 
levels of viral proteins that together with vRNA are assembled into progeny virions 
(Clyde et al., 2006) (figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The flavivirus life cycle. (A) Virions bind to cell-surface attachment molecules and receptors, and 
are internalized through endocytosis. (B) In the low pH of the endosome, viral glycoproteins mediate fusion 
of viral and cellular membranes, allowing disassembly of the virion and release of vRNA into the cytoplasm. 
(C) vRNA is translated into a polyprotein that is processed by viral and cellular proteases. (D) Viral NS 
proteins replicate the genome RNA. (E) Virus assembly occurs at the endoplasmic reticulum (ER) 
membrane, where C protein and vRNA are enveloped by the ER membrane and glycoproteins to form 
immature virus particles. (F) Immature virus particles are transported through the secretory pathway. In the 
low pH of the trans-Golgi, network (TGN) furin-mediated cleavage of prM drives maturation of the virus. 
(G) Mature virus is released from the cell. Numbers shown in colored boxes refer to the pH of the respective 
compartments. Reprinted by permission from Copyright Clearance Centre Inc, Elsevier, Antiviral Res. 
Rushika, et al., Antiviral Res. 2008 Oct; 80(1): 11–22, © 2008. 
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2.2.4 The structural proteins C, prM, and E 
Translation and replication of DENV are dependent on intracellular membrane structures. 
The C-terminal regions of C, prM, and E contain hydrophobic amino acids that serve as 
signal sequences for insertion of the remaining protein into the ER membrane (Salonen et 
al., 2005). An ER signal peptidase together with the viral NS2B-NS3 protease cleaves the 
structural proteins and NS1 protein into individual membrane-bound proteins (Lobigs, 
1993, Yamshchikov and Compans, 1993, Pethel et al., 1992). 
 
Prior to secretion of new viral particles, the prM protein is processed into the mature M 
protein in the TGN by furin host protease (Stadler et al., 1997). It is believed that prM 
protects the E proteins from pH-induced reorganization and premature fusion during 
secretion; hence the maturation event is necessary for infectivity (Guirakhoo et al., 1991, 
Guirakhoo et al., 1992, Zhang et al., 2003) (figure 6). 
 
There is a general consensus that the viral E glycoprotein affects host cell receptor 
binding, viral entry, and is a major target for humoral immunity. The E protein is 
composed of three domains: domain I, domain II harboring the fusion peptide at its distal 
tip, and domain III responsible for receptor-binding activity (figure 7). In the mature state, 
E exists as a homodimer with the fusion peptide inaccessible. Low-pH induced 
trimerization exposes the hydrophobic fusion peptide in a manner consistent with class II 
fusion protein mediated membrane fusion (Modis et al., 2004). Mutations of residues  
constituting the ligand pocket at the interface of domain I and II alter the required pH 
threshold and affect virulence (Rey et al., 1995). There are two potential asparagine (N)-
linked glycosylation sites at positions Asn-67 and Asn-153, whereof the former is unique 
for DENVs and the latter is conserved in most flaviviruses (Heinz and Allison, 2003). The 
glycosylation pattern differs according to DENV serotype and even among different 
strains, as well as the cells in which the virus is propagated. The degree and position of N-
linked glycans affect the antigenic properties of DENV (Johnson et al., 1994, Lee et al., 
1997, Navarro-Sanchez et al., 2003). 
 
 
 
 
 
Figure 7. (A). The three domains of dengue E protein. Domain I is red, domain II is yellow, domain III is 
blue. (B). This is the conformation of an E dimer in the mature virus particle and in solution above the 
fusion pH. (C). Packing of E on the surface of the virus. Reprinted by permission from Nature Publishing 
Group Ltd, Nature, Modis et al. 2004 Jan; 427:313-319, © 2004. 
 
2.2.5 NS1 
The NS1 is a glycoprotein with two glycosylation sites that are conserved among 
flaviviruses. It is synthesized in the ER as a hydrophilic monomer, but exists as well as a 
more hydrophobic homodimer. The NS1 dimer is transported to the Golgi apparatus 
where it undergoes carbohydrate trimming (Winkler et al., 1989, Winkler et al., 1988). 
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The role of NS1 in virus replication is unknown, but is believed to facilitate viral infection 
and DENV pathogenesis (Libraty et al., 2002b). NS1 is in addition secreted from infected 
cells (sNS1), and has been shown to be immunologically important (Schlesinger et al., 
1987, Avirutnan et al., 2006). Antibodies raised against sNS1 proteins have been 
proposed to cause endothelial dysfunction due to cross-reactivity to host proteins and 
endothelial cells (Lin et al., 2006). Data indicates that sNS1 could be an important 
modulator of the complement pathway and is proposed to protect DENV from 
complement-dependent neutralization in solution (Avirutnan et al., 2010). 
 
2.2.6 NS2B-NS3 
The NS3 protein acts, together with its cofactor NS2B, as the viral serine protease needed 
for polyprotein-processing through its N-terminal end (Bazan and Fletterick, 1989, 
Gorbalenya et al., 1989a, Chambers et al., 1990). This heterodimer protein complex 
cleaves on the cytoplasmic side of the ER membrane at the junctions between NS2A-
NS2B, NS2B-NS3, NS3-NS4A, and NS4B-NS5, as well as on the internal sites within C, 
NS2A, NS3, and NS4A. 
 
The C-terminal end of the NS3 protein has three enzymatic properties: a 5‟ RNA-
triphosphatase (RTP), a nucleoside triphosphatase (NTPase), and a helicase (Gorbalenya 
et al., 1989a, Gorbalenya et al., 1989b, Li et al., 1999, Wengler, 1993, Bartelma and 
Padmanabhan, 2002). NS3 forms a complex with NS5 and assists in viral replication 
through unwinding of RNA and dephosphorylation prior to 5‟-end capping (Kapoor et al., 
1995, Cui et al., 1998, Johansson et al., 2001). 
 
2.2.7 NS2A, NS4A and NS4B 
The remaining NS proteins are cleaved by the viral serine protease NS3 that requires 
NS2B as a cofactor for catalytic activity (Chambers et al., 1991). A host cell signal 
peptidase, however, mediates post-translational modifications on the NS4A-4B proteins 
(Preugschat and Strauss, 1991). The small hydrophobic proteins NS2A, NS4A, and NS4B 
are less well characterized. Recent findings propose an inhibitory role in interferon (IFN)-
mediated signal transduction (Munoz-Jordan et al., 2005, Munoz-Jordan et al., 2003). 
Their hydrophobic nature potentially implicates them in proper localization of viral 
proteins and vRNA during replication and virion assembly (Lindenbach and Rice, 2003). 
Formation of DENV-induced cytoplasmic membrane structures are believed to be an 
arrangement of the NS4A protein (Miller et al., 2007).  
 
2.2.8 NS5 
The largest NS protein encoded in the DENV genome is the NS5 protein, approximately 
103 kDa big. The NS5 protein has three major functional domains: the N-terminal S-
adenosyl methionine methyltransferase (MTase), the nuclear localization sequences 
(NLS), and the RdRp activity in its C-terminal domain. 
 
The MTase spans amino acid residues 1 to 239 and is responsible for guanine N-7 and 
ribose 2´-O-methylations required for the capping of the DENV genome. The cap 
structure is recognized by the host cell translational machinery (Bartholomeusz and 
Wright, 1993, Egloff et al., 2002, Ray et al., 2006, Koonin, 1993). The NLS (residues 
320-405) interacts with the NS3 viral helicase and is recognized by cellular factors, 
allowing protein transport to the nucleus (Bartholomeusz and Wright, 1993, Brooks et al., 
2002). The NS5 polymerase domain RdRp (residue 273-900) is responsible for 
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synthesizing new vRNA genomes (Koonin, 1993, Tan et al., 1996, Ackermann and 
Padmanabhan, 2001). 
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3 DENGUE – THE DISEASE 
 
DENV pathogenesis remains a challenging jigsaw puzzle with most pieces missing to 
understand the complex interplay of viral and host factors. Despite intensive research, it is 
not well understood. The severity of DENV infection is modulated by multiple risk 
factors such as age (Gubler, 1998a, Guzman et al., 2002a), the genetic background of the 
host (Guzman et al., 2002b, Halstead et al., 2001), viral serotype (Balmaseda et al., 2006, 
Gubler, 1998a) and genotype (Messer et al., 2003, Rico-Hesse et al., 1997), and 
secondary DENV infection by a heterologous serotype (Guzman et al., 2002b, Burke et 
al., 1988, Halstead et al., 1970, Sangkawibha et al., 1984, Thein et al., 1997). 
 
3.1 CLINICAL FEATURES 
The four DENV serotypes can cause a wide range of diseases in humans even though 
DENV infections may also be asymptomatic. The diseases range in severity from 
undifferentiated acute febrile illness, classical DF, to the life-threatening conditions 
DHF/DSS (Gubler, 2002) (figure 8). The WHO has defined criteria for classification of 
dengue disease, and recognizes four grades according to severity (table 1) (WHO, 1997).  
 
Grade of 
disease 
Signs and symptoms 
I Non-complicated undifferentiated febrile illness, or asymptomatic. 
II High fever, rash, headache, arthralgia, myalgia, stomach ache, petichae (DF). 
III Thrombocytopenia, various degrees of vascular leakage, rapid and weak pulse 
and hypotension (DHF). 
IV Profound shock with undetectable blood pressure and pulse due to severe 
vascular leakage (severe DHF grade IV, DSS). 
Table 1. The WHO criteria for classification of dengue patients (WHO, 1997). 
 
The WHO classification of dengue originated primarily from descriptions of pediatric 
cases in Thailand during the 1970s (WHO, 1973), and variations from these original 
description have been reported. Epidemiological changes of dengue have led to problems 
with the use of the existing WHO classification (Guha-Sapir and Schimmer, 2005, Deen 
et al., 2006, Rigau-Perez, 2006). In addition, atypical clinical features of dengue are 
increasingly being reported, but are probably underappreciated (Gulati and Maheshwari, 
2007). These alternative symptoms include encephalitis, myocarditits, hepatitis, 
pancreatis, retinitis, and acute respiratory distress syndrome (Sen et al., 1999, Stephenson, 
2005, Thisyakorn and Thisyakorn, 1994, Kabra et al., 1999).  These atypical presentations 
may be due to pathology at different endothelial surfaces (Gulati and Maheshwari, 2007). 
The clinical features of DF vary according to patient age (Gubler, 1998a), and some 
investigations have suggested that only 60 to 70 % of the DHF cases meet the WHO 
criteria (Maguire et al., 1974, Gubler, 1989). In response to criticism against the rigid 
WHO criteria, excluding certain DHF/DSS cases with alternative symptoms unless it is 
accompanied by thrombocytopenia and hypovolemia, the WHO guidelines were revised 
(Balasubramanian et al., 2006, Bandyopadhyay et al., 2006, Kroeger and Nathan, 2006, 
Rigau-Perez, 2006). A simplified categorization for dengue case classification has been 
proposed by WHO‟s Special Program for Research and Training in Tropical Diseases 
(TDR) where DHF and DSS cases are grouped together as “severe dengue” (group C) to 
avoid false-negative DHF/DSS diagnosis (WHO, 2009). 
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Figure 8. A DENV infection can be cleared by the immune system without any clinical symptoms, or 
develop into a flu-like disease, classical DF, or the more severe forms of DHF and DSS that may be lethal.  
 
3.1.1 Dengue fever 
After an incubation period of 3-15 days (usually 5 to 8), classical DF begins with an 
abrupt onset of high fever. During the febrile phase, dehydration may cause neurological 
disturbances and febrile seizures in young children (WHO, 2009). The condition is self-
limiting through debilitating illness with headache, retro-orbital pain, myalgia, arthralgia, 
petechiae rash and leucopenia. A macular-papular recovery rash appears 3-5 days after the 
onset of fever, and usually starts on the trunk before spreading peripherally (Henchal and 
Putnak, 1990). DF is sometimes referred to as “break bone fever” due to its incapacitating 
symptoms with severe muscle and joint pain (Rush, 1789); or “seven-day fever” since the 
symptoms usually persist for 7 days. 
 
3.1.2 Dengue hemorrhagic fever and dengue shock syndrome 
Early symptoms of DF and DHF are indistinguishable, but DHF is associated with 
hemorrhagic manifestations, plasma leakage resulting from an increased vascular 
permeability, and thrombocytopenia (<100, 000 platelets/mm3) (figure 9 and 10). 
Thrombo-cytopenia is not necessarily restricted to severe dengue, and minor bleeding 
may occur in mild infections, which can be severe in those with peptic ulcer disease (Tsai 
et al., 1991). Plasma leakage is characterized by haemo-concentration (haematocrit 
increase of 20 %), development of ascites, or pleural effusion. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. I am holding the hand of a little girl with DHF 
diagnosis, at the Children‟s Hospital in the Kampong 
Sham province of Cambodia, where I collected clinical 
DENV samples. DENV infections are a major public 
health concern in Cambodia, and one of the most 
common causes for hospitalization for children. The 
plastic bags contain ice cubes that are often placed on the 
stomach to ease the abdominal pain. 
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DSS is distinguished from DHF by the presence of cardiovascular compromise, which 
occurs when plasma leakage into the interstitial spaces results in shock. It is a fatal 
condition with mortality rates for DSS as high as 20 %, but can also be less than 1 % in 
places with sufficient resources and clinical experience. Common clinical warning signs 
for DSS include a rapidly rising haematocrit, intense abdominal pain, persistent vomiting, 
and narrowed or absent blood pressure (Gubler, 2002). 
 
Figure 10. The incubation 
period before the development 
of signs of infection generally 
ranges from 5 to 8 days. Hypo-
volemic shock can develop 
during the late stage of disease 
and usually lasts 1 to 2 days. 
Modified and re-printed by 
permission from Nature Pub-
lishing Group Ltd, Nature 
Reviews Microbiology, Step-
hen, et al., 2007 July; 5:518-
528, © 2007. 
 
3.1.3 Laboratory diagnosis 
Since laboratory-based dengue diagnosis is often unavailable at the time of care, the 
preliminary diagnosis relies on a combination of travel history and clinical symptoms. 
Travel history provides key information that can rule out other potentially life-threatening 
diseases since the incubation period of DENV is less than two weeks (Rigau-Perez et al., 
1998). A confirmed diagnosis for a DENV infection, however, is established by culture of 
the virus, polymerase-chain reaction (PCR), or serologic assays. There are limitations 
with each test and detection is based on different virological markers; infectious virus, 
vRNA, and DENV specific antibodies, respectively. 
 
Culturing the virus requires an acute patient serum with sufficient levels of virus, and the 
period when DENV can be successfully isolated in patient serum is short. Viremia peaks 
prior to the onset of symptoms, hence virus levels might have dropped significantly once 
the patient seeks medical care. Furthermore, rising levels of antibody interfere with virus 
culture already within a day or two after the subsidence of fever (figure 11). Apart from 
sample collection limitations, practical considerations limit the use of this method. 
Culture of the virus is both time- and labor intensive; infectious patient material must be 
kept cold, and a bio-safety level 3 laboratory is required, demanding professional training 
of the personnel. These requirements limit this diagnostic tools use, especially in rural 
areas (WHO, 1997). 
 
The Ae. albopictus cell line C6/36 (CRL 1660, ATCC) is commonly used to isolate 
DENVs from patient material. Specimens that may be suitable for virus isolation include 
acute phase serum, plasma or washed buffy coat from the patient, autopsy tissues from 
fatal cases, especially liver, spleen, lymph nodes and thymus, and mosquitoes collected in 
nature (WHO, 1999). C6/36 cells are most often used to amplify DENVs for research, 
even though other laboratory cell lines from various vertebrate species are also employed 
depending on experimental design. Persistent infection in cell culture and multiple rounds 
of propagation in cells result in laboratory-acquired mutations, leading to cell culture 
adaptation and altered wild-type features, e.g. the plaque size is altered (Igarashi, 1988). 
The commercial DENV strains available (e.g. DENV-2 16681 and P23085) are often 
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passaged in suckling mice, or may be tissue culture adapted, and can in certain cases be a 
pool of several patient isolates (www.atcc.org). 
 
Detection of vRNA from serum, plasma, or cells with PCR is based on DENV-specific 
oligonucleotide primers, and is fast and robust, although sensitive only in the very early 
stages of disease (Rigau-Perez et al., 1998). PCR is particularly useful in situations when 
virus culture has not been successful, but nevertheless depends on sample collection 
during the symptomatic phase (figure 10). 
 
The third laboratory diagnostic option is not based on direct detection, but on the presence 
of anti-DENV antibodies. Thus, it is not hindered by the limitations of virus culture and 
PCR, and the timing of sample collection can be more flexible. The acute anti-DENV 
IgM antibody response lasts for a couple of weeks after infection and the IgG antibodies 
for several years (figure 11). The immunoglobulins (Ig) are not easily inactivated and do 
not have the same strict requirements for low temperature as infectious virus specimen. 
The assay techniques are relatively simple and there are commercial diagnostic kits 
available (WHO, 1997). The major drawback with serological tests is the considerable 
risk for false-positive results due to potential cross-reactivity with other flaviviruses, e.g. 
vaccination against YFV (Schwartz et al., 2000). 
 
+  
 
Figure 11. The diagnostic tool that is best suited depends on when the patient seeks medical assistance post-
infection since infectious virus and anti-DENV antibodies appear at different time periods. Reprinted by 
permission from Nature Publishing Group Ltd, Nature Reviews Microbiology, Guzman, et al., 2010 Dec; 
8:S7-S16, © WHO, on behalf of TDR (WHO/TDR) 2010. 
 
Due to the drawbacks of serological methods to reliably diagnose acute infections, 
alternative methods based on the detection of the viral NS1 protein have been developed. 
NS1 can be found both membrane-associated inside the host cell and in a soluble, secreted 
form.  
 
The amount of secreted NS1 in patient serum correlates with viremia and DENV 
pathogenesis (Wang et al., 2006, Hang et al., 2009, Libraty et al., 2002b, Vaughn et al., 
2000, Young et al., 2000) and the NS1 protein is detectable in serum by enzyme-linked 
immunosorbent assay (ELISA) from the first day of fever up to nine days  post-infection 
(Libraty et al., 2002b, Alcon et al., 2002, Lapphra et al., 2008, Schilling et al., 2004). 
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NS1-based ELISAs have become an important diagnostic tool for acute samples in which 
IgM is not detectable and where PCR is not available. Several commercial NS1 antigen 
kits are available and are widely used in endemic as well as non-endemic countries. The 
sensitivity varies from 63 % to 94 % (Hang et al., 2009, Lapphra et al., 2008, Dussart et 
al., 2008, Phuong et al., 2009), and depends on sample time-point, DENV serotype, and if 
it is a primary or secondary DENV infection (Duong et al., 2011). 
 
3.1.4 Vaccines 
Unlike flaviviruses such as YFV, JEV and TBEV, no licensed vaccine exists for dengue. 
Vaccination must protect against all four serotypes without predisposing for antibody-
mediated enhanced disease (see 6.2 “Antibody-dependent enhancement”) and has proven 
difficult to design. Nearly eighty years of vaccine-related research and development have 
passed, and over 25 unique DENV vaccine candidates have been tested in clinical trials 
during the past decade. 
 
To be safe, a dengue vaccine must be functionally tetravalent, eliciting simultaneous 
protection against all four DENV serotypes (figure 12). Hence, vaccination cannot 
proceed in an analogous sequential manner, and herein lies the greatest obstacle (Gibbons 
et al., 2007, Raviprakash et al., 2006, Konishi et al., 2006). Live attenuated vaccines can 
induce durable humoral and cellular immune responses that mimic natural infection 
(Wisseman, 1963). The viral replication must, however, be discrete to preclude the 
development of significant illness. A reasonable range of viremia for a live attenuated 
vaccine is believed to be approximately 101-102 infectious units/mL (Guirakhoo et al., 
2006) compared to high levels of viremia upon natural infection that can be 105-107 
infectious units/mL (Vaughn et al., 2000). 
 
 
 
 
 
 
 
Figure 12. A schematic of the DENV genome is shown on the left. The Sanofi Pasteur vaccine contains four 
chimeric live flaviviruses, each derived from the YFV genome with the prM and E gene segments replaced 
by the corresponding gene segments of each of the four DENV serotypes. The US National Institutes of 
Health (NIH) vaccine contains a mixture of four recombinant DENV genomes; the DENV-2 component is a 
chimeric DENV derived from a DENV-4 genome with prM and E gene segments replaced by those of 
DENV-2. This vaccine also contains attenuating mutations in the 3′ NTR that are not shown in the figure. 
The CDC-Inviragen vaccine contains a mixture of four recombinant DENV-2 genomes; the DENV-1, 
DENV-3 and DENV-4 components are chimeric DENV genomes. The Merck/Hawaii Biotech vaccine is a 
recombinant protein vaccine containing the E glycoprotein ectodomains of all four DENV serotypes. Other 
vaccines in development use plasmids or heterologous viral vectors to express only the prM and E gene 
segments of all four DENV serotypes. Reprinted by permission from Nature Publishing Group Ltd, Nature 
Reviews Immunology, Alan, et al., 2011 Aug; 11: 532-543, © 2011. 
 
It is expected that a live attenuated vaccine would be successful and require only a single 
dose since the vaccine against YFV is based on a live attenuated virus. However, it is 
more likely that booster immunizations will be required based on results from clinical 
trials using tetravalent formulations of live vaccine candidates aimed at eliciting 
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neutralizing antibodies (Kanesa-Thasan et al., 2003, Sabchareon et al., 2002, Edelman et 
al., 1994, Sun et al., 2003). The obvious challenge is when and how to boost; infectivity 
and immunogenicity in NHP models have not always clearly predicted the outcome of 
human trials (Men et al., 1996, Guirakhoo et al., 2001). Vaccination compliance may also 
be lower with a multi-dose vaccination strategy, especially in regions where resources are 
scarce, and at the same time where the need for a vaccine often is the most acute. 
 
There are currently two live attenuated tetravalent vaccine candidates in phase II clinical 
evaluation, several live attenuated vaccine candidates in phase I clinical evaluation, and 
many subunit, -deoxyribonucleic acid (DNA), and vectored vaccines in pre-clinical stages 
of development. It is hoped that clinical trials evaluating novel recombinant subunit 
proteins, DNA, and vectored vaccines be initiated in the coming years. These approaches 
could be part of a prime-boost strategy, or stand-alone. The use of different types of 
vaccines depends on the purpose of vaccination and target group reflecting the disease 
setting. In endemic areas, there is an urgent need for routine immunization against dengue 
for infants and young children 1-3 years of age. A dengue vaccine would be coordinated 
with current childhood immunization schedules. Due to the socioeconomic status of many 
endemic countries, this type of vaccine ought to be inexpensive. In contrast, a protective 
vaccine for international travel, seasonal work personnel, and military staff that visit or 
work in DENV endemic areas are more tolerant to increased cost. Vaccination in this case 
will need to be rapid. 
 
Hence, the different requirements for a dengue vaccine vary according to target group and 
their specific needs (life-long immunity or temporal protection), and efficient antiviral 
drugs would be a useful complement for protection and/or treatment. In addition, antiviral 
drugs would be more potent in an outbreak situation than a vaccine when there is no time 
to complete a multi-dose immunization schedule spanning six months or more. 
 
3.1.5 Treatment and therapeutic approaches 
Currently, vector control, regarded as both expensive and ineffective, is the only method 
for disease prevention (see 1.1.5 Prevention and Control) (Gubler, 1998b, Halstead and 
Deen, 2002). In the absence of available vaccines and antiviral drugs against DENV 
infection, specific treatment for dengue patients consist primarily of supportive care 
including bed rest, antipyretics, and analgesics. Urgent resuscitation with intravenous 
fluids to replace lost intravascular volume in DSS patients is a pre-requisite; Ringer‟s 
lactate has been shown to be effective in moderately severe dengue, and starch or dextran 
have been suggested for more severe cases (Wills et al., 2005). Aspirin and other 
salicylates should be avoided due to plasma leakage (WHO, 2009). 
 
The design of novel therapeutic approaches for dengue disease has focused on the various 
stages of the viral replication cycle. The conformational changes of the E protein and its 
interaction with prM or M have been a major interest. These transition states present 
opportunities for antiviral targeting of the entry, assembly or maturation steps of the virus 
life cycle. Antiviral peptides have been designed and tested for blocking of both DENV 
and WNV entry with positive results, indicating that antiviral peptides could be a 
promising form of DENV therapy (Hrobowski et al., 2005, Bai et al., 2007). Targeting of 
mature virus entry into host cells is an extremely promising candidates since delivery of 
target compounds into the host cell during stages of fusion and maturation is significantly 
more challenging. 
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Another approach to inhibit the structural changes of the E-prM protein interactions has 
been to synthesize peptides mimicking the pr peptide of the M protein thereby preventing 
membrane fusion and release of newly synthesized virions. The viral protease is another 
interesting target for antiviral discovery, since proteases are common to most viruses and 
generally important for efficient replication. Protease inhibitors for hepatitis C virus 
(HCV) may eventually be further developed to inhibit the DENV protease NS2B-NS3 
(Tomlinson et al., 2009). 
 
Nucleoside analogues are usually prodrugs that need to be converted to their antiviral 
nucleotide metabolite forms (Parker, 2005). Ribavirin (1-β-d-ribofuranosyl-1H-1, 2, 4-
triazole-3-carboxamide) possesses broad spectrum antiviral activity (Streeter et al., 1973, 
Sidwell et al., 1972) and is used in combination with IFN to HCV infection (Benarroch et 
al., 2004). Ribavirin depletes the nucleotide pool and thereby indirectly affects capping 
and polymerase activities of both cellular and viral proteins (Benarroch et al., 2004). In 
addition, ribavirin causes a more error-prone replication of several viral genomes 
(Contreras et al., 2002, Crotty et al., 2000, Eigen, 2002, Lanford et al., 2001, Zhou et al., 
2003). Despite successful in vivo results with several RNA viruses, ribavirin has a 
cytostatic effect in DENV infected cells, and has not been effective in animal models 
(Koff et al., 1983, Crance et al., 2003, Malinoski et al., 1990). 
 
Nucleic acid-based therapies offer various alternatives. RNA interference (RNAi) is 
thought to protect the host from viral infections by degrading the extraneous genetic 
material like vRNA (Ma et al., 2007). It has been used in therapeutic approaches for 
several infectious diseases, tumors, and metabolic disorders. Small interfering RNA 
(siRNA) treatment reduces viral load of WNV in mice (Bai et al., 2005), but there are 
several obstacles yet to overcome; the RNA of flaviviruses are resistant to RNAi since 
replication occurs in reorganized ER membrane packets (Geiss et al., 2005). In addition, 
HCV replication was found to be stimulated by the RNAi machinery (Jopling et al., 
2005). 
 
Another nucleic acid-based antiviral approach is antisense DNA or RNA decoys, e.g. 
phosphorodiamidate morpholino oligomers (PMOs). These compounds act by forming a 
stable, sequence-specific duplex with RNA, and thereby blocking access to target RNA 
by biomolecules required for replication. PMOs targeting the translation initiation site of 
DENV RNA, the 3‟ NTR, 5‟SL and 3‟CS were effective in reducing the viral load in 
various cell lines (Kinney et al., 2005, Holden et al., 2006). These compounds meet most 
of the requirements for an anti-DENV therapeutic; non-toxic, cheap, easy to administer, 
stable for months at variable temperatures, but remain to be tested in animal models 
(Kipshidze et al., 2001, Iversen et al., 2003). 
 
Sulphated polysaccharides have been investigated for anti-DENV activity, although 
inconsistency in the activity results indicates that they need to be further tested both in 
vitro and in vivo (Chen et al., 1997, Marks et al., 2001, Talarico et al., 2005, Lee et al., 
2006a).  
 
The processing of N-linked oligosaccharides in the ER is important for viral glycoprotein 
maturation, and inhibition of glucosidase-mediated trimming affects the replication cycle 
of several enveloped viruses (Mehta et al., 1998). DENV production was inhibited in 
mouse neuronal cells by two ER α-glucosidase inhibitors, castanospermine (CST) and 
deoxynojirimycin (Courageot et al., 2000). CST was effective against all four serotypes in 
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human hepatoma cells, and prevented mortality in DENV-2 infected mice. This effect was 
restricted to DENV, not being observed against other flaviviruses like WNV and YFV 
(Whitby et al., 2005). A third ER α-glucosidase inhibitor, N-nonyl-deoxynojirimycin, 
inhibits DENV-2 infection in BHK-cells (Wu et al., 2002). These results with α-
glucosidase inhibitors are encouraging and should be investigated further in vivo. 
 
Nitric oxide (NO) is generated by macrophages, monocytes, dendritic cells (DCs) and 
neutrophils; the same cells that are supposed to be the main sites of replication for DENV 
(Lin et al., 2002b, Wu et al., 2000). In vitro assays have revealed that NO specifically 
affects the viral RdRp activity, suggesting possible viral targets of NO during DENV 
infection (Takhampunya et al., 2006). 
 
Hence, there are multiple options for designing novel therapeutics for dengue disease. The 
main concern with most therapeutic approaches, however, is that they are not validated 
for inhibitory effects on all four DENV serotypes. Additonally, several studies have not 
been examined in an animal model, and several reported antivirals have been tested at 
only one time point, pre- or post- infection in tissue culture systems, and therefore need to 
be subjected to more diverse regimes, and different cell types. 
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4 DENGUE VIRUS PATHOGENESIS 
 
DENV infection is a systemic and dynamic disease with a wide clinical spectrum. Gross 
pathological findings in cases of DHF or DSS include hemorrhages in the skin, 
subcutaneous tissues, gastrointestinal tract, and heart (Bhamarapravati, 1989). 
Hemorrhage, dilatation and congestion of vessels, and edema of arterial walls are 
commonly found, and hemorrhagic manifestations in other organs combined with fluid 
accumulations in body cavities may be substantial (Hotta, 1969, Bhamarapravati, 1967).  
 
The underlying mechanisms, however, of vascular leakage and hemorrhage are not well 
characterized. Elevated plasma levels of pro-inflammatory and vasoactive cytokines 
before and at the time of plasma leakage in patients with DHF suggest that excessive 
cytokine production (a “cytokine storm”) induce vascular permeability. Available data 
propose that the outcome of a DENV infection depends on a balance between favorable 
and unfavorable immune responses; the former providing control of viral replication, 
whereas the latter enhances inflammatory and vascular permeability. The lack of reliable 
immunological markers for either protective or pathological immune responses to DENV 
and the lack of a suitable animal model for dengue disease hamper the understanding of 
dengue pathogenesis. Insights into the immune response against DENV infection rely 
primarily on clinical and epidemiological studies. 
 
4.1.1 Tropism 
Identification of the primary target cells of DENV replication has proven to be extremely 
difficult. Existing data is based on virus detection by immunohistochemical (IHC) 
analysis with antibodies against viral structural proteins, or by in situ hybridization to the 
positive-strand vRNA. However, it is difficult to prove direct infection of specific target 
cells by these methods as a positive signal could be due to virus endocytosed or 
phagocytosed by uninfected cells. Detection of negative-strand vRNA and/or DENV NS 
proteins would provide much stronger evidence of active DENV replication. 
 
After inoculation by an infected mosquito, the initial round of viral replication is believed 
to occur in the subdermal Langerhans DCs (Ho et al., 2001, Libraty et al., 2001, Marovich 
et al., 2001, Wu et al., 2000). These infected cells become activated and migrate to 
draining lymph nodes (Johnston et al., 2000). The activated DCs elicit a robust IFNα/β 
and tumor necrosis factor alpha (TNFα) response together with a strong pro-inflammatory 
response to limit contiguous spread (Libraty et al., 2001). Viral replication continues in 
still undefined cells in the lymph node. There is a general consensus that candidate cell 
types belong to the macrophage-monocyte lineage. Autopsies and human biopsies 
confirm that cells from the mononuclear phagocyte linage probably are the primary 
targets of DENV infection following initial dissemination from the local skin site. 
Infiltrating mononuclear cells in affected tissues have been shown to contain DENV 
antigen (Boonpucknavig et al., 1979, Boonpucknavig et al., 1976, Sahaphong et al., 
1980), and DENVs can occasionally be isolated from peripheral blood leukocyte fractions 
(Scott et al., 1980). Similar observations have been made in rhesus macaques where 
DENV was recovered from leukocyte-rich tissues such as regional lymph nodes, systemic 
lymphatic tissues, and disseminated skin sites. 
 
Infection is amplified within the lymph nodes and viremia can be detected when the 
infectious virus enters the circulation via the efferent lymphatic system and thoracic duct. 
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Circulating monocytes in the blood are believed to be infected due to the viremia 
facilitating spread to secondary visceral organs where macrophages within the spleen, 
liver and bone marrow are infected (Jessie et al., 2004, Diamond et al., 2003, Solomon 
and Vaughn, 2002, Xiao et al., 2001a, Xiao et al., 2001b, Durbin et al., 2008). 
 
There has been limited and inconsistent dissemination to solid organs (Marchette et al., 
1973); DENV antigen has been detected in lymphocytes (Bhoopat et al., 1996, Jessie et 
al., 2004), hepatocytes (Bhoopat et al., 1996, Couvelard et al., 1999, Huerre et al., 2001, 
Miagostovich et al., 1997), endothelium (Bhoopat et al., 1996, Hall et al., 1991, Jessie et 
al., 2004, Ramos et al., 1998), and cerebral neurons and astrocytes (Ramos et al., 1998, 
Bhoopat et al., 1996). There are in addition other studies with contradicting results where 
the same tissues have been examined without any detected DENV antigen (Hall et al., 
1991, Jessie et al., 2004, Miagostovich et al., 1997). 
 
A further controversy surrounds the role of endothelial cells as the target for DENV 
infection. Severe dengue disease is characterized by systemic endothelial dysfunction 
accompanied by vascular leakage, even though destructive vascular lesions are generally 
absent in fatal cases (Gubler, 1998a). Primary human endothelial cells and human 
endothelial cell lines are permissive for DENV infection (Andrews et al., 1978, Avirutnan 
et al., 1998), but endothelial infection, however, does not seem to be required for severe 
pathologic changes in individual tissues (Balsitis et al., 2009). Their contribution in vivo 
remains to be established. 
 
The presence of DENV antigens in various organs and cell types suggest that the host 
receptor(s) is broadly distributed. Host receptors for DENV are believed to include 
mannose binding protein, heparan sulphate, chondroitin sulphate and DC-SIGN (Wang et 
al., 2011, Miller et al., 2008, Avirutnan et al., 2007). Following DENV infection natural 
antibodies (IgM), complement, and possibly NK cells control the initial levels of viremia 
and to certain extent tissue dissemination. Infected cells are targeted by the cellular 
immune system, upon recognition by cytotoxic T lymphocytes, which will be discussed 
below. 
 
4.1.2 The humoral immune response  
The humoral immune response is hypothesized to be vital for controlling DENV infection 
and dissemination, and infection with one serotype provides long-lasting protection to that 
specific serotype (homotypic immunity). Subsequent infection by another serotype results 
in short-lived protection (heterotypic immunity), and may eventually be harmful and 
increase the risk of severe dengue disease (see section 6.2) (Sabin, 1950). The transient 
nature of heterotypic immunity is believed to be due to cross-reactive viral E-protein 
specific antibodies which are protective above a certain concentration threshold 
(Whitehorn and Simmons, 2011). 
 
The principal targets of the antibody response to DENV infection in humans are the prM, 
and E structural proteins, and the NS1 protein.  Weak antibody responses to other NS 
proteins, e.g. NS3 and NS5, have also been detected (Valdes et al., 2000, Churdboonchart 
et al., 1991). Neutralizing antibodies are directed against the viral E protein and inhibit 
viral attachment, internalization, and replication within cells. There are multiple epitopes 
residing within each of the three E domains (Roehrig et al., 1998, Sukupolvi-Petty et al., 
2010), but not all are equally accessible for antibody binding due to the dimeric 
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conformation of the E protein on the virion surface, and its tight packing in the mature 
form (Lok et al., 2008, Kaufmann et al., 2006, Cherrier et al., 2009). 
 
Domain III of the E protein, which contains the putative host receptor-binding site, is the 
most variable in amino acid sequence between serotypes. As a result, antibodies specific 
for this domain show the greatest degree of serotype specificity (Lai et al., 2008). 
Mutations in domain III of the E protein, however, are common for escaping neutralizing 
antibody (Lin et al., 1994, Lok et al., 2001). Loss of an effective neutralizing antibody 
response due to sequence variation has also been detected for the C and NS2B proteins 
(Wang et al., 2002a, Wang et al., 2002b). 
 
Antibodies against DENV may also bind to complement proteins and promote their 
activation. Anti-prM and/or E protein antibody-mediated complement fixation to virions 
can inhibit viral infection (Mehlhop et al., 2007). As for other host immune responses to 
dengue, complement involvement may also be pathological. Complement activation is a 
feature of severe dengue and is temporally related to plasma leakage. This suggests that 
complement activation constitutes a major factor in the pathogenesis of dengue 
hemorrhagic shock (Bokisch et al., 1973, Malasit, 1987). Increased complement 
activation at endothelial cell surfaces could contribute to the vascular leakage (Avirutnan 
et al., 2006), and the viral protein NS1 is proposed to be a modulator of the complement 
pathway. By promoting efficient degradation of C4 to C4b, NS1 may protect DENV from 
complement-dependent neutralization in solution (Avirutnan et al., 2010). 
 
4.1.3 The cellular immune response 
In addition to the humoral immune response, cellular immune responses are also crucial 
in dengue pathogenesis. The DENV can infect both CD4+ T-cells and CD8+ T-cells 
(Mentor and Kurane, 1997), and similar to DENV-specific antibodies, the cellular 
immune responses can be either protective or harmfully reactive. DENV-specific T-cells 
respond with a diverse set of effector functions, including proliferation, target cell lysis 
and the production of a range of cytokines. CD4+ T-cells produce IFNγ, TNFα,  TNFβ, 
interleukin (IL)‑2, and CC‑chemokine ligand 4 (CCL4; also known as MIP1β) which 
may contribute to pathogenesis (Gagnon et al., 1999). The production of T helper type-2 
cytokines, such as IL‑4, is less common (Mangada et al., 2004, Bashyam et al., 2006, 
Imrie et al., 2007, Dong et al., 2007). In uncomplicated DENV infections, relatively more 
CD8+ T-cells are present resulting in lower levels of IFNγ and TNFα (Duangchinda et al., 
2010).  CD8+ T-cell clones specific for DENV partially protect mice from lethal DENV 
challenge (An et al., 2004) (figure 13a). 
 
The role of T-regulatory cells is unclear in dengue, but there is a study suggesting they are 
functional and expand in acute DENV infection (Luhn et al., 2007). 
 
Following primary infection, both serotype specific and serotype cross-reactive memory 
T-cells are generated. Upon secondary exposure, both the protective and cross-reactive 
memory T-lymphocytes are activated and the non-protective memory T-cells will 
augment infection (Kurane et al., 1990). Activated memory T-cells recognize both 
conserved and altered peptide ligand epitopes. The antigen sequence differences depend 
on the specific DENV epitope, but will nevertheless affect the quality of the effector T-
lymphocyte response. This in turn modifies the immunological repertoire, and is 
suggested to be involved in the development of plasma leakage (Rothman and Ennis, 
1999). A full agonist peptide will induce a full range of T-cell responses including 
   33 
production of multiple cytokines (e.g. IFNγ, TNF and CCL4) and lysis of the infected 
cell. A partial agonist peptide, i.e. varying at one residue, will cause cross-reactivity in 
memory T-cells and induce a skewed functional response, involving production of some 
cytokines but little of other cytokines and inefficient cell lysis (figure 14). Thus, because 
of sequence diversity between DENV serotypes, the memory T-cells (and B cells) that are 
re-activated during a secondary DENV infection may not have optimal avidity for the 
epitopes of the new infecting virus. The “memory” of the primary DENV infection alters 
the immune response to the secondary infection influencing the clinical outcome. 
 
There is a correlation between the level of T-cell responses and disease severity (Zivna et 
al., 2002, Mongkolsapaya et al., 2003). The phenomenon of low affinity for the current 
infecting serotype but a high affinity for a past infection with a different serotype is 
referred to as Original Antigenic Sin, and is the net effect of an altered balance between a 
protective and pathological outcome (Mongkolsapaya et al., 2003, Mangada and 
Rothman, 2005). 
 
The pattern of antibody/T-cell responses in secondary DENV infections is also influenced 
by the sequence and interval between DENV infections (Valdes et al., 1999, Halstead et 
al., 1983, Alvarez et al., 2006b, Guzman et al., 1999, Gibbons et al., 2007, Pelaez et al., 
2004). As for the ADE scenario (see section 6.2), memory T-cell responses exhibiting 
serotype cross-reactive proliferative activity decades after the primary infection could 
potentially alter the balance from a protective immune response towards an improper and 
non-protective immune response. Interestingly, most of the identified CD4+ and CD8+ T-
cell epitopes reside in the NS3 protein, which represents only ~20% of the DENV amino 
acid coding sequence (figure 13b) (Duangchinda et al., 2010). 
 
 
 
Figure 13. The DENV life cycle and antigen sources are shown. Newly synthesized viral proteins enter the 
major histocompatibility complex (MHC) class I and II presentation pathways and viral peptide epitopes are 
presented on the cell surface within the peptide binding groove of MHC molecules. MHC class II molecules 
present peptides to CD4+ T-cells, which principally produce cytokines but are also capable of lysing 
infected cells. MHC class I molecules present peptides to CD8+ T-cells, which principally lyse infected cells 
but also produce cytokines. (b). A schematic of the DENV polyprotein is shown at the top and the locations 
of well-defined epitopes recognized by human T-cells are marked by arrows. Reprinted by permission from 
Nature Publishing Group Ltd, Nature Reviews Immunology, Alan, et al., 2011 Aug; 11: 532-543, © 2011. 
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Figure 14. Variant epitopes alter the T-cell functional response. The figure shows two examples. The full 
agonist peptide (top) induces a full range of T-cell responses; production of multiple cytokines (e.g. IFNγ, 
TNF and CCL4) and lysis of the infected cell. A partial agonist peptide varying at one residue (bottom; 
altered residue in red) induces a skewed functional response, involving production of some cytokines (CCL4 
in this example) but little production of other cytokines (such as IFNγ) and inefficient cell lysis. Reprinted 
by permission from Nature Publishing Group Ltd, Nature Reviews Immunology, Alan, et al., 2011 Aug; 11: 
532-543, © 2011. 
 
4.1.4 Cytokines in dengue pathogenesis 
Viral recognition by the host cell occurs immediately upon virus entry to raise an 
appropriate antiviral response. Two main families of pathogen recognition receptors 
mediate DENV sensing; the extracellular/endosomal toll-like receptors (TLRs) (Akira and 
Takeda, 2004, Bowie and Haga, 2005), and the cytoplasmic receptor family of DExD/H 
box RNA helicases (e.g. retinoic acid inducible gene 1 (RIG-1) and melanoma 
differentiation-associated gene-5 (MDA5)) (Meylan and Tschopp, 2006).  Binding to a 
TLR leads to activation of two families of transcriptional factors: the interferon regulatory 
factors (IRFs), and the nucleic factor-kappa B (NF-kB). These signaling cascades activate 
production of IFNα/β and proinflammatory cytokines that stimulate maturation of DCs 
and elicits an antiviral response (Severa and Fitzgerald, 2007, Libraty et al., 2001). 
 
DENV is believed to primarily infect cells of the DC/macrophage/monocyte lineage via 
receptor-mediated endocytosis and/or enhanced uptake via antibody-virus complexes 
attached to Fc-gamma receptors (FcγR) (Anderson, 2003). The exact mechanisms behind 
DHF/DSS are not understood, but the consensus is that infected cells and activated 
endothelial cells produce TNFα (Carr et al., 2003, Espina et al., 2003), and NO 
(Charnsilpa et al., 2005, Neves-Souza et al., 2005), increasing vascular wall permeability 
(Borish and Steinke, 2003). The coincidence of severe disease manifestations with 
abatement of fever and virus control suggests that the symptoms may be a consequence of 
the immune response against the virus rather than virus-induced cytopathology. 
Consistent with this hypothesis is the increased levels of many different cytokines that 
have been observed in DENV infection (Basu and Chaturvedi, 2008).  
 
Elevated serum levels of cytokines and chemokines include IL-2 (Green et al., 1999, 
Kurane et al., 1991, Hober et al., 1993), IL-6 (Iyngkaran et al., 1995, Juffrie et al., 2001), 
IL-8 (Talavera et al., 2004), IL-10 (Libraty et al., 2002a, Green et al., 1999), IL-13, IL-18 
(Mustafa et al., 2001), IFNγ (Azeredo et al., 2001, Chakravarti and Kumaria, 2006), 
TNFα (Iyngkaran et al., 1995, Hober et al., 1996, Bethell et al., 1998, Azeredo et al., 
2001), and monocyte chemotactic protein-1 (MCP-1) (Sierra et al., 2010). Furthermore, 
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these cytokines are associated with secondary infections and severe disease in DHF/DSS 
patients, implying that severe dengue disease is indeed correlated to immunopathogenesis 
(figure 15). 
 
It is not fully understood how these cytokines cause malfunction of vascular endothelial 
cells leading to plasma leakage. A Th1-type response is linked to recovery from acute 
infection, whereas a Th2-type response is associated with exacerbation of infection and a 
poor clinical outcome. Patients with DF predominantly have a Th1-type response. Cross-
regulation of Th1 and Th2 is primarily mediated by IL-10 and IFNγ, respectively 
(Mosmann and Sad, 1996). In addition, activated macrophages recruit CD4+ T-cells that 
produce human cytotoxic factor (hCF), which in turn induces a cytokine cascade that 
leads to a Th1-type or Th2-type response (Chaturvedi et al., 2000). Levels of hCF can be 
elevated in severe dengue cases and hCF autoantibodies protect against severe disease 
(Chaturvedi et al., 2001). As the severity of the illness increases, the response shifts to a 
Th2-type response, characterized by secretion of IL-4, IL-5, IL-6, IL-10, and IL-13. 
Infections primarily eliciting a humoral immune response induce a higher expression of 
Th2-related cytokines (Mosmann and Sad, 1996, Chaturvedi et al., 2000). 
 
Pathological features of DHF are increased capillary permeability in the absence of 
morphological damage to the capillary endothelium, altered number and functions of 
leukocytes, increased haematocrit and thrombocytopenia. Thrombocytopenia is 
accompanied by plasma leaking and deregulated coagulation, and the latter is likely to be 
mediated by cytokines, e.g. TNFα (Chen et al., 2007). Increased levels of IL-6 and IL-8 
are associated with deregulated coagulation and fibrinolysis in dengue (Lei et al., 2001, 
Martina et al., 2009). Thus, it is believed that indirect effects of virus infection render the 
vascular wall permeable. Secreted TNFα from activated, infected cells promotes increased 
endothelial permeability and increases the expression of adhesion molecules on 
endothelial cells (Kallmann et al., 2000, Madan et al., 2002, Dagia and Goetz, 2003, 
Javaid et al., 2003), whereas increased IL-10 levels correlate to reduced levels of platelets 
and reduced platelet function (Anderson et al., 1997, Libraty et al., 2002a).  This could 
contribute to the development of bleeding complications. Extensive plasma leakage into 
various serous cavities of the body, including the pleural, pericardial and peritoneal 
cavities, may result in profound shock. 
 
The immunopathogenesis of dengue has to a large extent been correlative in nature 
describing temporal associations between cytokine concentrations and the clinical events 
of plasma leakage. There is a need to identify causal immunopathogenic mechanisms 
compared to the abundance of descriptive studies of dengue pathogenesis. It is worth 
noting that other infectious diseases and inflammatory disorders with elevated cytokine 
levels are not accompanied by increased vascular permeability as seen in severe dengue. 
Thus, the challenge is to identify the key elements of the host immune response that are 
causally linked to papillary permeability from those that constitute the normal host 
immune response. 
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Figure 15. Pathogenesis of DHF and DSS.  DENV initially infects a cell of the DC/macrophage/monocyte 
lineage via receptor-mediated endocytosis and/or enhanced uptake via antibody-virus complexes attached to 
FcγRs. The heterotypic antibody is not protective, but cross‐reacting antibodies attach to the virus and 
enhance macrophage infection through Fc receptor–mediated endocytosis (as depicted in the bottom part). 
The secondary antibody response to the new infecting DENV plus the enhanced virus output lead to 
formation of phlogistic immune complexes. The resulting activated complement components may cause 
damage directly, and also through interactions with the coagulation system. The cellular immune system is 
also important. (DV, dengue virus; PAF, platelet activating factor). Memory T-cells (Tm) that recognize 
cross‐reacting epitopes on the new DENV species are activated, proliferate, and secrete IFNγ, TNF, and 
other cytokines. IFNγ upregulates the FcRs on the macrophages, further increasing the ADE of infection of 
the dengue target cell. The T-cells also interact with macrophages, with cross-reactive CD8+ T cells able to 
lyse infected macrophages. The result of this extensive cytokine release and other mediators is the abrupt 
onset of a shock state due to enhanced vascular permeability. This is referred to as DSS and changes in 
vascular permeability in DENV infections have classically been measured by monitoring levels of albumin 
in the plasma. At the time of defervescence, the vascular leak leads to a rising haematocrit as serum proteins 
leave the vascular system. The resulting falling blood pressure can usually be treated effectively with 
infusions of crystalloid or, at times, colloid until the condition reverses. Reprinted by permission from 
ImagesMD, Viral Hemorrhagic Fevers in Atlas of Infectious Diseases, Peters, et al., 2002 Jan, © 1997, 
2004 by Current Medicine LLC. 
 
4.1.5 Related hemorrhagic viruses 
Viral hemorrhagic fever (VHF) is a clinical definition incorporating several diseases 
caused by viruses from four families: Arenaviridae, Bunyaviridae, Filoviridae, and 
Flaviviridae (table 2).  Common for these viruses are that they are zoonoses and have a 
single-stranded RNA genome. Since these viruses are zoonotic agents, their epidemiology 
is linked to the host-human relation, and the main causes of their outbreaks are associated 
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to recent ecological perturbations induced by the growing human population. Rodent-
borne viruses such as the hantaviruses and the arenaviruses shed infectious particles in 
urine, faeces and saliva throughout the life of their rodent host (Bowen et al., 1997).  
Outbreaks are limited to specific geographical regions where these animals live, and 
humans are infected either by the respiratory route through aerosols contaminated by the 
urine or faeces of the rodents, or by direct contact of mucous membranes or skin 
abrasions with excrement or blood of the animal. 
 
In contrast to rodent-borne viruses, mosquito-borne viruses allow large and often 
unpredictable epidemics. Abundance of water is clearly associated with outbreaks, and 
freshwater areas created by dams provide breeding sites for mosquitoes and attract 
humans. Tick-borne viruses, on the other hand, have little opportunity to cause large 
human epidemics since ticks wait on a vegetative support until an animal/human passes 
by. The large distribution of ticks, however, is suggested to be due to migratory birds 
carrying ticks. 
 
The pathogenesis of VHF is not clearly understood, and may vary according to virus. The 
general symptoms are similar (headache, myalgia, arthralgia and nausea), and the main 
cause of death is hypovolemic shock due to plasma leakage at the capillary level (Le 
Guenno, 2001). Macrophages and endothelial cells are assumed to be the most important 
targets for viral replication (Lewis et al., 1989), except for YFV. These target cells 
produce TNFα and IL-6 in addition to other proinflammatory cytokines when infected. 
Thrombocytopenia and/or platelet dysfunction are thought to be due to either infection of 
endothelial cells causing modifications of the cell membranes, favoring platelet 
aggregation, or cytokine-mediated actions that inhibit platelet production. Cytokines, 
coagulation factors and complement factors are involved, but the exact mechanisms 
underlying VHF are poorly understood (Le Guenno, 2001). 
 
Family Genus Virus Disease Vector Geographic location 
Arenaviridae Arenavirus Junin Argentinean HF Rodents South America 
  Machupo Bolivian HF Rodents South America 
  Guanarito Venezuelan HF Rodents South America 
  Sabia Brazilian HF Rodents South America 
  Lassa Lassa fever Rodents South America 
      
Bunyaviridae Phlebovirus Rift Valley Fever Rift Valley Fever Mosquitoes Africa (south of 
Sahara) 
 Nairovirus Crimean-Congo HF CCHF Ticks  Asia, Europe, Africa 
 Hantavirus Hantaan HFRS Rodents Asia 
  Seoul HFRS Rodents Asia and world-wide 
  Belgrade/Dobrava HFRS Rodents Europe 
      
Filoviridae Filovirus Marburg HF Unknown Africa 
  Ebola HF Unknown Africa 
      
Flaviviridae Flavivirus Yellow Fever Yellow fever Mosquitoes South America, Africa 
  Dengue 1-4 DHF, DSS Mosquitoes South America, Africa, 
Asia, Oceania 
  Kyasanur Forest Kyasanur Forest 
disease 
Ticks South Asia 
Table 2. HF, hemorrhagic fever, CCHF; Crimean-Congo hemorrhagic fever; HFRS, hemorrhagic fever with 
renal syndrome; HPS, hantavirus pulmonary syndrome; DHF, dengue hemorrhagic fever; DSS, dengue 
shock syndrome. 
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5 ANIMAL MODELS OF DENGUE VIRUS INFECTION 
AND DISEASE 
 
The pathogenesis of DENV infections is, despite intensive research, not well understood. 
Many fundamental questions in dengue pathogenesis are difficult to address due to the 
lack of appropriate animal models of infection and disease. No non-human species 
naturally exhibits the more severe forms of dengue disease that mimic human DF, DHF, 
and DSS, and this has hampered the development of a suitable animal model. 
 
5.1 NON-HUMAN PRIMATES 
NHPs are the only vertebrates apart from humans known to be naturally infected by 
DENV. The viral strains isolated from NHPs, however, are genetically distinct from those 
infecting humans indicating that these transmission cycles diverged a long time ago 
(Wang et al., 2000). In addition, NHPs do not develop DHF, but only a mild infection. 
 
Animal models of DENV infection were however initially limited to NHP despite the fact 
that NHPs only develop mild viremia without severe clinical symptoms. Attempts to 
induce dengue-like disease in other animals failed and the suboptimal NHP models 
remained the only available model for a long time. Studies in rhesus macaques revealed 
no abnormalities in haematocrit or prothrombin time, and only a minority of animals 
displayed a limited decrease in platelet counts (Halstead et al., 1973b, Halstead et al., 
1973c, Halstead et al., 1973a). Thus, DENV infection in macaques has been unable to 
offer any major insights into the molecular mechanisms of DENV pathogenesis. 
 
In contrast, NHPs are widely used in vaccine testing as they are capable of developing 
neutralizing antibodies in response to DENV infection (Bente and Rico-Hesse, 2006). 
 
5.2 MOUSE MODELS 
Rodents are susceptible to DENV infection although they do not exhibit disease similar to 
that in human DENV infections. To compensate for these limitations, murine models have 
relied on mouse-adapted DENVs that appear to be attenuated with respect to human 
infection. New mouse models have been developed to render the mice more susceptible to 
infection, but none have been able to mimic DENV-specific immune responses. 
 
Mouse models based on intracranial inoculation of DENV have for long been used in 
parallel to studies in NHPs. Mice usually exhibit a neurovirulent phenotype quite unlike 
human dengue disease, and succumb to intracranial infection (Bente and Rico-Hesse, 
2006). Multiple efforts have generated a diverse set of mouse models for DENV 
infection, each with distinct advantages and disadvantages (Yauch and Shresta, 2008). 
The various approaches can be divided into four groups: 
 
 Immunocompetent mouse models 
 Severe combined immunodeficient (SCID)-tumor transplant mouse models 
 Humanized mouse models 
 Interferon-deficient mouse models 
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Consequently, the various models have contributed in different ways to understanding 
mechanisms underlying DENV pathogenesis and immunity, and in the development of 
antiviral drugs and vaccines. 
 
5.2.1 Immunocompetent mouse models 
The unimpaired nature of the immune system renders the immunocompetent mice poorly 
susceptible for DENV infection. Despite the lack of clinical symptoms, these models have 
been used extensively to study other aspects of DENV pathogenesis (Barreto et al., 2007, 
Paes et al., 2005, Huang et al., 2000, Chen et al., 2007). In addition, immunocompetent 
mouse models of DENV infection have been popular for drug and vaccine development 
studies since the intact immune system is valuable for assessing vaccine immunogenicity. 
 
Clinical and neurological disease can be induced by high-dose infection and/or 
intracranial injection, as well as mouse-adapted DENV strains that render mice more 
susceptible to DENV infection (Atrasheuskaya et al., 2003, Zulueta et al., 2006). The 
relevance of observations made with manipulated DENV strains, however, should be 
interpreted with caution regarding their relevance to wild-type infections. 
 
5.2.2 Severe combined immunodeficient tumor transplant mouse models 
Measurable viremia is a desired trait when studying DENV infection and a common 
strategy to render the mouse more susceptible to DENV infection is to manipulate the 
mouse in one or several ways. Transplanted human tumor mass that provides a replication 
site for infectious DENVs have been applied in SCID mice. Since SCID mice lack an 
adaptive immune system, DENV infection has been successfully established within the 
transplanted cells and even some dengue disease features have been reproduced (An et al., 
1999, Lin et al., 1998, Blaney et al., 2002). However, it is unclear how any insights into 
pathogenesis might apply to human pathogenesis since viral replication in restricted 
primarily to the transplanted cells. 
 
5.2.3 Humanized mouse models 
An improved strategy based on the SCID-tumor model is „humanized‟ SCID mice that are 
irradiated to destroy the haematopoietic progenitors in the bone marrow, prior to 
transplantation with human CD34+ haematopoietic stem cells (figure 16). The result is an 
adaptive immune system consisting exclusively of human cells, with certain parts of the 
innate system being humanized as well (Bente et al., 2005, Kuruvilla et al., 2007). The 
advantage with this model is the increased susceptibility to clinical DENV isolates 
without adaptation to mice, and the mice display some signs of human disease. The exact 
cell types in which DENV replicates in humanized mice remains to be identified.  
 
The difficulties with the humanized mouse model are multiple, such as the genetic 
variation in stem cell donors, the hardship to generate sufficient numbers of humanized 
mice, variability in the degree of human cell engraftment, and radiation sensitivity of 
SCID-mice (Shultz et al., 1995).  A limitation of crucial importance is the lack of lymph 
nodes that support a human immune system (Cao et al., 1995, DiSanto et al., 1995, Ohbo 
et al., 1996), as well as the lack of a robust immune response in these humanized mice; 
both fluctuations in the elicited immune response as well as poor reproducibility (Ifversen 
and Borrebaeck, 1996, Murphy et al., 1996). Human-specific cytokines required for 
human cell development and survival are not successfully generated, and there is a low 
and variable level of T-cell-dependent antibody responses (Shultz et al., 2005, Ishikawa et 
al., 2005). Thus, humanized mouse models are time-consuming and labor-intensive and, 
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therefore, not optimal for most drug and vaccine development purposes. These new 
models may eventually have the potential to answer important and fundamental questions 
concerning infection of human cells in vivo, but there are still major issues to be resolved 
regarding stem cell development in order to obtain a functional and intact adaptive 
immune system. 
 
 
Figure 16. This figure shows schematically the proposed 
use of humanized mice as a pre-clinical bridge between 
basic in vitro studies and the in vivo analysis. On the left 
(top) are cultures of human stem cells (embryonic stem-
cell-derived and adult stem-cell-derived populations) 
generated in vitro and available for analysis of in vivo 
efficacy in humanized mice. Depicted bottom left is a 
humanized mouse engrafted with human stem cells by 
various routes of injection or implantation. Reprinted by 
permission from Macmillan Publishers Ltd, Nature 
Reviews Immunology, Shultz et. al., 2007 Feb; 7: 118–
130, © 2007. 
 
 
 
5.2.4 Interferon-deficient mouse models 
Another way to increase the susceptibility of mice to DENV infection is to generate mice 
deficient in the IFN pathway (Johnson and Roehrig, 1999, Shresta et al., 2004). The IFN 
system is potent suppressor of DENV replication, and mice lacking the IFN-α/β and –γ 
receptors (AG129 mice) can be lethally challenged without intracranial inoculation 
(Johnson and Roehrig, 1999). The AG129 mouse strain exhibits viral replication in 
relevant peripheral cell types like macrophages and DCs in spleen and lymph node (Kyle 
et al., 2007), hepatocytes, and myeloid cells in bone marrow (Balsitis et al., 2009). 
 
A variety of DENV isolates have been used and the clinical symptoms are either 
neurological disease or a DSS-like vascular permeability syndrome depending on the 
virus isolate and route of inoculation (Huang et al., 2003, Johnson and Roehrig, 1999, 
Kyle et al., 2007, Lee et al., 2006b, Schul et al., 2007, Shresta et al., 2006, Stein et al., 
2008). Consequently, AG129 mice have been used for numerous studies including 
tropism, pathogenesis, immune protection and enhancement, as well as for antiviral drug 
testing and vaccine development (Johnson and Roehrig, 1999, Kyle et al., 2007, Kyle et 
al., 2008, Schul et al., 2007, Shresta et al., 2004, Shresta et al., 2006, Prestwood et al., 
2008). The genetically deficient background does not, however, make the AG129 mouse 
suitable for genetic studies since it would be time-consuming to introduce a third knock-
out gene. 
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6 RISK FACTORS FOR SEVERE DENGUE 
 
Although the exact mechanisms underlying severe dengue are not known, some risk 
factors that influence disease outcome have been identified. Among these, host 
determinants are a key issue in susceptibility to severe dengue disease and include age, 
chronic disease, ethnicity, and host genotype. An additional contributing risk factor that 
plays a major role in disease outcome is secondary infection by a heterologous DENV 
serotype. Finally, the virus serotype and genotype also influence the symptomatic picture 
of disease and outcome (figure 17). These observations were initially based on 
epidemiological findings, but accumulating laboratory and experimental data have 
contributed to the recognition of DENV virulence as an important risk factor. 
 
Figure 17. The complex interplay of risk factors for 
severe dengue disease can be illustrated as a triangular 
interplay dominated by the three main risk factors: host 
factors, pre-existing DENV-specific antibodies 
mediating ADE, and intrinsic virus features influencing 
strain virulence. The exact contribution of each risk 
factor may vary from case to case. 
 
 
 
 
6.1 HOST GENETICS 
Apart from the influence of viral genetic determinants, the host‟s genetic background with 
varying polymorphisms might have important consequences for disease susceptibility 
(Casanova and Abel, 2007). Improvements in high-throughput genotyping of genetic 
polymorphisms have permitted a genome-wide approach to the investigation of host 
genetic susceptibility. Most studies, however, have not attempted functional trials to try to 
link genetic association with any process in disease pathogenesis. 
 
Indirect evidence of the host‟s genetic importance has been derived from Cuban dengue 
epidemics where a reduced risk for DHF/DSS was observed in those with an African 
ancestry compared to those with European ancestry (Bravo et al., 1987, Gonzalez et al., 
2005, Guzman et al., 1990, Guzman et al., 1999, Guzman and Kouri, 2002, Sierra et al., 
2007). The Cuban observations coincide with the low susceptibility to DHF reported in 
African and Black Caribbean populations (Halstead et al., 2001, Saluzzo et al., 1986b). It 
is interesting that despite the circulation of DENV in 19 African countries, there are only 
sporadic reports of DHF cases (Gubler et al., 1986, Saluzzo et al., 1986a, Sharp et al., 
1995). 
 
In order to better understand these population differences, the polymorphic HLA genes 
have been among the most studied candidates for genetic associations with DHF/DSS. 
Several serological studies of HLA class I alleles have been performed in ethnically and 
geographically distinct populations, and positive correlations of various HLA class I 
alleles with susceptibility to DHF have been found (Chiewsilp et al., 1981, Loke et al., 
2001, Paradoa Perez et al., 1987). A significantly higher frequency of HLA class I alleles 
A*31 and B*15 have been found in Cuban individuals with symptomatic DENV infection 
compared to asymptomatic controls, who showed an elevated frequency of HLA II alleles 
DRB1*07 and DRB1*04 (Paradoa Perez et al., 1987, Sierra et al., 2007).  The DRB1*04 
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was also the most frequent allele associated with resistance to DHF in the Mexican 
Mestizo populations of the Americas (LaFleur et al., 2002). Since the Mexican Mestizo 
population and the Cuban population share the same Amerindian genetic background, it is 
possible that the identification of the same HLA class II allotype could explain the 
association to dengue disease protection (Centro, 1976, Rivero de la Calle, 1984). 
 
A case-control study in ethnic Thai cases also reported the association of HLA class I 
alleles (A2, A*0207, B46, B51) with different clinical outcomes (Stephens et al., 2002). A 
similar study in a Vietnamese population confirmed the association with polymorphism of 
the HLA class I loci and DHF susceptibility. The same study also found that 
polymorphisms in the HLA-DRB1 allele are not associated with DHF susceptibility, 
highlighting the findings in the Amerindian populations (Loke et al., 2001). 
 
The number of studies on polymorphisms within genes other than the HLA loci remains 
low. Variants of the vitamin D receptor and the FcγRIIA gene are associated with 
resistance to severe dengue (Loke et al., 2002). Additionally, an allelic variant of the DC-
SIGN1 coding gene CD209 is believed to protect against DHF(Despres et al., 2005). 
 
6.1.1 Host health and age 
An increased association between severe dengue and bronchial asthma, diabetes mellitus, 
peptic ulcers, and sickle cell anaemia has been observed (Rigau-Perez, 2006, Rigau-Perez 
and Laufer, 2006, Bravo et al., 1987, Diaz et al., 1988, Gonzalez et al., 2005, Limonta et 
al., 2008, Valdes et al., 1999, Guzman et al., 1999). The impact of dengue on chronic 
diseases and other pathogens, however, needs to be further investigated. 
 
Primary infections are supposed to cause mild disease in children, compared to secondary 
infections that tend to lead to severe dengue (Egger and Coleman, 2007). In South-East 
Asia, DHF/DSS is predominantly an illness of children. The greater relative prevalence of 
DSS in children relative to adults is believed to be due to the intrinsically more permeable 
vascular endothelium in children (Gamble et al., 2000). There is no clear consensus; 
studies conducted in South American countries have reported similar (Guzman et al., 
2002a) as well as contradictory results indicating that adults are the most affected (Rigau-
Perez et al., 2001). 
 
6.1.2 Autoimmune responses in dengue virus infection 
Anti-DENV antibodies can cross-react to host proteins and endothelial cells, and this 
could enhance the endothelial dysfunction observed in DHF/DSS. Antibodies against the 
viral surface E protein cross-react with plasminogen and have been associated with 
bleeding in acute DENV infection (Chungue et al., 1994, Markoff et al., 1991), and anti-
DENV NS1 antibodies cross-react to host proteins and endothelial cells (Lin et al., 2006, 
Falconar, 1997). Additionally, immune activation markers (e.g. IL-6, IL-8, TNFα, IFNγ, 
and complement components 3A and 5A) together with altered platelet, DC, monocyte, 
and T-cell functions suggest that immune responses to various DENV components could 
contribute to autoimmune processes resulting in DHF/DSS (Falconar, 1997, Lin et al., 
2002a, Lin et al., 2003).  
 
6.2 ANTIBODY-DEPENDENT ENHANCEMENT 
A secondary infection by a heterologous DENV serotype is an important risk factor for 
developing DHF/DSS.  The explanation lies within the cross-reactive antibodies raised 
after a primary DENV infection (Endy et al., 2002, Kurane et al., 1998, Kurane, 2007, 
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Thaung et al., 1975, Burke et al., 1988, Sangkawibha et al., 1984). Serotype-specific 
antibodies confer life-long immunity to the homologous serotype, whereas cross-
protection against heterologous serotypes last for 3-4 months (Sabin, 1952). Beyond this 
time period of cross-protection, the pre-existing antibodies of sub-neutralizing 
concentration will instead cross-react with the heterologous virus facilitating viral 
infection of FcγR bearing cells (figure 18). This phenomenon is known as Antibody-
dependent enhancement (ADE) (Mady et al., 1991, Green and Rothman, 2006, Kurane, 
2007, Littaua et al., 1990). The limited cross-protection between the four DENV 
serotypes has allowed them to coexist in the same or overlapping geographical areas. 
Thus, their antigenic uniqueness has implied an evolutionary advantage (Ferguson et al., 
1999). 
 
 
 
Figure 18. ADE of virus replication occurs when heterotypic, non-neutralizing antibodies present in the host 
from a primary DENV infection binds to an infecting DENV particle during a subsequent heterotypic 
infection but cannot neutralize the virus. Instead, the antibody–virus complex attaches to the FcγR on 
circulating monocytes, thereby facilitating the infection of FcγR cell types in the body not readily infected in 
the absence of antibodies. The final outcome is an increase in overall viral replication, potentially leading to 
more severe disease (Vaughn et al., 2000). Reprinted by permission from Nature Publishing Group Ltd, 
Nature Reviews Microbiology, Stephen, et al., 2007 July; 5:518-528, © 2007. 
 
Low-affinity/sub-neutralizing antibodies and DENV form virus-antibody immune 
complexes that bind to FcγRs on monocytes. The net result will be a larger number of 
infected cells compared to the primary infection when there were no cross-reactive 
antibodies present, or compared to earlier after the primary infection when antibody levels 
are high enough to achieve neutralization of the heterologous virus. Hence, the viral 
biomass will be larger during a secondary DENV infection compared to during a primary 
DENV infection. 
 
In vitro studies indicate that non-neutralizing antibodies against the viral prM protein can 
potentially mediate ADE. These anti-prM antibodies are in addition non-neutralizing even 
at high concentrations (Dejnirattisai et al., 2010, Rodenhuis-Zybert et al., 2010). The 
proposed hypothesis for prM-mediated ADE is based on the fact that the viral prM protein 
needs to be cleaved to render the virus infectious. Hence, immature virus particles that 
would otherwise be non- or less-infectious are rendered infectious in combination with 
anti-prM antibodies that mediate ADE to infect new host cells (Dejnirattisai et al., 2010) 
(figure 19). 
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Figure 19. (a). The DENV life cycle and antigen sources are shown. Dengue virions bind to cell surface 
receptors (these have not been completely characterized), and the virions are internalized through 
endocytosis. Acidification of the endocytic vesicle leads to rearrangement of the surface E glycoprotein, 
fusion of the viral and vesicle membranes and release of vRNA into the cytoplasm. Viral genomic RNA is 
then translated to produce viral proteins in ER-derived membrane structures, and the viral proteins and 
newly synthesized vRNA assemble into immature virions within the ER lumen. Cleavage of the viral prM 
protein by the host cell enzyme furin leads to the formation of mature virions, which are secreted from the 
cell. In addition, some of the synthesized NS1 protein is expressed on the plasma membrane or secreted, and 
some virions are secreted in an immature form. Mature and immature virions induce antibody responses to 
the E protein, and these antibodies can function in neutralization or in ADE of infection. Immature virions 
also induce antibody responses to the prM protein. Antibodies specific for NS1 can interact with membrane-
bound NS1 and cause complement-dependent lysis of virus-infected cells. (b). The structure of the DENV E 
glycoprotein ectodomain and characteristics of E protein-specific antibodies are shown. The three domains 
of the E protein are coloured in red (domain I), yellow (domain II) and blue (domain III). (c). The 
mechanisms of neutralization and enhancement by DENV-specific antibodies are shown. At high levels of 
epitope occupancy, antibodies can block the binding of virions to the cellular receptor or can block fusion at 
a post-binding stage. At lower epitope occupancy levels, antibodies can enhance the uptake of virions into 
cells by interacting with Ig (Fc) receptors. Reprinted by permission from Nature Publishing Group Ltd, 
Nature Reviews Immunology, Alan, et al., 2011 Aug; 11: 532-543, © 2011. 
 
The time interval between heterotypic DENV infections is another parameter influencing 
the magnitude of ADE; a longer interval between heterologous DENV infections causes 
higher DHF/DSS ratios (Guzman et al., 2002b). The differences in DENV genotype could 
influence the pathogenic consequences, but a contributing risk factor is the progressive 
loss of heterotypic neutralizing antibodies (Guzman et al., 2007). The time effect of 
   45 
DENV-specific antibodies can be seen in DENV-immune mothers and their infants. 
Before the age of 3-4 months, the maternally derived DENV-specific antibodies confer 
protection against a DENV infection. Primary infections in infants aged between 4 and 12 
months of age, however, run a higher risk of developing severe dengue due to maternally 
derived non-neutralizing antibodies. The risk of severe dengue decreases after the age of 1 
year as the concentration of cross-reactive antibodies declines (Kliks et al., 1988, Chau et 
al., 2009, Pengsaa et al., 2006). 
 
A higher viral burden elicits a greater host inflammatory response and increased plasma 
levels of proinflammatory cytokines. Secondary DENV infections and severe disease in 
DHF/DSS patients with severe disease have elevated serum levels of IL-2, IL-6, IL-8, IL-
10, IL-13, IL-18, IFNγ, TNFα, and MCP-1 (Azeredo et al., 2001, Chakravarti and 
Kumaria, 2006, Nguyen et al., 2004, Mustafa et al., 2001, Perez et al., 2004, Pinto et al., 
1999, Yang et al., 1995b). Thus, an increased infected cell mass would stimulate T-cell 
and cytokine responses that are proportional to the antigenic stimulus. This hypothesis is 
consistent with the observations that a high initial viremia or high NS1 concentrations in 
blood during secondary infections are associated with DHF/DSS (Libraty et al., 2002a, 
Libraty et al., 2002b, Vaughn et al., 2000, Wang et al., 2003). 
 
Accumulating evidence questions whether ADE of infection alone is sufficient to explain 
DHF/DSS (Vaughn et al., 2000). Severe dengue with plasma leakage can occur in 
primary infection without ADE. In addition, by the time plasma leakage occurs, viral 
titers are several logs below peak levels, and there are patients with high viral titers that 
do not develop plasma leakage (Vaughn et al., 2000, Vaughn et al., 1997, Libraty et al., 
2002a). Thus, increased viremia alone is not the direct cause of plasma leakage and other 
mechanisms are involved in the cytokine storm. Furthermore, ADE is not a useful 
correlate of disease risk (Laoprasopwattana et al., 2005, Libraty et al., 2009). 
 
6.3 DENGUE VIRULENCE 
ADE has dominated as the explanatory model for severe dengue disease in secondary 
infections. Evidence for ADE in humans, however, is indirect and controversial results 
against ADE exist (Endy et al., 2004, Laoprasopwattana et al., 2005). Many parts of the 
world have become hyperendemic, implying that all four serotypes of DENV co-circulate 
in the same country (figure 20 and 21), with the consequence that secondary infections are 
common scenarios. Epidemiological data also indicate that not all secondary infections 
cause DHF/DSS, and that there are even cases of tertiary and quaternary DENV infections 
(Halstead, 2007). Studies from Thailand report that 0.08-0.8 % of dengue hospitalizations 
may be caused by tertiary and quaternary DENV infections (Gibbons et al., 2007). In 
Cuba, 17.5 % of the total DHF dengue cases were caused by third or fourth infections 
(Alvarez et al., 2006b). 
 
The four DENV serotypes 1-4 diverge at ~30 % across the polyprotein  (Westaway, 
1997), but each serotype also consists of phylogenetically distinct „subtypes‟ or 
„genotypes‟, which have different geographical distributions (Monath et al., 1986, Trent et 
al., 1989). The hypothesis that some DENV genotypes have a greater virulence and 
epidemic potential than others was introduced during the 1970‟s around the same time 
that the ADE phenomenon was coined (Barnes and Rosen, 1974, Rosen, 1977, Gubler et 
al., 1981). In contrast to the ADE hypothesis, however, experimental evidence for 
increased virulence was for long absent and, therefore, primarily based on 
epidemiological observations. Recent work has shed light on this question and confirmed 
46 
what Rosen, et al. proposed almost four decades ago (Barnes and Rosen, 1974, Rosen, 
1977). 
 
Figure 20. Cambodia in South-East Asia is a hyper-endemic country where all four DENV serotypes are 
circulating. As a direct result of the presence of multiple DENV serotypes, secondary infections are 
common. Data come from five sentinel hospitals, coordinated by the Pasteur Institute in Cambodia, from 
five geographic regions conducting DENV surveillance and serology by ELISA IgM and IgG tests and RT-
PCR. Courtesy  Prof. Ngan Chantha, Asia-Pacific Dengue Program Managers Meeting, Singapore 2008, p. 
48. 
 
Figure 21. The distribution of DENV has increased dramatically during the last decades. The figure 
illustrates the distribution in (a). 1970, and (b). 2004. Reprinted by permission from Nature Publishing 
Group Ltd, Nature Reviews Microbiology, Guzman, et al.,2010 Dec; S7-S16, copyright 2010. 
 
There have been specific geographic examples of the appearance of DENV genotypes 
correlating to DHF/DSS epidemics. The appearance of a South-East Asian DENV-2 
strain in the Americas in 1981 resulted in the sudden emergence of DHF/DSS cases. It 
turned out that DENV-2 could be subdivided into a variety of genotypes, minimally Asian 
and American. The Asian genotype is more virulent and more likely to result in 
DHF/DSS than the American genotype even after a secondary infection (Rico-Hesse et 
al., 1997, Rico-Hesse, 1990). Viruses to the South-East Asian DENV-2 lineage replicate 
to higher titers in human DCs than American genotype viruses. It was also seen that the 
South-East Asian genotype infects and disseminates to the head tissue of Ae. aegypti 
mosquitoes more rapidly and in a greater proportion compared to the American genotype 
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viruses (Anderson and Rico-Hesse, 2006, Armstrong and Rico-Hesse, 2001, Armstrong 
and Rico-Hesse, 2003, Cologna et al., 2005). 
 
The emergence of group B subtype III DENV-3 strain in Sri Lanka in 1989 is another 
example of clade replacement correlating with an increase in DHF/DSS (Messer et al., 
2002, Messer et al., 2003, Kanakaratne et al., 2009). As for the South-East Asian DENV-
2 strain, the invasive DENV-3 strain replicated to higher levels in mosquitoes and 
disseminated to the head tissue more readily than the displaced, native DENV-3 strain 
from Sri Lanka (Hanley et al., 2008). Both traits likely enhanced the capacity to spread 
and displace endemic strains. 
 
Based on the examples given, one hypothetical mechanism for increased virulence 
suggests that highly pathogenic DENV strains have been selected for enhanced ability to 
replicate in key human targets, such as macrophages and DCs (Cologna et al., 2005, 
Cologna and Rico-Hesse, 2003, Vasilakis et al., 2007). Thus, virulent DENVs would 
produce more viruses per cell, resulting in higher viremia and inflammatory response, 
than with a low pathogenic strain (Cologna and Rico-Hesse, 2003, Leitmeyer et al., 
1999). 
 
The second hypothesis for increased virulence proposes that strains associated with severe 
DHF/DSS better escape neutralization by serotype cross-reactive antibodies present in the 
semi-immune host compared to strains associated with DF (Kochel et al., 2005). 
Enhancement of virus replication following heterologous infection may favor coexistence 
of multiple serotypes. If such enhancement also results in increased transmission, DENVs 
from different serotypes would benefit from prior and concurrent circulation of several 
serotypes in the same location (Ferguson et al., 1999). 
 
It is still not known if the tendency of certain genotypes to cause severe disease results 
from greater intrinsic virulence, or if greater virulence is a result of enhanced infectivity in 
the presence of heterologous antibodies, or a combination of the two. Determining 
whether DENVs differ in virulence, as well as identifying the genetic basis of such 
differences, is of fundamental importance. This has been the primary focus of this thesis. 
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7 AIMS OF THE STUDY 
 
Despite the global burden of dengue and intensive research, the mechanisms underlying 
DENV pathology are not well understood. Dengue research has been hampered by a lack 
of appropriate animal models of infection and disease. Furthermore, fundamental 
knowledge such as host cell tropism and virulence markers are still not established. The 
overall aim of this thesis was to identify viral features involved in dengue virulence by in 
vitro and in vivo characterization of clinical DENV. All four serotypes and dengue disease 
conditions (DF, DHF, or DSS) are represented, and only DENVs passaged once have 
been used in order to resemble wild-type viruses as much as possible. 
 
The specific aims were: 
 
1. To understand the self-priming phenomenon of the DENV genome and its 
implications for the development of a strand-specific qRT-PCR for DENV. A 
strand-specific qRT-PCR would be a valuable tool for identification of target cells 
for DENV replication. 
 
2. To investigate if clinical DENV isolates from patients experiencing the various 
forms of dengue (DF, DHF, and DSS) can be differentiated based on their 
replication profiles and/or apoptosis induction in mammalian Vero cells and 
mosquito C6/36 cells, and to determine whether any particular virus phenotype 
correlates with clinical disease severity. 
 
3. To extend the in vitro characterization of clinical DENV isolates to in vivo 
conditions using a mouse model and study replication kinetics and organ tropism. 
 
4. To compare the genomes from clinical DENV isolates from all four serotypes and 
to investigate whether any particular genotype correlates with clinical disease 
severity and our findings from the in vitro and in vivo experiments. 
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8 RESULTS AND DISCUSSION 
 
Below follows a summary of the key findings in each scientific paper included in this 
thesis. Please see the paper per se for details regarding material and methods, complete 
results including tables and figures, and a comprehensive discussion.  
 
8.1 SELFPRIMING OF THE DENGUE VIRUS GENOME (paper I) 
Understanding of the pathophysiological events leading to dengue disease remains limited 
partly because viral target cells in humans are poorly characterized. One of the most 
sensitive methods to detect cells supporting active replication of DENV is by 
identification of the replicative intermediate, the viral anti-genome of negative single-
stranded polarity, with RT-PCR. 
 
Attempts to develop a strand-specific qRT-PCR to identify primary target cells for DENV 
replication, was hampered due to the phenomenon of self-priming of the viral genome. 
This false priming of the reverse transcriptase (RT) prevented strand-specific detection. 
The results of the study showed that this event corresponds to cDNA synthesis 
independent of exogenous primers. 
 
Self-priming applied to all RNAs tested, including negative-sense RNA and cellular 
mRNA, and was not restricted to any particular regions of the viral genome. Thus, the 
lack of a poly(A)-tail at the 3‟ end was not a requirement for self-priming since cellular 
mRNA (18S and β-actin) were also found to yield cDNA in the absence of exogenous 
primers. In vitro transcribed templates revealed that endogenous priming was not 
restricted to specific template sequences. Furthermore, self-priming of the template was 
not associated with small free nucleic acids, such as tRNAs and microRNAs. 
 
Interestingly, self-primed cDNA was slightly shorter than DNA-primed cDNA, 
suggesting that the 3‟ end of the RNA looped back on itself to form a short and transient 
RNA-RNA duplex potentially serving as a primer for the RT. This model is conceivable 
since the minimal length requirement for AMV RT priming by DNA can be as short as 
four nucleotides (Falvey et al., 1976). Destabilization of secondary RNA structures by 
addition of DMSO (10 % of the final concentration), and increased RT temperature to 
63˚C did not abolish the intrinsic feature of self-priming. 
 
Hence, self-priming can occur in samples where DNA priming occurs and a significant 
amount of unexpected cDNA is synthesized, presenting a limitation when designing 
strand-specific RT-PCR. First-strand synthesis of the DENV genome in situ is believed to 
be due to spontaneous loop-back structures functioning as transient primers for the RT, 
originating at the 3‟ end.  
  
The phenomenon of self-priming could explain why many assays proposed for detection 
of a replicative intermediate are suboptimal and lack specificity. The issue of self-priming 
needs to be considered when developing molecular methods for virus replication studies, 
e.g. target cell identification. 
 
8.2 IN VITRO CHARACTERIZATION (paper II and IV) 
DENV strain variations have been acknowledged as a risk factor for severe dengue 
disease and epidemiological data indicates that virulence differs among DENV genotypes 
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within the same serotype (Rico-Hesse, 1990, Cologna and Rico-Hesse, 2003, Leitmeyer 
et al., 1999, Anderson and Rico-Hesse, 2006, Rico-Hesse et al., 1997). Except for 
attenuated strains generated for vaccine purposes, there is no phenotypic profile of a 
“virulent” or “avirulent” DENV strain. No specific genetic markers have been identified 
so far that correlate with increased virulence traits of DENV. 
 
In an attempt to identify viral features involved in virulence, DENV isolates from all four 
serotypes were characterized phenotypically in vitro by analyzing replication kinetics and 
host cell apoptosis. Human DENV isolates passaged once and originating from 
Cambodian patients with DF, DHF, or DSS, respectively, were used in order to resemble 
wild-type viruses as much as possible. 
  
A lower level of replication for all DENV isolates from DSS patients was observed in 
mammalian Vero cells regardless of serotype compared to DENV isolates from DF 
patients that all had a higher efficiency of replication. Since Vero cells are commonly 
used for titration of DENVs, these results have practical implications as wild-type 
DENVs may have different replication efficiency in these cells. 
 
The difference in viral replication was most notable when measuring viral titers, in 
contrast to quantifying vRNA copies that almost abolished the observed replication 
differences. The similar levels of intracellular vRNA despite differences in infectious titer 
indicate that a significant amount of produced viral particles are not budding competent 
and/or infectious. DENV virulence is believed to correlate to viral load within the host 
(Cologna and Rico-Hesse, 2003, Leitmeyer et al., 1999) and defective interfering viral 
particles have been suggested to influence virulence and interfere in the host immune 
response (Cave et al., 1985, Huang et al., 1986, Bangham and Kirkwood, 1990). Thus, 
measuring extracellular infectious viral titer best resembled replication differences 
between the DENV isolates and the fact similar vRNA levels were observed despite 
replication differences may have immunological implications in the host during infection. 
 
The replication patterns of isolates from DHF patients were not consistent between the 
serotypes, resembling either the DF- or DSS-derived DENV isolates. Hence, isolates 
derived from DHF patients had mixed phenotypes and could not be grouped together with 
either the DSS or the DF isolates, but instead formed an intermediate group between these 
two phenotypes. 
 
The DSS isolates were further distinguished from other DENV isolates from milder cases 
by their ability to induce apoptosis in mosquito C6/36 cells. Apoptosis was not a direct 
result of viral load since all DENV isolates replicated at equal efficiency in this cell line, 
and neither the DF, nor the DHF isolates induced apoptosis. 
 
The replication kinetics and apoptosis data gathered groups the four serotypes from DSS 
cases together, with a common phenotype clearly distinguished from the isolates derived 
from DF patients. The DHF isolates form an independent group resembling both the DSS 
and DF isolates. Results showed that phenotypic differences could be associated with 
different clinical outcome suggesting that DENVs within the same genotype may differ. 
These intrinsic virus properties could influence pathogenesis in humans.  
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8.3 IN VIVO CHARACTERIZATION IN BALB/C MICE (paper III) 
There is no appropriate animal model of DENV infection and disease, and fundamental 
knowledge such as host cell tropism, and virulence markers are still not established. The 
aim of this study was to compare wild-type features of DENV-1 isolates passaged only 
once in vitro and never previously inoculated in mouse or cultured in mouse cells prior to 
direct intravenous inoculation into BALB/c mice. BALB/c mice are susceptible to DENV 
infection although with discrete pathological features. The mice did not develop clinically 
apparent disease, and showed only discrete lesions in internal organs. However, vRNA 
was detected in various organs depending on the inoculated DENV isolate. 
 
Infection with the DF and DHF isolates peaked during the first week and the primary 
infection sites were lungs, liver, and to a certain extent brain. In contrast, the DSS isolate 
was primarily neurotropic, infection persisted longer compared to the DF and DHF 
isolates, and infected the largest number of mice. Neurotropism in mice has been linked 
with DENV virulence when studying DENV-3 isolated from Brazilian patients (Ferreira 
et al., 2010). The DSS isolate could be regarded as more virulent than the two other 
DENV-1 strains since a majority of the DSS-inoculated mice had detectable levels of 
vRNA. Furthermore, infection by the DSS isolate was less affected by the inoculum dose 
and persisted longer in a majority of mice. 
 
Cytokines involved in inflammation were quantified in serum collected from inoculated 
mice and compared in regard to DENV-1 isolate, virus titer inoculated, and time-point 
post-infection. Overall, the levels of the proinflammatory cytokines (IFNγ, IL-1β, IL-2, 
IL-6, IL-10, IL-13, MCP-1, RANTES, and TNFα) quantified were low most probably due 
to poor susceptibility of BALB/c mice to wild-type DENVs. Common for several 
cytokines, however, was a dose-dependent response to inoculated virus (IFNγ, IL-6, IL-
13, and RANTES). In general, the highest levels of measured cytokines were at the 
beginning of the experimental period (IFNγ, IL-10, and MCP-1 peaked at day 3 post-
infection). 
 
A curious finding was that DF-inoculated mice had higher serum levels of IL-10, MCP-1, 
and RANTES, which are increased in patients with severe DHF and DSS (Chaturvedi et 
al., 2000, Chaturvedi, 1999, Green et al., 1999, Azeredo et al., 2001, Chakravarti and 
Kumaria, 2006, Yang et al., 1995a, Yang et al., 1995b).  The DHF-and, most notably, the 
DSS-infected mice had vRNA in predominantly in the brain, which could imply locally 
high levels of proinflammatory cytokines that do not circulate systemically. This could 
explain why the IL-10, MCP-1, and RANTES levels dominated in the DF-inoculated 
mice, since the thoracic and abdominal organs were the primary target for the DF isolate. 
There was no difference in cytokines like IL-1β, IL-2, and TNFα compared to mock-
infected controls and this could be due to the transient nature of many cytokines as well as 
the limited susceptibility of DENVs in mice. 
 
In summary, these results indicate that DENVs within the same serotype and genotype 
may differ sufficiently to cause distinct clinical conditions in vivo. Furthermore, they 
confirm a phenotypic distinction observed in vitro with the same DENV-1 isolates where 
the DSS isolate replicated less efficiently in mammalian Vero cells compared to the DF 
and DHF isolates, but induced apoptosis in mosquito C6/36 cells (paper II). These 
findings could ultimately provide evidence for differences in virus replication, which in 
turn could influence the clinical outcomes of the infection, and partially explain some 
clinical differences observed in humans. 
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8.4 GENOMIC CHARACTERIZATION (paper II and IV) 
Despite accumulating evidence that DENVs differ in their potential to cause disease, no 
specific genotype or particular genetic signature has been directly associated to increased 
virulence and severe dengue. The genomic sequences of the open reading frame of the 
clinical, low passaged, DENVs representing the four serotypes were compared to identify 
genes potentially involved in the observed in vitro phenotypes. 
 
Genomic sequencing revealed in 81 amino acid substitutions in total and a preference for 
amino acid substitutions in the viral structural E protein, as well as the NS1, NS2A, and 
NS5 proteins. The twelve clinical DENVs compared differed at eleven positions in the E 
protein, suggesting that they elicit antibodies that may differ in their epitope specificity. 
The E protein mediate receptor binding and anti-E antibodies inhibit viral attachment, 
internalization, and replication within cells which in turn may influence host immune 
response (Johnson et al., 1994, Lee et al., 1997, Navarro-Sanchez et al., 2003). The 
SerAsn203 in the E protein of the DENV-2 DF isolate could be modified by 
glycosylation and influence target cell tropism and epitopes for antibodies. Thus, different 
E protein epitopes could ultimately modulate the course of infection. 
 
Ten amino acid substitutions were localized to both the NS1 and NS2A proteins whose 
functions are less well characterized. The NS1 protein is believed to be involved in 
dengue pathogenesis (Schlesinger et al., 1987, Avirutnan et al., 2006, Lin et al., 2002a), 
and the small hydrophobic protein NS2A is suggested to have an inhibitory role in IFN-
mediated signal transduction (Munoz-Jordan et al., 2003). Thus, these two proteins could 
be involved in the pathogenesis of dengue, but further studies are required to fully 
understand their significance.  
 
The NS5 protein contained the highest proportion of amino acid substitutions (38 % of the 
total) and the enzymatic role of NS5 in replication could explain the various replication 
profiles of the DENV isolates studied. NS5 has three major functional domains and is the 
largest DENV protein. The N-terminal MTase portion is required for the capping of the 
DENV genome, which crucial for recognition of the host cell translational machinery 
(Bartholomeusz and Wright, 1993, Egloff et al., 2002, Ray et al., 2006). The NLS part 
interacts with NS3 and cellular factors, whereas the C-terminal polymerase domain RdRp 
is responsible for synthesizing new viral RNA genomes. This suggests that the different 
phenotypes with distinct replication profiles could be due to genomic variations in the 
NS5 gene. Enhanced replication capacity in key target cells resulting in higher viral load 
and a stronger inflammatory response in the host has been proposed to increase virus 
virulence (Messer et al., 2002, Messer et al., 2003, Kanakaratne et al., 2009, Cologna et 
al., 2005, Cologna and Rico-Hesse, 2003, Vasilakis et al., 2007). Based on the examples 
given, one hypothetical mechanism for increased viral virulence suggests that virulent 
DENVs would produce more viruses per cell, resulting in higher viremia and stronger 
inflammatory response, than with a low pathogenic strain (Cologna and Rico-Hesse, 
2003, Leitmeyer et al., 1999). 
 
Reverse genetics and a larger samples pool are required to identify crucial genes and 
amino acid sequences involved in dengue pathogenesis. This comparative genomic study 
highlights certain viral genes known to be involved in antibody response, host immune 
pathways, and virus replication. 
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9 GENERAL CONCLUSIONS 
 
Dengue pathogenesis is an interplay between virus and host factors that remain 
incompletely understood (Guzman and Kouri, 2008). Explaining the heterogeneity 
between clinical presentations due to a DENV infection is a vital area of research, but has 
been hampered by the lack of suitable animal models. This thesis work has focused on 
characterization of clinical DENV-isolates originating in Cambodian children that fell ill 
to dengue in 2007 (ten patient virus isolates) and 2008 (two patient virus isolates), 
respectively. Thus, the viral isolates are derived from a homogenous group of individuals 
with similar age and ethnicity, and the DENV strains within the same serotype belong to 
the same genotype being >99 % identical. Despite these similarities, the patients 
developed dengue disease of different severity. The general aim of this thesis was to 
investigate whether these DENV strains, based on the clinical outcome in their human 
host, could be discriminated in vitro and in vivo by phenotypic discrepancies. To 
complement the phenotypic characterization, whole-genome sequencing was performed 
to relate any experimental findings with sequence data. 
 
Part of the original characterization was to be based on cell tropism preferences among 
the twelve viruses analyzed. Cell tropism was to be studied by detection of the replicative 
intermediate during active virus replication, using a strand-specific RT-PCR. However, it 
was not possible to develop a strand-specific RT-PCR due to the recognized phenomenon 
of self-priming, an intrinsic feature of the viral DENV genome. The properties of self-
priming required a complete blockage at the 3‟ end to prevent non-specific, extrinsic, 
primer independent reverse transcription (paper I). 
 
The phenotype of each clinical DENV isolate was defined by studying the viral 
replication kinetics and apoptosis induction in mammalian and mosquito cells. Regardless 
of DENV serotype, all four virus isolates from DSS patients replicated with decreased 
efficiency, compared to the virus isolates from DF patients. The four virus isolates 
derived from DHF patients had replication profiles resembling either the ones for the 
DSS-isolates, or the DF-isolates. 
 
The virus isolates derived from DSS patients were more prone to induce apoptosis in 
mosquito cells, compared to the virus isolates from milder clinical cases. This feature was 
independent of replication capacity, since all DENV isolates replicated with equal 
efficiency in mosquito cells. 
 
Genomic comparison revealed mutations spanning the whole viral genome, affecting both 
structural genes and NS genes. A majority of the mutations were located in the structural 
E protein, and in the NS1 and NS5 proteins. The E protein is crucial for virus attachment 
to the host cell, virus entry, and harbors epitopes recognized by the host humoral immune 
response. The NS1 protein exists both inside the host cell as well as in a soluble form, 
being a target for anti-NS1 antibodies. There is a general consensus based on several 
studies that the NS1 protein is implicated in dengue pathogenesis. The NS5 protein has a 
dual enzymatic activity, harboring both the MTase and the RdRp playing a vital role in 
virus replication. NS5 has also been demonstrated to induce transcription and translation 
of IL-8 (Medin et al., 2005), a neutrophil chemoattractant elevated in severe dengue cases 
(Talavera et al., 2004). Hence, the amino acid differences identified may explain the 
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different phenotypes observed in vitro, and that they could ultimately influence 
pathogenesis in humans by being more virulent (paper II and IV). 
 
The three DENV isolates of serotype-1 were characterized in vivo in BALB/c mice. 
Infection was studied during a two week period and the virus isolate from the DSS case 
was again discriminated from the two milder case isolates. The DSS isolate was unique 
with its strong preference for brain tissue compared to the two other virus isolates for 
which vRNA was found primarily in lungs and liver, and only to a limited extent in the 
brain. Infection of the DF and DHF isolates peaked during the first week, compared to the 
DSS isolate that peaked during the second week. Hence, the phenotype differences in 
vitro that revealed unique features for the DSS-isolate was confirmed in vivo, where the 
phenotype of the DSS-isolate could be regarded as more virulent (paper III). 
 
The results summarized within this thesis propose that DENVs originating from the same 
epidemic may differ in phenotype as well as in genotype. All experiments have been 
performed using minimally passaged viruses (passage 1 from mosquito cells) in order to 
resemble the wild-type virus as much as possible. The differences could be seen both in 
various cell systems in vitro, and in mice in vivo, and were correlated to unique amino 
acid substitutions in the viral genome. Hence, DENVs within the same serotype and 
genotype have different intrinsic features that may potentially be involved in virulence, 
affecting the clinical outcome of DENV infection in humans. 
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Dengue virus infection is the most frequent arthropod-borne infection affecting humans in the world.
Our understanding of the pathophysiological events leading to mild or severe outcomes of the
disease remains limited by the fact that viral target cells in the human body are poorly characterized.
One of the most sensitive strategies for detecting cells supporting active replication of this positive-
strand RNA virus is the search for the replicative intermediate, an antigenome of negative polarity, by
RT-PCR. However, a phenomenon described as ‘false priming’ of the reverse transcriptase (RT)
prevents strand-specific detection. The results of the current study showed that this event
corresponds to cDNA synthesis that is independent of any primer addition. This property was
general to all RNAs tested and was not associated with small free nucleic acids, such as tRNAs and
microRNAs. Rather, it corresponded to initiation of cDNA synthesis from the 39 end of the RNA
template, and a model is proposed in which the template RNA snaps back upon itself and creates a
transient RNA primer suitable for the RT. Such a property would explain why many assays proposed
for detection of a replicative intermediate are not specific, and may help in the development of a
molecular biology protocol that could allow replication studies of RNA viruses of human interest,
such as dengue virus, hepatitis C virus and enteroviruses.
INTRODUCTION
Dengue virus (DENV) is the most frequent mosquito-
borne virus infection affecting humans in the world (http://
www.cdc.gov/ncidod.dvbid/dengue). It is a member of the
genus Flavivirus, family Flaviviridae, and is represented by
four viral serotypes, DENV1–4, that each year affect 50–100
million people in tropical and subtropical areas. Most D-
ENV infections lead to a self-limiting febrile illness (dengue
fever), but can also result in more severe diseases, such as
dengue haemorrhagic fever and dengue shock syndrome.
The mechanisms underlying the more severe outcomes of
the infection are poorly understood.
A significant number of host factors have been shown to be
required for DENV propagation in insect and human cells
(Sessions et al., 2009), but the crucial target cells for DENV
remain controversial. DENV infection gives rise to a
viraemic phase, and the presence of DENV proteins and
nucleic acids has been detected in multiple organs (liver,
spleen, kidney, lung and bone marrow; Jessie et al., 2004)
and in circulating peripheral blood mononuclear cells,
where monocytes, but not B or T cells, have been shown to
be permissive to DENV infection (Blackley et al., 2007).
However, this detection is not necessarily associated with
active replication.
DENV has a positive-sense RNA genome of approximately
11 kb encoding three structural and seven non-structural
proteins, and is flanked by 59- and 39-untranslated regions
(UTRs) that are partially complementary (Alvarez et al.,
2005). A hallmark of active DENV replication, as with
other members of the family Flaviviridae, is the presence of
the negative-sense antigenome, which is synthesized
directly from the genome and serves as a replicative
intermediate (Cleaves et al., 1981; Peyrefitte et al., 2003).
Sensitive methods for specific detection of the negative
strand of flavivirus RNA have been repeatedly researched.
The most sensitive and specific approach for low-copy-
number nucleic acid detection is RT-PCR, and the use of
either a reverse or a sense primer during the reverse
transcription was first proposed to synthesize cDNA of
specific polarity that could be further amplified by PCR.
A supplementary figure showing Mfold RNA structure predictions for the
DENV2 in vitro transcripts used in this study is available with the online
version of this paper.
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This solution rapidly appeared to be unreliable due to a
phenomenon referred to as ‘false priming’ of the reverse
transcriptase (RT) used (Lanford et al., 1995) from avian
myeloblastosis virus (AMV) and Moloney murine leuke-
mia virus (MoMLV). Other methods have been proposed,
such as RNase-protection assays (Novak & Kirkegaard,
1991), in situ hybridization (Nouri Aria et al., 1993), high-
temperature reverse transcription (Lerat et al., 1996) and
tagged primers at the RT step (Lerat et al., 1996). New
proposals periodically emerge for improved strand-specific
RT-PCRs regarding various positive-strand RNA viruses
(Bessaud et al., 2008; Billam et al., 2008; Peyrefitte et al.,
2003). None, however, has proved to be a convincing
solution, and all face the ‘false priming’ problem of the RT.
Some hypotheses have been proposed for this ‘false
priming’: partial inactivation of the RT after the RT step
that would still be active in the PCR when forward and
reverse primers are present, possible RT activity of the Taq
DNA polymerase, the existence of a thermostable hairpin at
the 39 end of the RNA template that serves as primer for
the RT, and priming by short RNAs such as tRNAs and
microRNAs (Lerat et al., 1996). The problem associated
with non-specific amplification of the non-targeted RNA
strand, however, has never been described precisely.
Considering the importance of establishing the list of target
cells during DENV infection, we decided to characterize the
‘false priming’ event of RNA during reverse transcription,
using DENV2 as a model, in order to establish a protocol
suitable for strand-specific detection during virus propagation.
RESULTS
As observed previously by others (Peyrefitte et al., 2003),
we confirmed that initiation of the RT during RT-PCR
with DENV RNA can occur without any exogenous
primers at the RT step (Fig. 1a). DENV RNA was added
to the RT, either with a reverse primer (exogenous
priming) encompassing the very 39 end of the genome or
without primer (endogenous priming). Three regions of
the genome were targeted for PCR: nt 2323–2947 (envelope
and NS1 genes), 8016–8546 (polymerase NS5 gene) and
10546–10723 (NS5 gene and 39UTR). A positive signal was
detected, whether the RT was exogenously primed or not.
Initiation of cDNA synthesis could not be attributed to any
background activity of the DNA-dependent DNA polymer-
ase (Taq polymerase) as RNA introduced directly into the
PCR mix, with forward and reverse primers, could not be
amplified (Fig. 1a). Identical results were obtained with
another flavivirus, West Nile virus (not shown). Such
endogenous priming of the RT in RT-PCR studies has
already been described for some single-stranded positive-
sense RNA viruses, such as hepatitis C virus (HCV) (Lerat et
al., 1996) and enterovirus (Bessaud et al., 2008). We found
that endogenous priming was not restricted to this class of
viruses, as we observed it with the segmented negative-
stranded RNA virus Puumala virus (PUUV; Fig. 1b) and
hantaan virus (not shown). Moreover, it was also observed
using cellular RNAs as template, such as b-actin mRNA and
18S RNA (Fig. 1b). In each case, contamination by DNA or
background RT activity of the Taq polymerase could be
excluded, as target RNA introduced directly into the PCR
mix did not lead to a significant signal (,10% of the
positive tracks). Experiments were conducted with both
MoMLV and AMV RT, with identical results. ‘False-
priming’ events in RT-PCR studies therefore involve
endogenous priming at the RT step and do not seem to be
restricted to genomes of positive-sense RNA viruses. The
following experiments focused on DENV 2Martinique only.
To decipher whether the endogenous priming was due to
cellular small nucleic acids (DNA, microRNA, tRNA, etc.)
or to an intrinsic property of the RNA template, we
Fig. 1. Endogenous priming of viral and
cellular RNAs during reverse transcription. (a)
Cell-free DENV RNA was reverse-transcribed
(AMV) with or without primer (+/”P), amp-
lified by PCR in three regions (nt 2323–2947,
8016–8546 and 10546–10723) and ana-
lysed by agarose gel electrophoresis. As
controls, RNA was added directly to the PCR
without reverse transcription (RT ”) and H2O
was used for whole RT-PCR (RNA ”), with
primer at the RT step. (b) The same analyses
were performed on PUUV extract with primers
S237/S304 and on uninfected cell extract for
b-actin (primers OS90/OS91 and OP56/
OP57) and 18S rRNA (18S universal primer
set). Dashed lines indicate that the molecular
markers and DNA bands of interest were in the
same agarose gel, but not in adjacent wells.
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investigated the comparative levels of endogenous and
exogenous priming, in correlation with the relative amount
of DENV RNA and cellular RNA. We first mixed a set
amount of DENV genomic RNA extracted from cell-free
virus (2 ml RNA extract from virus particles released into
the supernatant of infected cells) with whole RNA purified
from uninfected cells (0, 15, 45 and 135 ng). We thereafter
performed reverse transcription with or without DNA
primer before the quantitative PCR (Leparc-Goffart et al.,
2009). The relative level of endogenous priming compared
with exogenous priming did not increase when the amount
of cellular RNA was increased (Fig. 2a). Thereafter, we
decreased the amount of cell-free genomic DENV RNA
(from 56107 to 56101 equivalent copies) in a set amount
of total cellular RNA (135 ng) and performed the same
reverse transcription and quantitative PCR analysis. We
did not observe any variation in the relative level of
endogenously primed RT compared with exogenously
primed RT (Fig. 2b). Thus, the level of endogenous
priming was not correlated to the amount of cellular
nucleic acids that could have acted as primer: endogenous
priming appeared to be a property of the template itself.
Assuming that PCR efficiency is the same whether the RT
was primed by DNA primer or not, the PCR quantifica-
tions allowed us to estimate the efficiency of the template-
mediated priming during cDNA synthesis: on average, it
represented 65±15% of the cDNA production during
exogenously primed reverse transcription.
However, we could not exclude the possibility that DENV
RNA, extracted from cell-free virus, might contain traces of
cellular nucleic acids co-packed in the viral particles that in
turn would be used as primers by the RT. This, to our
knowledge, has never been described for DENV, but in
order to reduce the amount of potential short nucleic acid
contaminants relative to the amount of targeted RNA
template, we used T7 or SP6 in vitro transcripts. These
bacteriophage polymerases are known to produce large
amounts of full-length RNA transcripts, and are even more
efficient with short RNA transcripts (Melton et al., 1984).
Therefore, we used dilutions of such in vitro transcripts to
limit the level of nucleic acid contaminants to a minimum.
An artificial mini-genome RNA of 750 nt (miniG) was
generated. This contained the first 463 nt of the DENV
genome (59UTR and capsid gene, nt 1–463) and the last
267 nt of the DENV 39UTR (nt 10456–10723), with 20
irrelevant nucleotides as a spacer (the spacer corresponded
to the multicloning site of the plasmid used for
construction of the initial DNA template). RT-PCR, with
or without primer, respectively, at the RT step was
performed, followed by a PCR spanning the entire
39UTR (nt 10456–10723). As observed previously on
DENV full-length genomes, there was a significant amount
of RT-PCR product resulting from the RT without added
primer. The same experiment was performed on a reverse
complementary SP6 in vitro transcript, corresponding to a
mini-antigenome (miniAG) of negative polarity.
Endogenous priming could once again be observed, even
in the region corresponding to the entire 39UTR of the
antigenome (nt 1–463 of DENV) (Fig. 3). As it is
practically impossible, even with DNase treatments, to
completely eliminate the initial DNA template from the in
vitro-transcribed RNA, we had some weak amplification
when using RNA template directly in the PCR (RT 2, Fig.
3). This background signal, however, was insignificant
compared with the signal observed with RT-PCR.
Due to the position of the reverse primers used at the RT
step and in the PCRs (hybridizing to the last 20 nt at the 39
end of the miniG or miniAG) used in the PCR, positive
PCR amplification in the endogenously primed samples
indicated that reverse transcription had initiated at the very
39 end of the template, or at least on the last 10 nt. This
Fig. 2. Lack of correlation between endogenous priming efficiency and the DENV : cellular RNA ratio. (a) A fixed amount of
DENV RNA extract (2 ml) was mixed with increasing amounts of total cellular RNA (0–135 ng) and, after reverse transcription
with or without exogenous DNA primer (+/”P), an equivalent copy number of DENV genomes was estimated by real-time PCR.
(b) A fixed amount of total cellular RNA (50 ng) was mixed with serial dilutions of cell-free DENV RNA (from 5 to 5�10”4 ml
diluted in water) and analysed as above. &, +P; X, ”P.
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could be concluded, as the synthesized cDNA would
otherwise have been too short for reverse primer
hybridization at the PCR step. Priming by small contam-
inating nucleic acids that randomly hybridize on short
sequences of the miniG or miniAG template would have
led to synthesis of mostly truncated cDNAs that would
have been initiated downstream from the 39 end of the
RNA template. This would have implied that no or weak
PCR amplification should have occurred. Thus, this result
confirms our previous observation that the endogenous
priming at the RT step is poorly associated with fragments
or small RNA, or even DNA. Rather, our results strongly
indicate that the major event leading to priming the RT, in
the absence of an exogenous DNA primer, is due to
priming close to the 39 end of the RNA template itself.
Thus, the event associated with ‘false priming’ of the RT
when targeting a specific RNA strand appears to be self-
priming of the RNA templates.
The 59 end (capsid gene) and 39UTR of the DENV genome
contain complementary sequences that allow long-range
RNA–RNA interactions (Alvarez et al., 2005). To check
whether intermolecular or intramolecular interactions
between DENV RNAs through their 59- and 39-end
sequences could play a part in self-priming, we assayed
self-priming with RNA in vitro transcripts that harboured
either the 39UTR (39Gen) or a reverse complementary copy
of the 59UTR (39AGen). Self-priming occurred in both
cases, thus excluding the possibility that overlap between
the genome 59 end and the 39UTR plays a significant role in
the event (Fig. 4a). Priming of the RT by RNA secondary
structures has also been proposed as an explanation for
false priming (Lerat et al., 1996). Flavivirus UTRs are
indeed highly structured (Romero et al., 2006), and false
priming events are somewhat limited when reverse
transcription is performed at high temperatures, for
instance using recombinant Thermus thermophilus (rTth)
Fig. 3. Self-priming on in vitro-RNA-tran-
scribed mini-genome or mini-antigenome. A
mini-genome (DENV nt 1–463+20 nt spacer
sequence+DENV nt 10456–10723) was
transcribed in vitro, as well as the reverse
and complementary mini-antigenome. Both
were assayed for endogenous priming by RT
(MoMLV) without primer, PCR in regions
corresponding to the 39 end and 59 end
(nt 1–463 and 10456–10723 and corres-
ponding primers) and agarose gel analysis of
the products. The absence of significant DNA
carry-over from the in vitro-transcription tem-
plate was assessed by submitting the RNA
directly to PCR (RT ”).
Fig. 4. Self-priming occurs despite the
absence of a recognizable 39 motif. (a) In vitro
transcripts covering the 39UTR of DENV
genome (39Gen, black line), or of DENV
antigenome (39AGen, grey line) were submit-
ted to reverse transcription (MoMLV) without
primer (”P), PCR (nt 10456–10723 for
39Gen, black arrows, and nt 1–463 for
39AGen, grey arrows) and agarose gel analysis
of the products. (b) In vitro transcripts
corresponding to inner regions of the DENV
genome (nt 1171–1568 and 9550–10161)
were also assayed for self-priming, with the
same controls. No particular sequence or motif
could be associated with these transcripts, as
shown by RNA structure prediction (see
Supplementary Fig. S1). The same controls
for DNA contamination were used as in Fig. 3.
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DNA polymerase at 72 uC, a temperature when RNA
structures are destabilized (Lerat et al., 1996). We used two
other in vitro RNA transcripts corresponding to the inner
regions of the DENV genome: nt 1171–1568 and 9550–
10161, respectively, which do not include the DENV UTRs.
Mfold predictions did not indicate a significant hairpin
structure for these transcripts (see Supplementary Fig. S1,
available in JGV Online). Self-priming of the two templates
could, however, be observed during the RT (MoMLV) step
(Fig. 4b). Identical results were obtained using AMV RT
(not shown). We also studied the influence of DMSO, a
chemical known to diminish the stability of RNA
secondary structures. Up to 10% DMSO in the reverse
transcription mix together with DENV RNA was used, but
we could not observe any decrease in self-priming (not
shown). Thus, our results do not indicate that a particular
RNA motif is involved in the self-priming process. This
result is perfectly compatible with the variety of RNA
templates that have been shown in previous experiments
(Fig. 1) to support the intrinsic phenomenon that we refer
to as self-priming.
We finally focused on the RT step. The in vitro transcript
corresponding to sequence nt 10456–10723 of the DENV2
genome (NS5 polymerase gene and 39UTR) was submitted
to reverse transcription by RT (MoMLV) without primer,
with a reverse primer, and with both a reverse and a
forward primer as additional controls. cDNAs were
analysed by electrophoresis on an 8 M urea/acrylamide
denaturing gel stained with ethidium bromide. Self-primed
cDNA appeared as a single band of ~250 nt, corresponding
to a full-length copy of the RNA template (Fig. 5, lane 2).
In particular, no other band or a smear was observed,
indicating, as described above, that cDNA that is
endogenously primed corresponds in a large majority to
a single product type, and corresponds to a full-length or
quasi-full-length copy of the RNA template. cDNAs
synthesized in the presence of a reverse primer appeared
to be a mixture of two products (Fig. 5, lane 3): a large
product corresponding to the primed cDNA, and a second
product, slightly less abundant, with a migration identical
to that of the self-primed cDNA of lane 2. As a control, a
third sample was analysed, with both forward and reverse
primers in the RT. The forward primer did not lead to the
synthesis of any additional band compared with RT with
only the reverse primer (Fig. 5, lane 4). Identical results
were observed with other synthetic RNAs. This confirmed
the above results: (i) endogenous priming does not occur
randomly along the RNA template, as would be expected if
free short nucleic acids were used to prime the enzyme;
(ii) endogenous priming, referred to as self-priming, can
occur even in samples where DNA priming occurs; and
(iii) self-priming of RNAs during reverse transcription
leads to the synthesis of significant amounts of unexpected
cDNA.
DISCUSSION
AMV and MoMLV RT are currently widely used to
synthesize cDNA from RNA templates, using various types
of DNA primers such as random oligonucleotides,
oligo(dT) and specific primers. These viral enzymes,
however, can initiate DNA synthesis from an RNA primer,
as described in the manufacturer’s instructions. This
property is linked to the replication of the virus they
originate from: AMV uses tRNATrp as a primer (Harada et
al., 1975), whilst MoMLV uses tRNAPro (Peters et al.,
1977); in addition, the well-studied human immunodefi-
ciency virus RT uses tRNA3
Lys. These tRNA primers are
even co-encapsidated in the virus particle (Ratner et al.,
1985). The self-priming of the RT that we observed in vitro
on various ‘wild-type’ or synthetic templates is therefore
not surprising, and has already been noted in the literature.
Our first results (Fig. 1) confirmed that the phenomenon is
not restricted to positive-sense RNA viruses and indicated
that it leads to a significant production of unexpected
cDNA, corresponding to ~65% of exogenous DNA
priming (Fig. 2), whatever the sequence or structure of
the template may be (Figs 3 and 4).
We showed that free nucleic acids are poorly associated
with endogenous priming (Figs 3, 4 and 5): this process
appears to be only template-mediated. However, we have
not characterized the exact molecular events leading to the
initiation of cDNA polymerization at the 39 end of the
RNA template. Fig. 5 indicated that self-primed cDNA are
slightly shorter than DNA-primed cDNA (see lanes 3 and
4). This could fit a snapped-back RNA priming model in
which the 39 end of an RNA loops back upon itself to form
short and transient RNA–RNA duplexes that could serve as
primers for the polymerase. Such a mechanism would
firstly imply that the RT will prime from an RNA–RNA
Fig. 5. Denaturing gel analysis of cDNAs produced during self-
primed and DNA-primed reverse transcription on in vitro tran-
scripts. The 39Gen in vitro transcript (lane 1, faint band, indicated
by an arrow) was submitted to reverse transcription (MoMLV)
without DNA primer (P”; lane 2), with reverse primer (Prse; lane 3)
or with reverse and forward primer (Prse+Pfwd; lane 4). cDNAs
were analysed by denaturing urea/acrylamide gels and ethidium
bromide staining.
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hybrid consisting of a few nucleotides, as the 39 end of an
RNA usually does not have any particular complementarity
to any sequence elsewhere in the molecule. During the
retrovirus cycle, AMV or MoMLV RT priming occurs
through hybridization between a primer-binding site,
situated at the 39 end of the retroviral genome, and 15–
18 nt of a tRNA (Wakefield et al., 1995). However, the
minimal length requirement for AMV RT priming by DNA
has been shown to be as few as 4 nt (Falvey et al., 1976).
This indicates that, although nucleic acid pairing on 4 nt is
thermodynamically unstable, the hybrid between the RNA
template and the short priming oligonucleotide can be
maintained long enough for the RT to initiate its activity
(Isel et al., 1996). The primer requirement by RTs therefore
appears to be quite weak. The situation is the same for
RNA-dependent RNA polymerases, which can even
perform de novo initiation (Laurila et al., 2005). As a
comparison, Taq polymerase can only prime from DNA–
DNA hybrids longer than 9 nt (Williams et al., 1990),
which may explain why the self-priming phenomenon is
not observed at the PCR step, as well as why random
hexamers when used in RT do not interfere with the PCR
step. Secondly, such snapped-back priming has already
been observed by others with RNA-dependent RNA
polymerases, such as phage w6 polymerase (Laurila et al.,
2005) and with RT: Simpson et al. (2004) studied cDNA
synthesis from a synthetic 90 nt RNA by retroplasmid RT
(pFOXC RT) and used MoMLV RT as a control. Both RTs
could perform cDNA synthesis with or without a DNA
primer. Self-primed RT products corresponded to an ~170
nt RNA–DNA hybrid (pFOX RT and MoMLV) that the
authors associated with elongation of the 39 end of the
RNA template that had snapped back upon itself. Self-
primed MoMLV additionally produced a simple DNA of
~80 nt, indeed a cDNA not bound to the 39 end of the
RNA template. Simpson et al. (2004) mentioned that
snapped-back priming can recover different forms,
depending on the enzyme and reaction conditions. This
may explain why we observed only a basic form of the
cDNA that has the same length as the RNA template (Fig.
5) but not a long hybrid form. The exact mechanism would
need further analysis, but this snapped-back priming
model is compatible with our observations and other
reports. As a comparison, it has been precisely described.
Enzyme suppliers mention that DNA primers are generally
more efficient than RNA primers, and one could expect
that self-primed cDNA synthesis could be a marginal event
when a specific DNA primer is added in a sample. Our
results (Fig. 5, lanes 3 and 4) indicate that this is obviously
not the case. Additionally, AMV RT has been shown to use
both tRNA and DNA primers efficiently to initiate cDNA
synthesis, on two loci of a single identical RNA template,
and exhibited no drastic preference for one or other primer
(Whitcomb et al., 1995). This implies that self-priming will
arise in conventional RT reactions where an exogenous
DNA primer is present. Any competition that could favour
DNA priming compared with RNA priming would be
balanced anyway by the fact that RT enzymes are present
nowadays in excess in standard RT reactions.
When working on strand-specific detection of viral RNAs,
self-priming at the RT step will therefore result in the
synthesis of cDNA copies of both positive and negative
polarity, in addition to the exogenously primed DNA,
whatever strand-specific primer is added. cDNAs of both
polarities will then be amplified at the PCR step, without
respect to orientation. Due to optimized RT conditions
(buffers and RT enzymes), long-range cDNA synthesis can
be completed, and any target region of the genome, even
far away from the RNA 39 end, will be affected by intrinsic
self-priming, as we confirmed (Fig. 1a).
Various strategies have been reported to achieve strand-
specific amplification. In tagged PCR, the RT primer has a
unique tag sequence at its 59 end in addition to the
complementary sequence that will be used for specific
amplification at the PCR step (Bessaud et al., 2008; Billam
et al., 2008; Lerat et al., 1996; Peyrefitte et al., 2003). The
tagged primer system, however, cannot overcome the
interference of snapped-back priming. During the first
cycle of the PCR, the forward primer can hybridize to the
self-primed cDNA, whereupon any tagged primer from the
RT step will hybridize to this second strand and initiate the
synthesis of an amplicon consisting of both the forward
and tagged primer sequence. The resulting amplicon will be
further amplified through efficient binding of the tagged
and forward primer, and the strand specificity will thereby
be lost.
Reports with data from purified in vitro transcripts or cell-
free virus extracts, however, have mentioned that some
strand specificity can be achieved, although to a limited
extent, using a tagged RT-PCR system. Discrimination
between the positive and negative strand can reach a factor
of 10
6 (Carriere et al., 2007; Lerat et al., 1996; Mizutani et
al., 1998), which should be satisfactory when studying
clinical samples of viruses that have a relatively low level of
replication, such as hepatitis A or C virus or DENV. Such
results were obtained with RNA extracted from quite pure
samples. Interestingly, strand specificity of an HCV tagged
RT-PCR assay was shown to be better with serum extracts
than with liver extracts, although the total quantities of
HCV RNA were comparable (Lerat et al., 1996). This
indicates firstly that the reliability of a strand-specific assay
validated under in vitro conditions may not be suitable for
clinical studies. Secondly, the discrepancy in the results
depending on the sample could find an explanation in a
snapped-back model: magnesium ions for instance, which
are essentially intracellular, are present at significantly
higher concentrations in liver extracts than in sera, and a
high Mg2+ concentration stabilizes nucleic acid hybridiza-
tion in RT-PCR. Snapped-back RNA could therefore be
favoured in tissue extracts, which would result in a reduced
specificity of the assay. Even though various HCV strand-
specific systems have been proposed, detection of the
negative RNA strand of HCV with tagged RT-PCR is still
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controversial (Carriere et al., 2007; Laskus et al., 1997; Lin
et al., 2002). Some protocols aimed at reducing the
problematic carry-over of tagged primers from the reverse
transcriptase to the PCR have also been proposed. These
methods involve nuclease digestion and size exclusion
(Bessaud et al., 2008; Craggs et al., 2001; Peyrefitte et al.,
2003), but none of these methods can completely remove
the tagged primers, and will in addition result in loss of
material. As detection of the replicative intermediate is of
major interest for viruses with a relatively low level of
replication (such as hepatitis A, C or E virus or DENV),
such methods appear to be of limited interest.
Some authors have used a thermophilic RT approach
(Craggs et al., 2001; Lanford et al., 1995; Laskus et al.,
1998). The Tth RT works efficiently at 65 uC and has been
shown in vitro to achieve a discrimination factor between
strands of up 108 transcribed HCV RNAs, whereas the
conventional MoMLV RT used at 42 uC could only achieve
a factor of 104 (Laskus et al., 1998). High-temperature
reverse transcription with various combined tagged RT-
PCR strategies, however, failed to completely overcome the
phenomenon of unwanted detection of the incorrect strand
of RNA (Craggs et al., 2001). The snapped-back priming
model is again compatible with these observations, as a
high temperature will reduce, but not eliminate, the
capacity of the template RNA to form short and transient
back-loops at its 39 end.
We investigated several alternative strategies to overcome
the snapping back of the non-targeted RNA strand. We
first designed tagged primers that had a DENV-specific
sequence of only 10 nt. Such primers were expected to
hybridize on DENV sequences at low temperature, and
thereby to allow the tagged reverse transcription to occur,
but would be too short for efficient binding on self-primed
cDNA at the PCR step. Endogenous priming of the RT was,
however, still efficiently detected at the PCR step (data not
shown). It has been reported that oligonucleotides blocked
at their 39 end (to prevent extension) and modified on the
last 59 bases by phosphorothioate (to resist any 59
exonuclease digestion) (Boiziau et al., 1994) or peptide
nucleic acids (Koppelhus et al., 1997) bound to RNA
templates can block AMV or MoMLV RT. A derived
antisense oligonucleotide strategy could thus stop the RT
on a non-targeted RNA strand and prevent full-length
cDNA synthesis on the wrong strand. In our hands,
however, such a protocol turned out to be unsuccessful
(not shown). The strong strand-displacement activity of
AMV and MoMLV RT, which is useful for the synthesis of
long cDNAs on highly structured RNAs, may have
impaired the blocking of the enzyme by the oligonuc-
leotides. RNase H digestion of the non-targeted strand
using a strand-specific 39-end blocked oligonucleotide
before the reverse transcription was also unsuccessful
(not shown). We then tried to avoid the RT step by
employing a ligation-mediated PCR (Hsuih et al., 1996).
This approach relies on the hybridization of non-
amplifiable hemiprobes on the template, ligation and
subsequent assembly of PCR-amplifiable DNA. Such a
protocol cannot be applied directly to RNA as there is no
enzyme that can ligate DNA oligonucleotides in DNA–
RNA hybrids. Strand discrimination could therefore occur
only after first-strand synthesis. Standard protocols (Hsuih
et al., 1996) or even a SALSA system (MRC Holland),
which has been developed for multiplex ligation-dependent
probe amplification with a specific ligase that should have a
poor activity on non-hybridized hemiprobes, could not
achieve satisfying specificity (not shown).
The search for replicative intermediates of flaviviruses
therefore remains unsolved, and all protocols published to
date remain to some extent unsatisfying. Our data favour a
snapped-back priming model of the reverse transcriptase,
which clarifies what was reported before as ‘false priming’.
This model is also compatible with previous observations
made on DENV, hepatitis viruses or enteroviruses and can
also provide an explanation for some controversial results
in in vitro or clinical assays. Depending on buffers, the
quality of the RT enzymes, reaction temperature and the
stability of the RNA back-loops, the rate of RT initiation
through snapped-back RNA would vary and thereby affect
strand-specific detection. As more efficient enzymes and
RT-PCR kits are being developed, snapped-back priming
of the RT is a problem of increasing importance in the
identification of target cells for flaviviruses and other
single-stranded RNA virus infections.
METHODS
Cells. C6/36 cells (Aedes albopictus larva cells, ATCC CRL-1660) were
grown at 28 uC in Leibowitz’s L15 medium (BioWhittaker Europe)
supplemented with 2% tryptose phosphate broth and 5% fetal calf
serum. Vero E6 cells (ATCC C1008) were grown at 37 uC in MEM
199 (Invitrogen) supplemented with 5% fetal calf serum.
Viruses. DENV2 strain Martinique (H/IMTSSA-MART/DEN2/98-
703) was propagated on C6/36 or Vero cells. PUUV (patient isolate)
or hantaan virus (strain 76-118) were propagated on Vero E6, as
described previously (Hardestam et al., 2008). For experiments with
cell-free virus, the supernatant of infected cells was collected before
cell death and clarified by centrifugation at 1500 g for 10 min before
RNA extraction.
Viral RNA extraction. Viral RNA was extracted from 140 ml infected
cell lysate or supernatant using a QIAmp Viral RNA Mini kit
(Qiagen) according to the manufacturer’s instructions. The eluted
RNA was stored at –80 uC until use.
RT-PCR. Reverse transcription was performed with AMV (Promega)
or MoMLV (Superscript III; Invitrogen) RT according to the
manufacturer’s instructions. AMV reactions comprised 2 ml RNA
extract in buffer containing 50 mM Tris/HCl (pH 8.3) at 25 uC,
50 mM KCl, 10mM MgCl2, 0.5 mM spermidine, 10 mM dithio-
threitol, 2 U AMV, 1 ml 10 mM dNTP mix (New England Biolabs)
and 1 ml specific 10 mM primer (where required; Eurogentec).
MoMLV reactions comprised 2 ml RNA extract in buffer containing
50 mM Tris/HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 1 ml 0.1 M
dithiothreitol, 40 U enzyme, 1 ml 10 mM dNTP mix and 1 ml specific
10 mM primer (where required). The reactions were incubated for
40 min at 40 uC, followed by 10 min at 95 uC to inactivate the RT
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enzyme. For cDNA analysis on polyacrylamide/8M urea gel, the
amounts of RNA were increased to 10 ml. Otherwise, 2 ml of the RT
reactions was added to the PCR in a final volume of 20 ml, using
standard protocols, using either using Taq PCR Mastermix (Qiagen)
(35 cycles of 95 uC for 20 s, 58 uC for 30 s and 72 uC for 1 min) for
standard PCR or Platinum PCR Supermix (Invitrogen) (40 cycles of
95 uC for 15 s and 60 uC for 45 s) for real-time PCR in a LightCycler
apparatus (Roche).
The results of end-point PCR were analysed on a 1% agarose gel
stained with ethidium bromide.
Primers. Most primers were synthesized in the laboratory and were
used in this study because of availability. They were based on the
DENV2 H/IMTSSA-MART/DEN2/98-703 sequence (GenBank acces-
sion no. AF208496), nt 2323–2343, 2947–2927, 8016–8036, 8546–
8526 and 10723–10703 (Fig. 1); nt 1–20, 463–443, 10456–10476 and
10723–10703 (Fig. 3); and 1171–1191, 1568–1548, 9550–9570 and
10161–10141 (Fig. 4). Other primers were from Eurogentec: OS90
(59-TCCTGTGGCATCCACGAAACT-39) and OS91 (59-GAAGCA-
TTTGCGGTGGACGAT-39), and OP56 (59-TGGAGTCCTGTGG-
CATCC-39) and OP57 (59-GTGTAACGCAACTAAGTCA-39) target-
ing human b-actin, an 18S PCR primer pair (Quantum RNA
Universal 18S; Ambion), S237 and S304 targeting PUUV (Evander
et al., 2007) and DenF, DenR and DenP from a pan-dengue Taqman
system (Leparc-Goffart et al., 2009).
In vitro transcription and PAGE analyses. In vitro transcription
was carried out using plasmid constructs or PCR products containing
the expected promoter sequences with a T7/SP6 Ribomax large-scale
RNA production system (Promega). For denaturing gel analysis, the
cDNA was mixed in equal volumes with a buffer containing 95%
formamide, 0.025% xylene cyanol, 0.025% bromophenol blue,
0.5 mM EDTA and 0.025% SDS, boiled for 5 min and put on ice
to prevent secondary-structure reformation, and loaded on a
denaturing 10% polyacrylamide gel [7.2 g urea, 3.75 ml 40%
ProSieve 50 (Takara), 16 TBE, 16 ml TEMED, 120 ml 10% APS],
which was eventually stained in an ethidium bromide bath and
visualized under UV.
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Abstract Dengue viruses (DENV) cause 50-100 million
cases of acute febrile disease every year, including 500,000
reported cases of dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS). Viral factors have been
proposed to influence the severity of the disease, but
markers of virulence have never been identified on DENV.
Three DENV serotype-1 isolates from the 2007 epidemic
in Cambodia that are derived from patients experiencing
the various clinical forms of dengue were characterized
both phenotypically and genetically. Phenotypic charac-
teristics in vitro, based on replication kinetics in different
cell lines and apoptosis response, grouped isolates from DF
and DHF patients together, whereas the virus isolate from a
DSS patient showed unique features: a lower level of
replication in mammalian cells and extensive apoptosis in
mosquito cells. Genomic comparison of viruses revealed
six unique amino acid residues in the membrane, envelope,
and in non-structural genes in the virus isolated from the
DSS patient.
Introduction
Dengue viruses (DENV) (serotypes 1, 2, 3 and 4) belong to
the genus Flavivirus, in the family Flaviviridae. They are
enveloped viruses with a positive-sense single-stranded
RNA genome of approximately 10 700 bases. Upon
infection, the genome is translated in the cell cytoplasm
into a polyprotein, which is secondarily cleaved into three
structural proteins (C, prM, E) and seven non-structural
proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5)
[1].
Dengue is the most frequent arthropod-borne viral
infection in the world affecting humans, with one hundred
million estimated cases per year. It is endemic in more than
one hundred countries and more than 500 000 severe forms
of the disease, dengue hemorrhagic fever (DHF) or dengue
shock syndrome (DSS), are reported annually, most of
them affecting children under 15 years of age [2]. DENV
has adapted completely to humans and is maintained in
large urban areas in the tropics in human-mosquito-human
transmission cycles that no longer depend on animal res-
ervoirs. Such reservoirs, however, can still be found in the
jungles of Africa and Southeast Asia in mosquito-monkey-
mosquito transmission cycles [3].
Most of dengue infections remain asymptomatic.
Apparent disease due to dengue virus varies from a
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relatively self-limited though debilitating febrile illness,
dengue fever (DF), to the more severe and potentially life-
threatening diseases DHF and DSS. The molecular mech-
anisms underlying dengue illness and the exact factors
contributing to disease progress, however, are far from well
understood. Host factors, such as age, gender, nutritional
status, and genetics are known disease parameters. Fur-
thermore, previous DENV infections and maternal anti-
bodies seem to interfere and affect the outcome of an
ongoing DENV infection [4–6].
Epidemiological data indicate, however, that viral fac-
tors should also influence the outcome of the disease and
that the virulence differs among DENV strains, including
strains within the same serotype [7–9].
Although dengue virus strains are easily differentiated
on a genotypic basis, no phenotypic profile of ‘‘virulent’’ or
‘‘avirulent’’ strains has been established, except for a few
strains that have been attenuated for vaccine purposes.
DENV isolates from children representing the three
clinically distinct forms of dengue disease were character-
ized genotypically by genomic sequencing and phenotypi-
cally by analyzing replication kinetics, apoptosis, and
adaptation to cell culture. Regarding phenotypic character-
istics (replication kinetics and apoptosis patterns), the strain
isolated from a patient experiencing DSS, the most severe
form of dengue disease, differed significantly from the
DENV isolates obtained from patients with DF and DHF.
This strain also showed a remarkable ability to rapidly adapt
to in vitro culture. Interestingly, at the genomic level, this
strain exhibited six unique amino acid substitutions.
These observations group DENV obtained from DF and
DHF cases together, whereas the DSS virus isolate stands
alone when comparing virus isolate characteristics. Toge-
ther, clinical observations and in vitro data suggest that the
virus isolated from a DSS case can be distinguished from
those obtained from DF and DHF patients, which appear
similar.
Materials and methods
DENVs
Three dengue serotype 1 viruses isolated during the 2007
outbreak from patients living in the Kampong Cham
province, Eastern Cambodia, were used during this study
(Table 1). The isolates were obtained from patients expe-
riencing the three distinct clinical forms of dengue disease:
DF, DHF, and DSS, according to the WHO classification
[10]. Blood samples were drawn between days 2 and 6 after
onset of disease. These samples were collected during the
DENFRAME study (a project supported by European
Union) and immediately anonymized as stated in the
research protocol. The DENFRAME project was approved
by the National Cambodian Ethics Committee, and a
patient’s enrolment was subject to obtaining a written
consent signed by the patient or, for those under 16 years
old, their legal representatives. The patients specifically
agreed that their blood samples may be stored and that
further tests on these samples may be undertaken in the
future to further understand dengue disease.
Each isolate had been isolated at the Institut Pasteur in
Cambodia (IPC) in the standard cell line C6/36, derived
from Aedes albopictus (CRL 1660, ATCC), and thereafter
had undergone only one in vitro passage (P1) in order to
avoid mutations that might be associated with tissue culture
adaptation. Cell culture supernatant was stored at -80�C
prior to shipment on dry ice to the French Army Bio-
medical Research Institute (IRBA, Marseille). The isolates
were serotyped at IPC by nested reverse transcriptase
polymerase chain reaction according to the Lanciotti pro-
cedure modified by Reynes et al. [11].
Cells
Mammalian Vero cells (CCL-81, ATCC) were grown at
37�C, 5% CO2, in cell culture medium 199 (Gibco) with
5% fetal calf serum (FCS). The A. albopictus cell line C6/
36 was grown at 28�C, in cell culture medium Leibovitz-15
with 5% FCS and 2% tryptose phosphate (TP).
Immunofluorescence with HB112 and J2 for detection
of DENV infection and DENV titration by fluorescent
focus assay (FFA)
5 9 105 C6/36 cells per well were seeded in 96-well plates
(Corning) and incubated for 24 h prior to infection. Viru-
ses, duplicates of 10-fold dilutions, were prepared with cell
culture medium (FCS-free), and 50 lL of diluted virus was
inoculated in each well and incubated for 2 h. To immo-
bilize the virus, an overlay medium (0.7% high-viscosity
carboxymethyl cellulose (CMC), Sigma-Aldrich, 1X
MEM-medium, 2% TP, 5% FCS) was added on top of the
cells, followed by a 72-h incubation. The overlay medium
was discarded, and the cell monolayer was gently washed
once with cell culture medium before fixation with para-
formaldehyde (3.7%, pH 7.4) and incubated for 15 min at
Table 1 Epidemiological and clinical characteristics associated with
dengue virus serotype 1 isolates used in the study
ID Epidemic
year
Sex Age Type of antibody
response
Clinical
outcome
R0627319 2007 M 7 Secondary DF
R0627321 2007 F 5 Indeterminable DHF
R0808258 2007 F 9 Secondary DSS
A. Tuiskunen et al.
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room temperature. The cell monolayer was then washed
once with PBS (1X) followed by a 5-min incubation with
Triton-X 100 (0.5 %) in order to permeabilize the cells.
Two washes with PBS (1X) followed before adding a
blocking solution (2.5% FCS, 1% BSA in PBS (1X)), and
the cells were incubated at 37�C for 30 min. A primary
panflavi anti-envelope monoclonal antibody (MAb)
(HB112TM, ATCC) or a MAb for staining double-stranded
RNA (J2, English and Scientific Consulting, Hungary) was
added to the fixed cells and incubated for 30 min at 37�C,
followed by two washes with PBS (1X) before applying a
goat anti-mouse IgG A488-conjugate (1:250 dilution,
Gibco) and incubating at room temperature for 45 min. In
order to stain the eukaryotic nuclei, Dapi (40,6-diamidino-
2-phenylindole; Sigma-Aldrich) was added at a 1:5000
dilution, and the cells were incubated for 30 min at 37�C.
The monolayer was then washed three times with PBS
(1X), and plaque-forming units (PFU) were counted under
a microscope.
Viral RNA extraction and real-time one-step
quantitative RT-PCR
Viral RNA was extracted from lysed cells and cell super-
natant using a QIAmp Viral RNA Mini Kit. RT-PCR
reactions were set up according to the manufacturer’s
instructions (SuperScript III Platinum One-Step Quantita-
tive RT-PCR System, Invitrogen) as already described
[12].
Kinetics of DENV replication in various cell lines
Replication kinetics was investigated under three different
conditions: on mosquito C6/36 cells at 28�C, on mamma-
lian Vero cells grown at 37�C (5% CO2) and on Vero cells
at 40�C (5% CO2). The C6/36 cells were seeded to con-
fluence at 170,000 cells per well (3.8 cm2) in a 12-well
plate, and the Vero cells were seeded to confluence at
110,000 cells per well. The cell medium was discarded,
and the monolayer of C6/36 cells was washed once with
L-15 medium (with 2% tryptose phosphate broth). The
monolayer of Vero cells was washed once with PBS (1X).
An inoculum of 500 lL per well was used for infection at a
multiplicity of infection (MOI) of one. The virus was
diluted in cell medium (FCS-free), and virus free-cell
culture medium was used for mock infection. The cells
were then incubated for 2 h at the appropriate temperature.
The inoculum was removed, and the cells were gently
washed with PBS (1X). Two mL per well of the appro-
priate cell medium (supplemented with 5% FCS) was
added, followed by incubation at the corresponding tem-
perature. Samples of both supernatant and cells were har-
vested daily throughout the week and used for viral RNA
extraction and virus titration. C6/36 cells were harvested by
scraping them off and dissolving them in 2 mL of cell
culture medium. Vero cells were harvested by adding
500 lL trypsin 2-3 minutes before adding 1.5 mL of cell
culture medium to obtain a homogenous cell suspension.
Evolution of DENV in persistently infected Vero cells
Four T-25 flasks were seeded with 433,000 Vero cells each
and infected with one dengue virus isolate each at an MOI
of one. The cell medium was discarded and the cell
monolayer washed once with PBS (1X) prior to infection
and incubated for 2 h at 37�C, 5% CO2. The inoculum was
then discarded and the cells washed with PBS (1X). Ten
mL of medium 199 (5% FCS, Invitrogen) was added to
each flask, and the cells were incubated for one week at
37�C, 5% CO2. Seven days post-infection, 2 mL of each
supernatant was transferred to a new T-25 flask containing
433,000 cells and infected as described above. This
supernatant was then used to infect new cells seven days
later, and so on for ten weeks.
The cells from the old flasks were split by first washing
with PBS (1X) and then trypsinizing (Gibco), and 1/7 of
the cells in a total volume of 10 mL were transferred to a
new T-25 flask and incubated for a week. Those cells were
subsequently split each week into a new T-25 flask, and the
infection was thereby maintained until week 10, when the
experiment was terminated.
Samples were harvested each week, and Lab-Tek slides
(Nunc) were prepared in parallel to the cell culture flasks to
perform immunofluorescence.
Apoptosis TUNEL assay
Vero and C6/36 cells were grown on Lab-Tek chamber
slides (0.8 cm2 per well). Vero cells were seeded with
20,800 and 41,600 cells per well to 50%, and 100% cell
confluence, respectively, at the start of infection. C6/36
cells were seeded with 5 9 105 and 16 9 105 cells per well
to approximately 50%, and 100% cell confluence, respec-
tively. The cells were infected at an MOI of one and
incubated for 24, 48, or 72 h or six days. The cells were
then stained for the presence of dengue virus antigen using
the HB112 and J2 MAbs, as well as for apoptotic cells
using TUNEL staining (terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick end labelling). Apoptosis was
detected using an In Situ Cell Death Detection Kit Red
(Roche) according to the manufacturer’s instructions, and
cells were stained for 1 h at 37�C. Staurosporine (Sigma)
was used as a positive control for apoptosis [13]. One
micromolar staurosporine was added to Vero and C6/36
cell cultures, followed by 24 and 48 h of incubation at
37�C and 28�C, respectively.
Characterization of dengue virus isolates
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Sequencing
Viral genomic RNA was isolated from infectious super-
natant from the first passage propagated in C6/36 cells,
which is believed to confer the lowest possible level of
selective pressure, using a QIAamp Viral RNA Mini Kit
(QIAGEN). RT was performed using the SuperScript First
Strand Synthesis System for RT-PCR (Life Technologies)
with gene-specific primers or by self-priming. Phusion
Hot-Start High Fidelity DNA Polymerase (Finnzymes) was
used to generate overlapping PCR fragments of approxi-
mately 1000 nucleotides, which were purified by gel
electrophoresis followed by gel extraction using a MinE-
lute Gel Extraction Kit (QIAGEN) and eluted in 10 lL
water. DENV1-virus-specific primers were used for two-
directional sequencing. Primers were designed for
sequencing both strands (Sanger sequencing using
ABI3739XL technology and the PhredPhrep program) of
the PCR product, from which consensus sequences were
assembled.
Results
FFA titration on C6/36 cells
The most common method to titrate DENV for a long time
has been based on cytopathic effect (CPE) in monkey Vero
cells or rodent BHK-21 cells. This method is widely used
for high-passage laboratory DENV strains. Unfortunately,
most of primary (or low-passage) DENV isolates from
patient sera do not give any CPE on these cells. To over-
come this problem, a FFA using C6/36 cells was developed
for DENV titration. C6/36 cells are commonly used for
DENV isolation and propagation, which explains why
these cells were the natural choice for the development of
the FFA for virus titration. As seen in Fig. 1, distinct foci
(clearly separated from each other) appeared as the virus
was more diluted, resulting in a manageable number of foci
to be counted for titre estimation.
Depending on the DENV strain, a decrease in the titre
was observed after a freezing step at -80�C. For all of our
experiments with a specified MOI, it was important to
ensure that the initial titre of each strain was stable at each
step of freezing and thawing. We have tested different
freezing solutions containing sucrose and/or HEPES. The
titre was stable for two years at -80�C for viruses frozen in
0.5 M sucrose and 50 mM HEPES and also after few
freezing/thawing cycles (data not shown).
Replication kinetics of wild-type DENV isolates
obtained from patients experiencing various degrees
of dengue illness severity
We investigated the replication kinetics of various clinical
DENV isolates in order to characterize them phenotypi-
cally in mammalian and mosquito cell lines. Viruses from
supernatants and cells were titrated by FFA and by quan-
tification of total viral RNA using a quantitative RT-PCR.
Similar kinetics were obtained using these two methods.
All of the isolates replicated with similar efficiency in
the mosquito cell line C6/36, with close to 100% of cells
infected (Figs. 2a, 4).
In mammalian Vero cells at 37�C, strains isolated from
patients experiencing DF and DHF showed identical
growth kinetics, reaching viral titres of 106 RNA copies/ml
(around day 5-6 post-infection). However, the isolate
obtained from the patient with the shock syndrome showed
restricted replication in Vero cells, with a loss of more than
one log in titre (Fig. 2). Immunofluorescence with a pan-
flavi anti-envelope monoclonal antibody and with a MAb
detecting active virus replication (J2, targeting double-
stranded RNA) showed a constantly low level of cells
infected with the DSS virus (around 10%) compared to DF
and DHF isolates, which infected 100% of the cells
(Fig. 3).
Fig. 1 Titration of a DENV serotype 1 DSS isolate on C6/36 cells, passage 1, stained with HB112 antibody (green) and Dapi (blue). The red
circle indicates a fluorescent focus that is well separated from its surroundings
A. Tuiskunen et al.
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Finally, there was no difference in the kinetic for the
three DENVs when infecting Vero cells at 40�C (data not
shown).
Apoptosis due to DENV infection
We studied apoptosis in C6/36 and Vero cells to investigate
whether the DSS isolate differed from the DF and DHF
isolates, as was observed in the replication kinetics. The
cells were stained at four time-points (?24, ?48, ?72 h
and ?6 days p.i.) in order to follow the development of
apoptosis along the course of infection. The experiment
was repeated at two different levels of cell confluence,
since this parameter influences the degree of apoptosis.
None of the DENV isolates induced a significant degree
of apoptosis on Vero cells, regardless of whether the cells
were fully confluent or only 50% confluent (data not
shown).
The DF and DHF virus isolates did not induce a sig-
nificant degree of apoptosis on C6/36 cells, regardless of
cell confluence (Fig. 4). With the DSS isolate, however, at
least 30% of the C6/36 cells were already undergoing
apoptosis during the first 24 h of infection, and the number
of apoptotic cells continued to increase to 50% during the
following days (Fig. 4). This did not depend on the initial
cell confluence at the time of infection (apoptosis in 50%
and 100% confluent cells was compared). The apoptotic
signal one day after infection was found in surrounding, not
yet infected cells, rather than in infected cells (Fig. 4).
Virus titration and viral RNA quantification using real-time
quantitative RT-PCR confirmed that all the three DENV
isolates had similar replication kinetics in C6/36 cells (data
not shown). Thus, the DSS isolate caused a much higher
degree of apoptosis in C6/36 cells compared to the DENV
DF and DHF isolates, regardless of replication kinetics.
Adaptation of DENV isolates in persistently infected
mammalian Vero cells
After having observed the strong replicative restriction of the
DSS strain in Vero cells, we investigated the ability of the
virus to establish a persistent infection compare to other
isolates. Infected Vero cells were propagated for ten weeks
by splitting them weekly, as well as by transferring the
infectious supernatant to newuninfectedVero cells. All three
DENV isolates had the characteristic of establishing a per-
sistent infection inVERO cells for at least tenweeks (Fig. 5).
For the DSS isolate, the two first weeks of infection
showed the same low level of replication with 10% of cells
infected, as observed during the kinetics’ experiment.
However, after 3 weeks, there was an increase in replication,
Fig. 2 Replication kinetics of DENV isolates in mosquito C6/36
cells and in mammalian Vero cells at 37�C determined by measuring
the copy number by quantitative RT-PCR in supernatants and in cells.
These data are the average of three independent experiments. The
standard deviation error bars are too small to be seen in this figure on
a log scale (see supplementary data)
Fig. 3 Replication of DHF and DSS isolates at day 6 p.i. in Vero
cells stained with J2 antibody (magnification X40) and DAPI
(nucleus) or stained with HB112 antibody and DAPI (magnification
X20)
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with 50% of the cells infected. At week four, there were no
longer significant differences in replication activity between
the three isolates with 100% of cells infected, leading to viral
titres as high as 106 to 108 FFU/ml (Fig. 5). The passaged
viruses showed the same characteristics both for the pas-
saged infected cells and the passaged infectious supernatant.
Thus, the DSS isolate could achieve adaptation to Vero cells
in only 3-4 in vitro passages despite the low level of repli-
cation during the first two passages.
Genomic analysis of the three DENV isolates
Complete sequences of viral genomes for the DF (accession
number: HQ624983), DHF (accession number: HQ624984)
and DSS (accession number: FJ639694) isolates were
obtained. These three isolates belong to genotype 1. There
are numerous sequence variations at the amino acid level
between these three DENV-1 strains, which were isolated
during the same outbreak (Table 2). The sequence of the
DSS isolate differed from the other two by six amino acids,
with mutations located in the membrane gene, the envelope
gene, and the non-structural (NS) 1, NS3 and NS5 genes.
The adapted DSS isolate after five passages of Vero cells
was also sequenced, and four amino acid changes had
appeared in the envelope, 2K,NS4b andNS5 genes (Table 2).
Discussion
Epidemiological, phylogenetic, clinical and experimental
data indicate that viral factors could influence the severity
of dengue infection [7–9, 14, 15].
Fig. 4 Apoptosis on confluent
C6/36 cells at 24 h postinfection
and 6 days postinfection.
TUNEL staining (red) and
DAPI staining (nucleus, blue)
combined with either HB112 or
J2 antibodies (green)
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This study was aimed at investigating phenotypic as
well as genotypic differences between clinical DENV
serotype-1 isolates from Cambodian patients experiencing
various degrees of dengue disease severity (DF, DHF and
DSS). These virus isolates, which were from the same
outbreak, represented a good model to investigate if phe-
notypic properties associated with a specific genetic
background could characterize them. It should be noted at
this point that this study is preliminary and is limited by the
number of isolates used. However, the data obtained
showed that both at the genotypic and phenotypic level,
differences could be found associated with different clini-
cal outcome.
Previous laboratory experiments have shown that DENV
could adapt to cells in vitro very quickly, associated with
genetic and phenotypic changes [16, 17]. In our study, we
also showed that the characteristic of the DSS isolate
replicating less efficiently in mammalian cells was lost
after three in vitro passages and was associated with
changes in the viral genome. These results emphasize the
importance of using primary viral isolates, or viruses res-
cued from infectious clones, when studying DENV char-
acteristics, i.e., virulence. Laboratory-adapted strains have
passage-acquired mutations that may involve loss of wild-
type virus features that are of significant importance for
understanding DENV virulence.
Some in vitro experiments on human peripheral blood
leukocytes have shown differences in DENV replication
correlating with the severity of the disease [18]. We
observed a similar phenomenon in mammalian Vero cells,
with differences in DENV replication depending on the
DENV isolate. The clinical DENV isolates derived from
patients exhibiting the non-complicated form DF and the
more severe form DHF replicated efficiently in Vero cells
compared to the DSS virus isolate, which showed a very
low level of replication, corresponding to a lower per-
centage of infected cells. This restricted replication of the
DSS isolate in Vero cells could be due to the establishment
of a persistent infection. Ten passages of Vero cells
infected by DF, DHF or DSS isolates showed that the three
isolates are able to establish a persistent infection in
mammalian cells. This characteristic has already been
described for a laboratory-adapted strain of DENV2 in
human mononuclear cell lines [19]. In mosquito cells, none
of the three DENV serotype 1 isolates studied showed any
differences at the level of viral replication. However, the
DSS isolate induce a high level of apoptosis in C6/36 cells
as early as 24 h postinfection. Whether apoptosis is the
result of infected cells releasing pro-apoptotic mediators
rather than being a direct effect of viral infection is difficult
to distinguish because most of the C6/36 cells were
infected. However, Kanthong et al. recently observed 40%
apoptosis in C6/36 cells persistently infected with DENV
and treated with 5-kDa filtrate from a supernatant of C6/36
cells acutely infected with DENV [20]. Therefore, it could
be hypothesized that the replication of the DSS isolate in
C6/36 cells induces the production of apoptosis-inducing
cytokines.
Regarding the phenotypic properties of the three dif-
ferent isolates, the DSS isolate behaved differently than the
other two isolates. This differentiation was also found in
another recent study using a genome-wide microarray to
look at the transcriptional profiles of samples from patients
presenting with the different clinical forms of DENV
infection [21, 22]. The lower level of replication of the
DSS isolate in mammalian Vero cells fits the observations
Fig. 5 Adaptation of DENV
isolates to VERO cells.
Immunofluorescence with
HB112 antibody (green) and
DAPI staining (blue, nucleus)
7 days postinfection on weeks 1
to 4 of passage of infected
VERO cells
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made by Duong et al., whose data indicate lower levels of
virus in patients suffering from DSS compared to patients
with DF [23]. This differs from earlier reports that lay the
foundation for the current dogma: the higher viremia, the
worse the outcome [24].
A significant number of sequence differences were
detected by the complete sequencing of the three DENV
serotype 1, genotype 1 isolates, showing that different
viruses are circulating during an outbreak. By looking at
the complete sequences published in GenBank of fifteen
DENV-1 genotype 1 isolates from the 2007 epidemic in
Cambodia, 69 positions with amino acid variations were
found. But even if some variations are unique to one
isolate, it can be seen that all of the isolates analyzed are
similar to DF sequence or to DHF/DSS sequences. Two
sequenced isolates from GenBank are identical to our DSS
isolate. The DSS virus had six unique amino acid changes
compared to the two other viruses isolated from patients
with DF or DHF. Two of these six amino acid substitutions
(P277S and L476F) are located in the transmembrane
regions of the membrane and envelope proteins. The
transmembrane region of the envelope is involved in virion
assembly and is required for translocation of the NS1
protein [25, 26]. The role of this domain in virion pro-
duction could explain a part of the restricted replication
observed with the DSS isolate in mammalian cells. The
Table 2 Amino acid
differences between DF, DHF
and DSS isolates in the open
reading frame
Amino acid position
in polyprotein
Amino acid position
in protein
Gene or region Virus and amino acid
DF DHF DSS DSS
adapted
75 75 Capsid Asn Ser Ser Ser
109 109 Val Met Met Met
158 43 Membrane Phe Leu Leu Leu
171 56 Ser Thr Thr Thr
229 114 Gly Ser Gly Gly
277 162 Pro Pro Ser Pro
335 56 Envelope Val Ile Ile Ile
450 171 Ser Thr Thr Thr
484 205 Lys Lys Lys Arg
755 476 Leu Leu Phe Phe
891 115 NS1 Lys Lys Arg Arg
1099 323 Lys Arg Arg Arg
1168 40 NS2a Phe Leu Leu Leu
1199 71 Met Thr Thr Thr
1345 217 Lys Arg Arg Arg
1594 118 NS3 Ser Ser Pro Pro
1807 331 Val Leu Val Val
2225 3 2K Asp Asp Asp Asn
2265 20 NS4b Glu Gly Gly Gly
2404 159 Val Val Val Leu
2496 2 Gly Gly Gly Arg
2512 18 NS5 His Gln Gln Gln
2527 33 Met Thr Met Met
2543 49 Thr Thr Ile Ile
2628 134 Val Ile Val Val
3018 524 Ser Pro Pro Pro
3044 550 Lys Arg Arg Arg
3058 564 Asn Lys Lys Lys
3280 786 Val Ile Ile Ile
3298 804 Ala Thr Thr Thr
3324 830 Ser Ser Asn Asn
3326 832 Glu Gly Gly Gly
A. Tuiskunen et al.
123
other mutations were in non-structural genes (NS1-K115R,
NS3-S118F, NS5-T49I, NS5-S830N). NS1, and more
specifically, the secreted form of NS1, associated with
complement has a potential role in the vascular leakage
responsible for the shock syndrome [27]. Finally, NS3 and
NS5 are proteins with enzymatic activities that are
important for viral replication. All of these mutations could
be implicated in the in vitro and in vivo phenotypic char-
acteristics of the DSS isolate. None of the amino acid
differences that were found affect the known glycosylation
sites or disulfide bonds. It should again be emphasized that
our study and our results are preliminary. Further studies
are required in order to understand and identify the viru-
lence markers of DENV. More strains of the different
DENV serotypes and for each clinical form should be
studied for association between phenotypic and genotypic
characteristics. Finally, reverse genetic and in vivo studies
will be required to further identify virulence markers for
DENV.
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from dengue shock syndrome
Anne Tuiskunen1,2,3*, Maria Wahlström2, Jakob Bergström2, Philippe Buchy4, Isabelle Leparc-Goffart3 and
Åke Lundkvist1,2
Abstract
Background: Dengue virus (DENV) infection is the most common arthropod-borne viral disease in man and there
are approximately 100 million infections annually. Despite the global burden of DENV infections many important
questions regarding DENV pathogenesis remain unaddressed due to the lack of appropriate animal models of
infection and disease. A major problem is the fact that no non-human species naturally develop disease similar to
human dengue fever (DF) or dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Apart from
other risk factors for severe dengue such as host genetics and secondary infection with a heterologous DENV, virus
virulence is a risk factor that is not well characterized.
Results: Three clinical DENV-1 isolates from Cambodian patients experiencing the various forms of dengue disease
(DF, DHF, and DSS) were inoculated in BALB/c mice at three different concentrations. The DENV-1 isolates had
different organ and cell tropism and replication kinetics. The DENV-1 isolate from a DSS patient infected the largest
number of mice and was primarily neurotropic. In contrast, the DENV-1 isolates from milder clinical dengue cases
infected predominantly lungs and liver, and to a lesser extent brain. In addition, infection with the DENV isolate
derived from a DSS patient persisted for more than two weeks in a majority of mice compared to the other DENV-
1 isolates that peaked during the first week.
Conclusions: These results confirm the in vitro findings of the same DENV-1 isolates, that showed that the isolate
derived from a DSS patient can be distinguished based on phenotypic characteristics that differ from the isolates
derived from a DF and DHF case [1]. We observed in this study that the DSS virus isolate persist longer in vivo with
extensive neuroinvasion in contrast to the other DENV-1 isolates originating in milder human cases. Genomic
characterization of the three clinical isolates identified six amino acid substitutions unique for the DSS isolates that
were located both in structural genes (M and E) and in non-structural genes (NS1, NS3, and NS5). The
characterization of these clinically distinct DENV-1 isolates highlight that DENVs within the same genotype may
have different in vivo phenotypes.
Highlights: • Clinical DENV-1 isolates have different organ tropism in BALB/c mice.
• The isolate from a DSS patient is primarily neurotropic compared to the other isolates.
• The DENV-1 isolates have different in vivo replication kinetics.
• The isolate from a DSS patient persists longer compared to the other isolates.
• These phenotypic differences confirm our earlier in vitro findings with the same DENV-1 isolates. Thus, DENVs
within the same serotype and genotype may differ enough to affect clinical conditions in vivo.
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Background
The dengue viruses (DENV) belong to the genus flavi-
virus of the Flaviviridae family, and consist of four (1-4)
antigenically related, but clearly distinct viruses (sero-
types). The DENV particle is enveloped, and has a sin-
gle-stranded positive-sense RNA genome of
approximately 11 kb that resembles a messenger RNA
with a cap on the 5’ end but no poly(A) tail at the 3’
end. The RNA genome encodes a 3411 long precursor
polyprotein that contains three structural proteins (C,
prM, and E), and seven nonstructural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The open
reading frame is flanked by two nontranslated regions
(5’ and 3’ NTR) of approximately 95-135 and 114-650
nucleotides, respectively, that have characteristic second-
ary structures that are required for efficient translation
and replication [2,3].
The DENVs are endemic in tropical and subtropical
areas and more than one hundred million people get
infected annually. Infection can be either asymptomatic,
or cause an acute febrile illness that is characterized by
fever, headache, retro-orbital pain, arthralgia, and myal-
gia. This condition can progress into dengue haemor-
rhagic fever (DHF), with cardinal signs such as
increased vascular permeability, thrombocytopenia, focal
or generalized haemorrhages. DF may progress into the
life-threatening state of dengue shock syndrome (DSS)
[4]. In the recent WHO guidelines, for case manage-
ment purposes, DHF and DSS cases are now grouped
together as “severe dengue” (group C) [5].
Uncontrolled urbanization and globalization have
resulted in the geographic spread of the DENV-trans-
mitting mosquitoes Aedes aegypti and A. albopictus, co-
circulation of different DENV serotypes, and increased
frequency of dengue epidemics [6]. There has been a
severe increase of DHF/DSS in many endemic regions,
emphasizing the urgent need of an effective vaccine.
Despite the global burden of DENV infections many
important questions regarding DENV pathogenesis
remain unaddressed due to the lack of appropriate ani-
mal models of infection and disease. A major problem is
the fact that no non-human species naturally develop
disease similar to human DF or DHF/DSS. Epidemiolo-
gical, clinical, and laboratory findings indicate that both
genetic differences in the virus and the host immune
response contribute to the occurrence and severity of
disease [7].
In the search for better animal models for dengue,
several approaches to investigate infection of DENV in
mouse have been proposed. One of two major strategies
have been to modulate the mouse to render it more sus-
ceptible to DENV infection, e.g. SCID mice transplanted
with cultured, DENV-susceptible tumour cells [8-10].
The other major alternative has been to modify the
DENV in order to make it more infection-competent in
the murine host, e.g. mouse-neuroadapted DENV
[11-14], or virus serially passaged in mouse [15,16]. The
relevance of these models to human pathogenesis
remains unknown.
The immunocompetent BALB/c mouse is susceptible
to DENV infection and has been used extensively to
study various aspects of DENV infection pathogenesis,
despite the lack of clinical symptoms [17-20]. Mouse-
adapted DENV strains increase the susceptibility to
DENV infection and elicit clinical symptoms in BALB/c
mice [11,21]. The relevance of these observations to
infection with wild-type DENV strains, however, should
be interpreted with caution due to the altered genotype
and phenotype of the passaged virus.
We have previously reported that DENV-1 isolates
only passaged once in C6/36 cells (passage 1), derived
from patients presenting the clinically distinct forms of
dengue (DF, DHF, and DSS), can be distinguished in
vitro based on different replication kinetics in mamma-
lian Vero cells and apoptosis in C6/36. The DSS-derived
isolate (accession number: FJ639694) had a unique phe-
notype compared to the DF- and DHF-derived isolates
(accession numbers: HQ624983 and HQ624984, respec-
tively) and genomic comparison revealed six amino acid
substitutions unique for the DSS isolate that were
located in the structural viral M and E genes that con-
stitute the extracellular mature virus particle, and in the
NS1, NS3, and NS5 genes. The E protein mediates host
cell receptor binding, viral entry, and is a major target
for humoral immunity [22,23]. The role of NS1 in virus
replication is not known, but is thought to be involved
in facilitation of viral infection and in the pathogenesis
of DENV infection [24,25]. The NS3 acts together with
its cofactor NS2B as the viral serine protease needed for
DENV precursor polyprotein-processing [3,26-28]. The
NS5 protein has a dual enzymatic activity with an RNA
dependent RNA polymerase activity in its C-terminal
domain, and a methyltransferase activity at its N-term-
inal end. Hence, these six mutations could ultimately
affect antibody response, host immune pathways, and
virus replication.
The primary aim of the present study was to investi-
gate whether there is a phenotype difference in vivo
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between the DENV-1 isolates similar to the in vitro
findings, by studying difference in infectivity in BALB/c
mice and to investigate the cell and organ tropism. The
second aim was to determine if the inoculated virus
concentration and the effects of the infection correlated,
primarily by measuring the levels of inflammatory cyto-
kines induced by the infection.
Results
DENV infection and Organ Tropism
All mice had detectable levels of DENV specific IgG
antibodies at day 15 post-infection (p.i.), confirming the
intravenous route to be appropriate choice in order to
successfully infect all mice. In total 54.3% of the DENV-
1 infected mice had detectable levels of viral RNA;
48.2% of the mice infected with the DF isolate; 55.6% of
the DHF isolate infected mice; and 59.3% of the DSS
isolate infected mice (table 1). All mice survived the
infection without presenting any clinical signs but
pathological lesions such as haemorrhage could be
detected, most notably in brain, liver, lung tissue, and to
some extent in spleen.
Haemorrhage in lungs was most pronounced in the
DF-infected mice, whereas the DHF-infected mice
experienced haemorrhage in lungs, liver and to some
extent in brain. The DSS isolate seemed to have some
neurotropism as the DSS-infected mice had extensive
bleedings in the brain, whereas the peripheral organs
showed only minor signs of haemorrhage. None of the
NC mice exhibited any clinical signs or tissue pathology.
The three DENV-1 isolates showed different tropism;
the two DENVs obtained from a DF and DHF case
infected primarily lungs, spleen, and liver, whereas the
DENV from a DSS patient infected lungs, spleen, and
exhibited a strong tropism for brain tissue (p = 0.001).
The results are summarized in table 1. The effects of
infection in lung tissue showed a positive correlation to
inoculated virus concentration and time-point, with a
peak of infection at day 6 p.i. (p = 0.003) combined with
the highest titer 1.5 × 106 PFU/mL in the inoclum (p <
0.001) (table 2).
Risk of Infection and Kinetics of Infection
The DENV-1 isolates exhibited different risks for infec-
tion that depended both on virus concentration in the
inoculum (p = 0.012) and on time-point p.i. (p = 0.014)
(Figure 1). The effects of inoculated dose of infectious
virus showed a positive correlation to the total number
of infected mice for each virus isolate, and infection
peaked on day 6 p.i. for all three viruses.
Kinetics of infection differed between the three
DENV-1 isolates. Viral RNA in the DF and DHF inocu-
lated mice was predominantly detected during the first
week of infection, and declined during the second week.
Six inoculated mice tested positive after inoculation
with the DF, and DHF isolates, respectively, both on day
3 and 6 p.i. During the second week (day 15 p.i.), how-
ever, only 1 and 3 mice tested positive after inoculation
with the DF- and DHF-viruses, respectively. The time-
course of infection differed in the DSS- infected mice
that showed a delayed response to inoculation compared
to the DF- and DHF-infected mice. Day 3 p.i. had the
lowest number of DSS-infected mice (3 positive mice)
whereas at day 6 p.i. 7 mice were infected, and 6 during
Table 1 Viral RNA was found in various organs depending on inoculated DENV-1 isolate (DF, DHF, or DSS), virus
concentration in inoculum, and time-point p.i. In total 54.3% of the DENV-1 infected mice had detectable levels of
viral RNA
DENV isolate DF DHF DSS
Titer (PFU/mL)* 1.5 × 104 1.5 × 105 1.5 × 106 1.5 × 104 1.5 × 105 1.5 × 106 1.5 × 104 1.5 × 105 1.5 × 106
Day (p.i.)** 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15 3 6 15
Heart - - - - - - - - - - - - - - - - - - - - - - - - - - -
Lungs - - - 2 3 - 2 3 1 - - - - 2 - 2 2 1 - - - - 3 1 1 1 1
Spleen 1 - - - - - 2 - - 1 - - - - 2 2 1 - - 1 - - 1 1 2 - -
Brain - - - - - - 1 - - 1 1 - - - - - 3 - - 1 2 1 3 2 - 2 -
Liver - - - - - - - - - - - - 1 1 - 2 - - - - - - - - - - -
Kidneys - - - - - - - - - - - - - - - - - - - 1 - - - - - - -
Infected mice 1 - - 2 3 - 3 3 1 2 1 - 1 2 2 3 3 1 - 3 2 1 3 3 2 2 1
Infected mice per titer 1 5 7 3 5 7 4 7 5
Infected mice per day p.i. 6 6 1 6 6 3 3 7 6
Σ infected mice per virus isolate 13 15 16
% infected mice per virus isolate 48.2% 55.6% 59.3%
* Titer of inoculum was significant (p = 0.012).
** Time-point post-infection was significant (p = 0.014).
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the second week of infection (day 15 p.i.). Thus, the
number of mice infected with the DF and DHF isolates
peaked during day 3 and 6 p.i. in contrast to the num-
ber of DSS-infected mice that peaked during day 6 and
15 p.i (Figure 2).
Overall, the DSS isolate replicated in a majority of
infected mice and for a longer period of time compared
to the DENVs obtained from milder cases (Figure 2).
Cytokine secretion in serum
IFNg levels peaked during the first week of infection and
most notably on day 3 p.i. that showed the highest levels
of IFNg (p = 0.007). There was also a positive
correlation to inoculated virus dose where the highest
titer (1.5 × 106 PFU/mL) elicited the strongest IFNg
response (p = 0.002). A positive titer dependent correla-
tion to IL-6 levels was observed in all three groups of
DENV-1 inoculated mice (p = 0.028) (data not shown).
There was a time and virus dependent difference regard-
ing detected IL-10 levels. The DF-inoculated mice had
higher levels of IL-10 compared to the DHF- and DSS-
inoculated mice (p = 0.007), with a peak at day 3 p.i (p
= 0.009) (Figure 3). The DF-inoculated mice also domi-
nated in serum levels of secreted MCP-1 and showed
the biggest difference compared to the DSS-inoculated
mice (p < 0.0001), followed by DHF-inoculated mice (p
= 0.011) (Figure 4). MCP-1 levels peaked at day 3 p.i.
whereupon it decreased (p = < 0.001). Inoculated virus
titer showed a positive correlation to measured serum
levels of RANTES in all DENV-1 inoculated mice (p =
0.0036), and DF-inoculated mice dominated (p = 0.048).
IL-13 and RANTES showed a dose-dependent response
to inoculated virus. IL-1b, IL-2, and TNFa did not show
any statistically significant relationships to any of the
analysed parameters (table 3).
Discussion
DENV infections are a major public health problem and
constitute a real challenge due to the absence of vac-
cines and effective antiviral drugs. There are no non-
Table 2 Risk of infection in lungs
Inoculated virus
(PFU/mL)
Risk of infection
1.5 × 104 0
1.5 × 105 0.41
1.5 × 106 0.52
Days p.i. Risk of infection
3 0.26
6 0.52
15 0.15
Both inoculated DENV-1 concentration and time-point were significant (p <
0.001 and p = 0.003, respectively). The risk for infection in the lungs with the
DF isolate was highest on day 6 p.i. and showed a positive correlation to
inoculated virus.
Figure 1 Estimated risk of infection depending on virus concentration, day p.i. and virus isolate.
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human species that naturally develops disease following
DENV inoculation into peripheral sites and that resem-
ble the clinical symptoms observed in humans [29]. The
mechanisms underlying the immune responses to
DENV infection are still poorly defined, and the lack of
suitable animal models has hampered investigation of
host- and virus-specific mechanisms that control pri-
mary and sequential DENV infections.
In this study, we have compared three minimally pas-
saged DENV-1 isolates from patients experiencing the
various clinical forms of dengue disease (DF; DHF; and
DSS, respectively) in vivo by infection in mouse. We
show that the isolate from a DSS patient infected the
largest number of BALB/c mice, with a different tropism
compared to the DENV-1 isolates obtained from milder
clinical cases during the same outbreak. This indicates
that DENVs within the same serotype and genotype
may differ enough to cause various clinical conditions in
vivo. These results confirm a phenotypic distinction pre-
viously observed in vitro with the same DENV-1 isolates
where the DSS isolate replicated less efficiently in mam-
malian Vero cells than the DF and DHF isolates, and
elicited apoptosis in mosquito C6/36 cells [1].
The aim of the study was to compare wild-type fea-
tures of DENV-1 isolates passaged only once in vitro
and never before inoculated in mouse or cultured in
mouse cells prior to direct intravenous inoculation into
BALB/c mice. BALB/c mice are known to be susceptible
for DENV infection although with discrete pathological
features [11,30]. We found that the mice did not
develop dengue disease, and did not present any symp-
toms of the infection. However, viral RNA was detected
Figure 2 Persistence of infection shown as the number of mice
infected out of the total mice inoculated, independent of
inoculated virus concentration. Nine mice per DENV isolate and
time-point in total were inoculated with the corresponding DENV
isolates; DF, DHF, and DSS, respectively.
Figure 3 Box plots showing median IL-10 (solid line) by DENV-
1 isolates independent of inoculated virus concentration and
days p.i. The line in the middle of each box represents the median;
the boxes consists of 1st and 3rd quartile, whiskers are 1.5*(3rd
quartile-1st quartile). Outliers are marked with an open circle. The
DF-inoculated mice had higher levels of IL-10 compared to the
DHF- and DSS-inoculated mice (p = 0.007), with a peak at day 3 p.i
(p = 0.009).
Figure 4 Box plots showing median MCP-1 (solid line) by
DENV-1 isolates independent of inoculated virus concentration
and days p.i. The line in the middle of each box represents the
median; the boxes consists of 1st and 3rd quartile, whiskers are 1.5*
(3rd quartile-1st quartile). Outliers are marked with an open circle.
The DF-inoculated mice had the highest serum levels of secreted
MCP-1 and showed the biggest difference compared to the DSS-
inoculated mice (p < 0.0001), followed by DHF-inoculated mice (p =
0.011). MCP-1 levels peaked at day 3 p.i. and whereupon it
decreased (p = < 0.001).
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in various organs depending on the DENV isolate
injected (table 1). We were unable to detect any sys-
temic viremia and this suggests an absence or a very
low level of virus replication in circulating peripheral
blood mononuclear cells. Alternatively, the lack of
detectable viraemia could indicate that the virus had
already disseminated into peripheral sites, since tissue
infection was measured from day 3 p.i.
In brief, viral RNA was detected by qRT-PCR in spleen,
liver, lungs, kidneys, and brain. Viral RNA was found in
the kidneys in only one mouse, which is in line with ear-
lier studies [31]. Organ tropism clearly differed between
the three clinical DENV-1 isolates and our findings sug-
gest that the disease severity may correlate with high tis-
sue viral burden, even if plasma viraemia was below the
detection limit. The DENV isolate from a DSS case
showed a strong preference for brain tissue, compared to
the two isolates from milder dengue cases that primarily
were found in other organs as lungs and liver. Neuro-
tropism in mice has been previously suggested to be
associated with DENV virulence when comparing
DENV-3 isolated from Brazilian patients [32].
Breakdown of the blood-brain barrier in DENV
infected mice have been described before, and were
shown to be dose-dependent [33]. Genomic sequencing
performed previously [1] identified a unique amino acid
substitution L®F476 in the E protein of the DSS isolate
compared to the DF and DHF isolates, that may explain
the neurotropic character of the DSS-isolate. The NS1
gene of the DSS isolate harboured another unique
amino acid substitution, K®R115 in comparison to the
two other DENV-1 isolates. The soluble form of NS1
(sNS1) is a dominant target of humoral immunity and
activates complement components in normal human
serum, and is proposed to play a significant role in the
pathogenesis of disease [25,34]. The NS1 glycoprotein is
glycosylated at two sites, N130 and N270, and glycosyla-
tion of both residues has been suggested to be required
for neurovirulence in mice [35]. It is remains to be elu-
cidated whether the possible breakdown of the blood-
brain barrier and neurotropic character of the DSS iso-
late has any correlation to the disruption of the
endothelium observed in humans suffering from vascu-
lar leakage. The three remaining amino acid substitu-
tions unique for the DSS isolate were located in the NS
protein 3 (S®P118), and 5 (T®I49, and S®N830).
These differences could potentially alter the enzymatic
activity of these proteins.
The DSS isolate seemed to persist longer in vivo since
viral RNA was detected in a majority of mice on day 15
p.i. compared to the DF and DHF infected mice, and
thereby exhibited infection kinetics differing from the
two other DENV-1 isolates (DF and DHF) where viral
RNA decreased after day 6 p.i. Thus, the DSS isolate
could be regarded as more virulent than the two other
DENV-1 strains, since a majority of the DSS-inoculated
mice had detectable levels of viral RNA, infection was
also less affected by the dose of inoculums and persisted
longer in a majority of mice (Figure 1). The wild-type
DENVs analyzed here could provide evidence for differ-
ences in virus replication, which in turn could influence
the clinical outcomes of the infection, and eventually
partitally explain some differences in virulence observed
in humans.
These results confirm the in vitro findings of the same
DENV-1 isolates, that showed that the strains derived
from a DSS patient can be distinguished based on phe-
notypic characteristics from the isolates derived from a
DF and DHF case [1]. We have previously shown that
the DSS virus isolate exhibit much slower replication
kinetics in mammalian Vero cells and an apoptotic
Table 3 Serum cytokine levels in mice inoculated with
DENV-1 isolates from patients with DF, DHF, and DSS,
respectively, and independent of inoculated virus
concentration
Day p.i. Cytokine DF DHF DSS Mock
3 IFNg 3.10 3.24 2.08 0.09
IL-1b 3.15 0.00 0.00 0.00
IL-2 1.46 2.00 1.05 0.00
IL-6 1.48 1.65 2.69 3.22
IL-10 4.20 3.13 0.00 0.00
IL-13 88.83 73.12 80.23 98.84
MCP-1 71.58 34.25 21.45 0.00
RANTES 35.11 13.17 15.93 9.76
TNFa 6.44 3.97 3.78 0.00
6 IFNg 2.53 1.65 1.92 0.00
IL-1b 3.15 0.00 0.00 0.00
IL-2 1.46 1.44 2.21 2.21
IL-6 0.36 0.77 3.10 2.69
IL-10 2.05 0.00 0.00 0.00
IL-13 70.84 62.33 51.19 121.60
MCP-1 22.12 14.54 3.37 0.00
RANTES 20.47 14.16 24.46 10.43
TNFa 2.45 2.15 0.00 0.00
15 IFNg 1.24 1.28 1.70 0.87
IL-1b 0.00 0.00 0.00 0.00
IL-2 2.20 1.19 5.61 0.00
IL-6 0.18 1.88 1.65 0.03
IL-10 1.03 0.00 0.00 0.00
IL-13 67.20 91.70 84.96 75.57
MCP-1 21.53 14.54 3.37 0.00
RANTES 27.68 17.22 20.75 15.02
TNFa 1.73 0.00 1.48 0.00
The cytokines were measured in pg/mL.
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response in mosquito cells, and we observed in this
study that the DSS virus isolate persist longer in vivo
with extensive neuroinvasion.
Cytokines involved in inflammation were quantified in
serum collected from inoculated mice and compared in
regard to DENV-1 isolate, virus titer inoculated, and
time-point p.i. Overall, the levels of the proinflammatory
cytokines (IFNg, IL-1b, IL-2, IL-6, IL-10, IL-13, MCP-1,
RANTES, and TNFa) quantified were low, which is
most probably due to fact that BALB/c mice is poorly
susceptible to wild-type DENVs. The mice did not
develop clinical apparent disease, and showed only dis-
crete lesions in internal organs. Common for several
cytokines, however, was a dose-dependent response to
inoculated virus (IFNg, IL-6, IL-13, and RANTES). The
highest levels of measured cytokines were also in general
at the beginning of the experimental period (IFNg, IL-
10, and MCP-1 peaked at day 3 p.i.). A curious finding
was that DF-inoculated mice had higher detectable
serum levels of IL-10, MCP-1, and RANTES, which
have been seen to be increased in patients with severe
DHF and DSS [36-42]. The preference for the brain of
the DHF-, and most notably the DSS-infected mice,
could imply locally high levels of proinflammatory cyto-
kines that do not circulate systemically. This could
explain why the IL-10, MCP-1, and RANTES levels
dominated in the DF-inoculated mice, since the thoracic
and abdominal organs were the primary target for DF
isolate. Cytokines like IL-1b, IL-2, and TNFa did not
show any differences compared to mock-infected con-
trols and this could be due to the transient nature of
many cytokines as well as the limited susceptibility of
DENVs in mice.
Conclusions
We have previously shown in vitro that the isolate from
a DSS case could be distinguished based on replication
kinetics and apoptosis from isolates originating in
milder cases. In this study we have extended the charac-
terization of those clinical DENV-1 isolates derived
from patients exhibiting the various forms of dengue ill-
ness. Despite their close relatedness, the DENV-1 isolate
from a DSS case was phenotypically different from the
other two isolates by significant brain invasiveness and a
higher infectivity in BALB/c mice. The isolates from a
DF and DHF case infected primarily lungs and liver, and
to a limited extent brain and infection declined faster
after day 6 p.i than in DSS-infected mice.
This is the first time different clinical South-East
Asian DENV isolates have been directly compared for
the in vivo characteristics in BALB/c mice. To define
key elements involved in the virulence of these charac-
terized DENV-1 phenotypes reverse genetics systems are
needed. Additional low-passage strains of the different
DENV serotypes of each clinical forms of dengue are
required to fully decipher the complex mechanisms gov-
erning DENV pathogenesis.
Materials and methods
Virus
Three dengue serotype-1 (DENV-1) virus strains isolated
from patient sera during a DENV outbreak in the Kam-
pong Cham province, Eastern Cambodia, in 2007, were
used. The isolates were obtained from patients experien-
cing the three distinct clinical forms of dengue disease:
DF, DHF and DSS, according to the WHO classification
[43]. Patient information regarding the analysed clinical
DENV isolates is presented in previous work by Tuisku-
nen, A. et al., 2011. Blood samples were collected
between day 2 and 6 after onset of disease and the sero-
types were determined at the Institute Pasteur in Cam-
bodia (IPC) by nested reverse transcriptase-polymerase
chain reaction, according to Lanciotti procedure modi-
fied by Reynes et al. [44]. The virus isolates were
obtained during the DENFRAME study, which has been
approved by the Cambodian National Ethics Committee
and patient’s enrolment was subject to obtaining a writ-
ten consent signed by the patients, or the under 16 year
old patient’s legal representatives.
Each DENV was isolated in A. albopictus mosquito
cell line C6/36 (CRL 1660, ATCC), and thereafter pro-
pagated by one passage. The C6/36 cells were main-
tained in Leibovitz-15 medium, supplemented with 2%
tryptose phosphate broth, and 5% fetal calf serum (Invi-
trogen, Stockholm, Sweden) and maintained at 28°C for
6 days. Cell culture supernatant was centrifuged for 10
min at 15000 rpm, titrated as previously described [1]
and stored at -80°C in a solution of sucrose [1.5 M] and
hepes [1 M]. Virus had not undergone any previous pas-
sage in mouse.
Animals
The animal experimental procedures were approved by
the Committee for Laboratory Animal Science of the
Swedish Board of Agriculture (ethical permit ID no:
339/07).
Female BALB/c mice (Nova, Sollentuna, Sweden) age
6 weeks weighing 20 g were maintained on a standard
laboratory diet with water ad libitum and housed under
specific pathogen-free conditions at the animal facility
of the Swedish Institute for Communicable Disease
Control (SMI) in Stockholm, Sweden. Mice subjected to
the same treatment were kept in groups of 4-5 mice per
cage and handled according to the international guide-
lines for experimentation on animals. DENV-1 infected
mice were housed in a biological safety level (BSL) 3
isolator, and negative control mice were housed in a
BSL 2 facility.
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DENV-1 infection in mice
There were 99 mice in total divided into four groups
with 27 mice each according to the 3 DENV-1 isolates
and 18 mock infected negative controls (NC). Each
group of 27 mice were subdivided into three groups of
nine mice that were injected intravenously (i.v.) in the
tail vein with a single dose (1.5 × 104 PFU/mL; 1.5 ×
105 PFU/mL; or 1.5 × 106 PFU/mL, respectively) of
infective DENV-1 without adjuvant. Similarly, the NC
group of 18 mice received 150 uL of Leibovitz-15 med-
ium supplemented with sucrose [1.5 M] and hepes [1
M] (table 4). The mice were monitored daily for clinical
signs.
Blood that was obtained via a cardiac puncture of
mice immediately after euthanasia by 4.5 - 4.8% isoflur-
ane gas inhalation on day 3; 6, and 15 p.i. All mice were
immediately splenectomised after euthanasia and there-
after stored at -80°C.
Detection of DENV RNA in BALB/c mice
To assess viral burden in tissues of infected mice, organs
such as liver, heart, spleen, lungs, brain, and kidneys
were harvested, weighed, and homogenized using Stain-
less Steel Beads (5.0 mm diameter) with a TissueLyser
apparatus (Qiagen, Hilden, Germany). Total RNA from
tissues was extracted immediately after dissection using
the RNeasy Mini kit according to the manufacturer’s
instructions (Qiagen).
Mouse sera were obtained by centrifugation of whole
blood for 3 minutes at 2000 g in microtainer EDTA
tubes (Becton, Dickinson and Company, Temse, Bel-
gium). Viral RNA from thawed aliquots of serum (140
uL) was extracted using QIAamp Viral RNA Mini kit
(Qiagen). RNA samples, eluted in RNAse-free water,
were stored at -80°C. Quantitative measurements of
total viral RNA were performed as previously described
[45].
IFA for virus-specific antibody detection
An in-house immunofluorescence assay (IFA) was used
as previously described [46] essentially to verify that all
DENV-1 infected mice had raised a DENV specific anti-
body response.
Cytokine dosage
Cytokine levels in mouse sera collected from all inocu-
lated mice, including mock infected, were measured as
duplicates with Milliplex Mouse Cytokine/Chemokine
Panel (Millipore) in a Luminex 100 (Luminex, Bio-Rad,
Sweden). The following cytokines and chemokines were
analysed according to the manufacturer’s instructions:
IFNg, IL-1b, IL-2, IL-6, IL-10, IL-13, MCP-1, RANTES,
and TNFa.
Statistical Analysis
To test the effect of virus, titer and days p.i. on the risk
of DENV infection in mouse organs binomial regression
with a log link was used. Parametric bootstrap with
10.000 replicates was drawn from an assumed binomial
probability model. The effect of virus, titer and day
between smaller and larger models were then evaluated
by comparing the deviance, extracted from the repli-
cates. The largest model, within each analysis of the
infection risk in an organ, included the main effects
virus, titer and day plus the interactions virus by titer,
virus by day and titer by day.
Median regression was used to evaluate the relation-
ship between virus isolate, day, and titer on the different
cytokines. As most cytokines displayed highly right
skewed distributions in some virus isolates the use of
median estimates yielded more robust results than with
the use of mean based methods. Day and titer were ana-
lyzed separately with two main models per cytokine:
Cytokine = group + day + group by day interaction; and
Cytokine = group + titer + group by titer interaction. P-
values < 0.05 were used as statistically significant results.
All analyses and graphs were performed using the statis-
tical software R (version 2.13.1, 2011).
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Summary 32 
The dengue viruses (DENVs) cause the most common arthropod-borne viral disease in man, but 33 
despite the global burden, the pathogenesis of dengue remains poorly understood. In addition to 34 
host genetics and previous DENV infection history, variations of DENV strain virulence are 35 
acknowledged to be a risk factor. The genetic traits that increase virulence, however, are yet to be 36 
discovered. 37 
In this study, clinical DENV isolates of passage one derived from patients experiencing the various 38 
symptomatic forms of DENV infection (dengue fever, DF; dengue hemorrhagic fever, DHF; and 39 
dengue shock syndrome, DSS) were characterized in human primary PBMCs, monocytes, 40 
monocyte-derived dendritic cells (moDCs), Vero cells and C6/36 with regard to replication kinetics 41 
and induction of apoptosis. The clinical isolates from all four DENV serotypes, derived from DSS 42 
patients, were clearly distinguished from the isolates derived from milder cases, based on 43 
replication kinetics in moDCs and Vero cells. The DSS isolates also induced apoptosis in C6/36 44 
cells, in contrast to the DENV isolates from milder cases. Replication differences were most notable 45 
when measuring infectious titer in comparison to viral RNA levels. This could suggest the presence 46 
of defecting interfering particles. 47 
 48 
Whole genome sequencing of the clinical DENV isolates revealed multiple amino acid substitutions, 49 
whereof a majority was located in the envelope glycoprotein, and in the non-structural protein 1 and 50 
5.  51 
These findings highlight genotype and phenotype differences between clinical DENV isolates that 52 
closely resemble wild-type viruses, and suggest that intrinsic viral traits may potentially influence 53 
virus virulence in dengue pathogenesis.  54 
  55 
Introduction 56 
Dengue is an acute febrile disease caused by the mosquito-borne dengue viruses (DENVs) that are 57 
members of the Flaviviridae family and consists of four serotypes (1-4) (Westaway et al., 1985). 58 
The single-stranded positive-sense RNA genome comprises approximately 10,700 nucleotides and 59 
encodes a 3,411 amino acid long precursor polyprotein that contains three structural proteins (C, 60 
prM/M, and E), and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 61 
NS5). 62 
 63 
DENV is transmitted by the mosquito Aedes aegypti, and to a lesser extent Ae. albopictus, and is the 64 
most common cause of arboviral disease in man today (WHO, 1997). All four serotypes can be 65 
found worldwide in tropical and subtropical regions where more than 2.5 billion of the world’s 66 
population live (Guzman and Kouri, 2002). DENV infection can cause a wide range of diseases in 67 
humans, even though DENV infections may also be asymptomatic. The diseases range in severity 68 
from undifferentiated acute febrile illness, classical dengue fever (DF), to the life-threatening 69 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (Gubler, 2002). The WHO 70 
estimates an annual occurrence of 100 million infections whereof approximately 500,000 people 71 
with DHF require hospitalization, a very large proportion of who are children. Classical DF begins 72 
with an abrupt onset of high fever and is a self-limited though debilitating illness with headache, 73 
retro-orbital pain, myalgia, arthralgia, rashes and leucopenia (Henchal and Putnak, 1990). Early 74 
symptoms of DF and DHF are indistinguishable, but DHF is associated with hemorrhagic 75 
manifestations, plasma leakage resulting from an increased vascular permeability, 76 
thrombocytopenia (<100, 000 platelets/mm3). Cardiovascular compromise accompanies DSS and 77 
occurs when plasma leakage into the interstitial spaces results in shock (Gubler, 2002). In the 78 
continuous seek for an effective vaccine and anti-dengue drugs the sole measure to prevent DENV 79 
transmission is still to reduce the vector population. 80 
 81 
The pathogenesis of dengue is complex, and despite intensive research in the area, not well 82 
characterized. Several risk factors influencing the severity of DENV infection has been identified 83 
such as age (Gubler, 1998, Guzman et al., 2002a), the genetic background of the host (Guzman et 84 
al., 2002b, Halstead et al., 2001, Sakuntabhai et al., 2005), viral serotype (Balmaseda et al., 2006, 85 
Gubler, 1998) and genotype (Messer et al., 2003, Rico-Hesse et al., 1997), and secondary infection 86 
by a heterologous serotype mediating antibody-dependent enhancement (ADE) (Guzman et al., 87 
2002b, Burke et al., 1988, Halstead et al., 1970, Sangkawibha et al., 1984, Thein et al., 1997). The 88 
impact and contribution of each individual risk factor, however, is far from fully understood.  89 
 90 
There have been specific geographic examples of the appearance of DENV genotypes correlating to 91 
DHF/DSS epidemics. The introduction of a South-East Asian DENV-2 strain in the Americas in 92 
1981 resulted in sudden emergence of DHF/DSS cases. The Asian genotype was later proved to be 93 
more virulent and more likely to result in DHF/DSS than the American genotype even after a 94 
secondary infection (Rico-Hesse et al., 1997, Rico-Hesse, 1990). There are no specific genetic 95 
markers, however, that have been identified so far to confer the increased virulence traits of DENV. 96 
It is not known if the tendency of certain genotypes to cause severe disease results from greater 97 
intrinsic virulence, or if greater virulence is a result of enhanced cross-reactivity in the presence of 98 
heterologous antibodies, or a combination of the two. Determining whether DENVs differ in 99 
virulence, as well as identifying the genetic basis of such differences, is thereby of fundamental 100 
importance. We have previously shown that clinical DENV-1 isolates passaged only once in 101 
mosquito cells, derived from patients experiencing DF, DHF, and DSS, respectively, differed both 102 
genotypically and phenotypically in vitro and in vivo (Tuiskunen et al., 2011a, Tuiskunen et al., 103 
2011b). In addition to unique amino acid substitutions in both structural and NS proteins, the isolate 104 
obtained from a patient experiencing DSS replicated less efficiently in mammalian Vero cells and 105 
elicited apoptosis in mosquito C6/36 cells, compared to the strains isolated from a DF and DHF 106 
patient (Tuiskunen et al., 2011a). The phenotypic difference was also observed in BALB/c mice 107 
where the DSS isolate persisted longer and was primarily neurotropic, in contrast to the two other 108 
DENV-1 isolates that infected predominantly internal organs (Tuiskunen et al., 2011b). 109 
 110 
The focus of the current study has been to extend the phenotypic and genotypic characterization of 111 
the DENV-1 isolates to include isolates of serotype 2, 3 and 4 (DENV-2, -3 and -4). Thus, we have 112 
characterized nine additional clinical DENV isolates from patients experiencing the various 113 
symptomatic forms of DENV infection; DF, DHF, and DSS. A genomic comparison of the clinical 114 
DENV isolates revealed several amino acid substitutions, and replication kinetic differences in 115 
mammalian Vero cells, human peripheral blood mononuclear cells (PBMCs), monocytes and 116 
monocyte-derived dendritic cells (moDCs). In addition, variations in the apoptotic response in 117 
C6/36 cells distinguished the DENV isolates from DSS patients from the remaining DENV isolates 118 
from milder dengue cases. These observations complement and agree with our previous findings on 119 
DENV-1, and suggest that DENVs derived from the same epidemic may differ both phenotypically 120 
as well as genotypically. 121 
 122 
Results 123 
Replication kinetics of wild-type DENV isolates obtained from patients experiencing the various 124 
degrees of dengue illness severity 125 
 126 
We investigated the replication kinetics of the various clinical DENV isolates in order to 127 
characterize them phenotypically both in mammalian and mosquito cell lines. Viruses from 128 
supernatants and cells were titrated by a focus forming assay (FFA) and the amount of viral RNA 129 
(vRNA) determined by quantification of total vRNA using a quantitative RT-PCR (qRT-PCR).  130 
 131 
All isolates replicated with similar efficiencies in the mosquito cell line C6/36 with nearly 100% of 132 
cells infected 5 days post-infection (pi) (data not shown). In mammalian Vero cells at 37°C, 133 
however, the strains isolated from patients experiencing DF replicated better than strains isolated 134 
from patients experiencing severe dengue (DHF or DSS) (Figures 1 and 2). Immunofluorescence 135 
was performed in parallel using a panflavi anti-envelope monoclonal antibody (HB112) and a mAb 136 
detecting active virus replication (J2, targeting double-stranded RNA). Cells infected with DSS 137 
viruses showed a constantly low level of replication, compared to DF-derived DENVs that 138 
replicated well, and the DHF isolates that resembled either the DSS isolates or the DF isolates, 139 
depending on serotype. The replication differences were most notable when measuring infectious 140 
titers, as compared to quantification of the vRNA levels (Figures 1 and 2). Both the DHF and DSS 141 
isolates of DENV-2 replicated less efficiently than the DF isolates, which was clearly 142 
distinguishable in infectious titre, but not when quantifying intracellular vRNA levels. The same 143 
phenomenon was observed with the DENV-3 clinical isolates. The isolates from DHF and DSS 144 
patients replicated at a similar low level as compared to the isolate from a DF patient that replicated 145 
better in Vero cells. The difference of replication efficiency was best illustrated when measuring 146 
infectious titer, whereas vRNA levels were similar for all three DENV-3 isolates. The DSS isolate of 147 
DENV-4 replicated less efficiently as compared to the isolates of DF and DHF that replicated with 148 
similar efficiency. The difference between the DF and DHF isolates, however, was smaller in 149 
intracellular virus levels and vRNA levels, than in supernatant. Together these results suggest that 150 
the viruses may differ in the amount of defective viral particles that are synthesized during the 151 
replication cycle. Despite similar levels of vRNA, the various strains analyzed differed in the 152 
amount of infectious particles produced that distinguished the DSS isolates from the isolates 153 
derived from milder cases. 154 
 155 
Infection in human primary cells 156 
The primary cells targeted by DENV are suggested to be cells from the mononuclear phagocyte 157 
linage (Boonpucknavig et al., 1979, Boonpucknavig et al., 1976, Sahaphong et al., 1980, King et al., 158 
1999, Alen et al., 2011). Therefore, we aimed to directly compare the susceptibility of total PBMC 159 
to infection with the twelve clinical DENV isolates (serotype 1-4) derived from patients 160 
experiencing DF, DHF, and DSS. C6/36 cells, PBMC, monocytes, and moDCs were infected with 161 
DENV at an MOI of 1 and 10, and RNA extracted 72hpi to quantify DENV RNA levels in the 162 
infected versus the uninfected cells. In contrast to the mosquito cells, a very low level of replication 163 
or none were observed in both PBMC and monocytes. Yet, significant levels of DENV RNA were 164 
found in moDCs at 72 hpi. The DSS isolates from all four serotypes had higher levels of vRNA 165 
compared to the DENV isolates derived from DF cases (Figure 3). 166 
 167 
Apoptosis due to DENV infection 168 
We studied apoptosis in C6/36 and Vero cells to investigate whether any difference between the 169 
clinical DENV isolates of serotype 2-4 could be found. The cells were stained at four time-points 170 
(24, 48, 72h and 6 days pi). None of the DENV isolates induced apoptosis of Vero cells (data not 171 
shown). Minimal amount of apoptosis was observed in the C6/36 cells infected by the patient 172 
isolates from DF and DHF cases compared to the DSS-derived DENV isolates (Supplemental figure 173 
1). The DSS-isolate belonging serotype-3 elicited the highest degree of apoptosis (23%), followed 174 
by the DSS-isolate of serotype-2 (21%), and serotype-4 (15%). Since virus titration and vRNA 175 
using real-time qRT-PCR confirmed that all nine DENV isolates had a similar replication kinetic in 176 
C6/36 cells, the DSS isolates induced a higher degree of apoptosis in C6/36 cells compared to the 177 
other viruses obtained from DF and DHF patients regardless of replication kinetics. A unique 178 
feature of the DSS-isolate of DENV-3 was the formation of syncytia. This cytopathic effect was 179 
clearly visible already on day 3 pi, and remained clearly visible throughout the week of infection 180 
(Figure 4).  181 
 182 
Genomic characterization 183 
There is no specific genetic marker that today is recognized to increase virulence of DENVs or that 184 
is linked to severe dengue disease in humans. In order to investigate whether certain DENV genes 185 
or particular mutations could be involved in virus virulence, the complete open reading frame of 186 
each DENV isolate characterized in this study was sequenced. In total, 58 amino acid substitutions 187 
were found with a preference for the structural E protein, and the NS proteins 1 and 5, followed by 188 
NS2A protein (supplementary table 1). Considerable sequence variation was found both in 189 
structural and NS genes (Table 1-3). The DENV-2 isolates obtained from a DF and DHF patient, 190 
respectively, were nearly identical, only differing at three positions in the NS5 gene (EQ262, 191 
VA613, and AV617), where DHF was identical to the DSS isolate. Regarding the three DENV-192 
3 isolates, there were multiple amino acid differences scattered throughout the genome, including 193 
both structural and NS genes. The DSS isolate had a unique amino acid substitution (VA59) in 194 
the prM gene, two in the E protein (YH132 and NS346), one in the NS1 gene (NS17 and 195 
AT288), and one in the NS3 gene (SN86). Additional amino acid substitutions were found in 196 
the NS2A and NS5 genes, and two in the E gene, that differed between the three isolates. The DF 197 
and DHF isolates from serotype-4 differed at four positions. The DF isolate had two unique amino 198 
acid substitutions in the E gene (ED177), and in the NS1 gene (SP166), whereas the DHF 199 
isolate had two unique amino acid substitutions, both located in the NS5 gene (SL393 and 200 
VS772). The DSS-isolate had six unique amino acid substitutions in the methyltranserase (MTase) 201 
region of NS5, and seven in the RNA-dependent RNA polymerase (RdRp) domain. Thus, the 202 
clinical DENV isolates were genotypically different with single amino acid substitutions 203 
predominantly in the E, NS1 and NS5 proteins (Table 1-3). 204 
 205 
Discussion 206 
Despite the public health importance of dengue disease, its pathogenesis remains unclear. There is a 207 
complex interplay of viral and host factors. Secondary infection by a heterologous serotype has 208 
been reported to be the greatest single risk factor for DHF/DSS, although the ability to cause severe 209 
dengue disease in primary infection varies by DENV strain (Balmaseda et al., 2006). There is no 210 
clear correlation, however, between a particular DENV serotype or genotype(s) and disease 211 
outcome, but there are indications that certain DENV-2 and DENV-3 genotypes are more often 212 
associated with severe disease (Messer et al., 2003, Rico-Hesse et al., 1997). DENV-2 strains of 213 
Asian genotype replicated to higher titers in human monocyte-derived macrophages and moDCs 214 
than American genotype DENV strains (Cologna and Rico-Hesse, 2003). The emergence of Group 215 
B subtype III DENV-3 strain in Sri Lanka in 1989 is another example of clade replacement 216 
correlating with an increase in DHF/DSS (Messer et al., 2002, Messer et al., 2003, Kanakaratne et 217 
al., 2009). The magnitude of intra-genotype virulence differences and its influence in pathogenesis 218 
during an epidemic, however, are not known. 219 
 220 
In this study, nine clinical DENVs belonging to serotype-2, -3 and -4 isolated in the Kampong 221 
Cham region in Cambodia were phenotypically and genotypically characterized and compared. This 222 
current study extends our previous analysis characterizing three DENV-1 isolates in vitro and in 223 
vivo (Tuiskunen et al., 2011a, Tuiskunen et al., 2011b). The DENV-1 to 3 strains originated from the 224 
same epidemic in 2007. The clinical isolates of serotype-4 were collected during the 2007 and 2008 225 
epidemics but still in the same region as the other strains. All clinical samples were isolated from 226 
young children in order to minimize the inter-host variability. Of note, children have an inherent 227 
higher vascular permeability relative to adults (Gamble et al., 2000). 228 
 229 
Common phenotype differences for all low-passage DENV isolates characterized in this study and 230 
previously, were poorer replication of the DSS isolates in Vero cells. In contrast, the clinical isolates 231 
derived from DF patients replicated most efficiently in Vero cells regardless of serotype. The 232 
DENV-2 and -3 isolates derived from DHF patients replicated at similar levels than the DSS isolates 233 
of the same serotype. In contrast, the DENV-4 strain isolated from a patient experiencing DHF 234 
resembled more the DF isolate than the strain obtained from a DSS patient. Hence, these results 235 
from DENV serotype-2, -3 and -4 viruses, after only one passage on mosquito cell culture, confirm 236 
the earlier observations made with DENV-1 viruses (passage one) that had highest replication rates 237 
when obtained from DF patient than from a DSS case (Tuiskunen et al., 2011a). 238 
 239 
Measuring extracellular infectious viral titre reflected best the true replication differences between 240 
the DENV isolates. The difference of intracellular vRNA levels between the DENV isolates within 241 
the same serotype was smaller than the difference of viral titre, indicating that a significant amount 242 
of viral particles produced are not budding competent and/or infectious. Disease severity is believed 243 
to be correlated to viral load measured in the blood (Cologna and Rico-Hesse, 2003, Leitmeyer et 244 
al., 1999) and defective interfering viral particles have been suggested to influence virulence and 245 
interfere with the host immune response (Cave et al., 1985, Huang et al., 1986, Bangham and 246 
Kirkwood, 1990). Thus, the observations that the DENV isolates have similar vRNA levels despite 247 
their replication differences are interesting findings that may have immunological implications in 248 
the host during infection. 249 
 250 
Infection with all twelve clinical isolates only passage once on mosquito cell lines was assessed in 251 
human primary cells. Immature DCs in the skin are believed to be the first target cells during 252 
natural DENV infection in humans (Wu et al., 2000), and other cells of the myeloid lineage such as 253 
macrophages are also crucial target cells for DENV replication (Palucka, 2000, Kyle et al., 2007). 254 
In this study, the moDCs seemed to be the most susceptible for DENV infection compared to the 255 
PBMCs and monocytes. Common for all three cell-types, however, was that the DSS-derived 256 
DENV isolates from all four serotypes had higher vRNA levels as compared to the DF isolates. This 257 
interesting finding supports the hypothesis that a higher viral biomass causes a worse clinical 258 
outcome (Vaughn et al., 2000). Additional low-passage, clinical DENV-isolates, however, are 259 
needed to extend this observation. 260 
 261 
In addition to replication differences in mammalian cell lines and in human primary cells, the DSS 262 
isolates from all three serotypes elicited a higher degree of apoptosis in mosquito cells. Efficiency 263 
of replication in C6/36 cells measured both in viral titre and in quantified vRNA were similar for all 264 
nine DENVs compared indicating that apoptosis was not a consequence of different levels of viral 265 
load. Previous results of a DENV-1 strain isolated from a DSS patient showed increased level of 266 
apoptosis in C6/36 cells compared to isolates obtained from milder clinical cases (Tuiskunen et al., 267 
2011a). The significance of these observations requires further investigation in order to identify the 268 
factors that modulate apoptosis in this arthropod cell line. An additional feature observed in 269 
mosquito cells infected with the DENV-3 strain isolated from a DSS case was the phenomenon of 270 
syncytia, fusion from within, or cell-cell fusion. This cytopathic effect was clearly distinguishable 271 
from the two other DENV-3 isolates characterized, and is proposed to be mediated by the viral E 272 
protein (Koblet, 1987, Omar, 1989, Omar and Koblet, 1988). The DENV-3 DSS-isolate had two 273 
unique amino acid mutations in the E protein (TyrHis132 in domain I, and AsnSer346 in 274 
domain III of the E protein), suggesting that these may be at the origin of the syncytia observed 275 
during cell infection. 276 
 277 
The genomic sequences of the open reading frame of all nine DENVs (serotype 2-4) were compared 278 
to identify potential markers associated with the different phenotypic expressions observed during 279 
in vitro experiments. In total, 58 amino acid substitutions were found with a preference for the 280 
structural E protein, and the NS proteins 1 and 5, followed by NS2A protein. The nine clinical 281 
DENVs compared in this study differed by eight amino acids in the E protein, which could elicit the 282 
production of antibodies that may differ in their epitope specificity. The E protein binds to receptors, 283 
e.g. DC-SIGN on immature DCs, and anti-E antibodies inhibit viral attachment, internalization, and 284 
replication within cells (Alen et al., 2011, Johnson et al., 1994, Lee et al., 1997, Navarro-Sanchez et 285 
al., 2003). Both receptor binding efficiency and initial translation may impact the cellular tropism of 286 
the virus. The SerAsn203 mutation in the E protein of DENV-2 DF strain could potentially be 287 
modified by glycosylation and influence target cell tropism and epitopes for antibodies since DENV 288 
entry in human cells is carbohydrate-dependent (Alen et al, 2011). Thus, different E protein 289 
epitopes may modulate the infection evolution. As for the E protein, eight amino acid substitutions 290 
were found in the NS1 protein. The exact function of the NS1 proteins remains unknown, but is 291 
believed to play a role in dengue pathogenesis (Schlesinger et al., 1987, Avirutnan et al., 2006). The 292 
NS1 protein is immunogenic and antibodies raised against soluble NS1 protein has been proposed 293 
to cause endothelial dysfunction due to cross-reactivity between anti-NS1 antibodies to host 294 
proteins and endothelial cells (Lin et al., 2006). The largest number of amino acid substitutions for 295 
all three serotypes (2-4) was located in the NS5 protein. The NS5 protein has three major functional 296 
domains and is the largest DENV protein.  Nine of the mutations were in the N-terminal S-adenosyl 297 
methionine MTase part of the protein, which spans amino acid residues 1 to 239 and is responsible 298 
for guanine N-7 and ribose 2_-O methylations required for the capping of the DENV genome. The 299 
cap structure is recognized by the host cell translational machinery (Bartholomeusz and Wright, 300 
1993, Egloff et al., 2002, Ray et al., 2006).  The nuclear localization sequences (NLS) (residue 320-301 
405) interact with the NS3 viral helicase and is recognized by cellular factors, allowing protein 302 
transport. Only one amino acid substitution was found in the NLS domain (DHF-isolate of DENV-303 
4 SerLeu393). The NS5 polymerase domain RdRp (residue 273-900) is responsible for 304 
synthesizing new vRNA genomes and 15 of the NS5 mutations were located in this domain, 305 
suggesting an influence in the different replication phenotypes observed. 306 
 307 
Hence, clinical DENVs of the same serotype, isolated during the same epidemic, and passaged only 308 
once to resemble wild-type as much as possible, may differ both in phenotypes and in genotypes. 309 
We have compared replication abilities in mammalian Vero cells, commonly used for titration of 310 
DENVs, human PBMCs, monocytes, moDCs, and C6/36 cells, and found replication differences 311 
distinguishing isolates obtained from severe dengue cases from those isolated from patients experi-312 
encing milder symptoms in all cell types except for C6/36. A similar diversification of the DENV 313 
isolates was seen in C6/36 cells, however, where the DSS isolates stimulated apoptosis. These find-314 
ings highlight genotype and phenotype differences between passage 1 clinical DENV isolates, and 315 
confirm what we previously found with three DENV-1 isolates originating from the same epidemic 316 
in Cambodia 2007 (Tuiskunen et al., 2011a). The viral genomes differed at multiple sites also with-317 
in the same serotypes, and the observed phenotypic differences may depend on external features of 318 
the viral E protein, NS1 and the multi-enzymatic activities of NS5, since 36 of 58 amino acid sub-319 
stitutions were found within these three proteins. Further studies are now required to understand the 320 
contribution of each mutation and its potential impact on dengue pathogenesis. These results strong-321 
ly suggest that DENVs from the same genotype and epidemic may differ both in their genomic set-322 
up as well as in their expressed viral proteins, and that these intra-genotype differences are not re-323 
stricted to one serotype. The contribution of these discrepancies in dengue pathogenesis in humans 324 
remains to be further characterized.  325 
 326 
Materials and methods 327 
DENVs 328 
Nine dengue viruses of serotypes-2, -3 and 4 isolated during outbreaks in 2007 and 2008 from 329 
patients living in the Kampong Cham province, Eastern Cambodia, were used during this study 330 
(Table 4). The isolates were obtained from patients experiencing either classical DF, DHF, or DSS, 331 
according to the WHO classification (WHO, 1997). Blood samples were drawn between day 2 and 332 
6 after onset of disease. These samples were collected during the DENFRAME study (a project 333 
supported by European Union) and immediately anonymized as stated in the research protocol. The 334 
DENFRAME project was approved by the Cambodian National Ethics Committee and patient’s 335 
enrolment was subject to obtaining a written consent signed by the patients or the under 16 year old 336 
patient’s legal representatives. 337 
Each strain had been isolated at the Institut Pasteur in Cambodia (IPC) in the standard cell line 338 
C6/36, derived from Ae. albopictus (CRL 1660, ATCC), and thereafter undergone only one in vitro 339 
passage (P1), in order to avoid mutations that might be associated with tissue culture adaptation.  340 
The isolates were serotyped at IPC by nested Reverse transcription (RT) PCR according Lanciotti 341 
procedure modified by Reynes et al. (Reynes et al., 2003). 342 
 343 
Cells 344 
Mammalian Vero cells (CCL-81, ATCC) were grown at 37°C, 5 % CO2, in cell culture medium 199 345 
(Gibco, Paisley, UK) with 5 % fetal calf serum (FCS). The Ae. albopictus cell line C6/36 was 346 
grown at 28˚C, in cell culture medium Leibovitz-15, with 5 % FCS and 2 % tryptose phosphate (TP) 347 
(all from Invitrogen Life Technologies, Gibco, Paisley, UK). PBMCs were obtained from healthy 348 
donors by collection of buffy-coats provided by the blood bank at the Karolinska Hospital, 349 
Stockholm, Sweden, and following Ficoll-Paque (GE Healthcare) density gradient centrifugation. 350 
PBMCs were plated in 96-well culture plates at a density of 300, 000 cells per well with RPMI-351 
1640 medium supplemented with 10 % FCS, 2 mM L-glutamin, 100 U/mL penicillin, 100 M 352 
streptomycin, 2 % HEPES (all from Invitrogen Life Technologies, Gibco, Paisley, UK). PBMCs 353 
were enriched for monocytes following plastic adhesion on to cell culture flasks for 2 h at 37°C, 5 % 354 
CO2. Adherent monocytic cells were detached from the flask and resuspended in the same RPMI-355 
1640 medium used for PBMCs. Isolated cells were plated in 96-well culture plates at a density of 356 
300, 000 cells per well. 357 
 358 
The moDCs were generated from monocytes separated from PBMC using CD14-positive magnetic 359 
beads (Miltenyi, Bergisch Gladbach, Germany) and were more than 98% pure, as assessed by flow 360 
cytometry. Monocytes were cultured in RPMI-1640 medium supplemented with 10% FCS, 50 U/ml 361 
penicillin, 50 g/ml streptomycin (all from Invitrogen Life Technologies, Gibco, Paisley, UK), and 362 
the following cytokines: 100 ng/ml rhIL-4 and 75 ng/ml rhGM-CSF (both from Peprotech, Rocky 363 
Hill, NJ, USA). On day 2 in culture, half of the cell culture medium was replaced, and new 364 
cytokines were added. On day five, moDCs were harvested and used in further experiments.   365 
 366 
DENV infection in cells 367 
The procedures for infection of Vero and C6/36 cells have been described elsewhere (Tuiskunen et 368 
al., 2011a). In short, an inoculum of 500 µL virus per well on a 12-well plate was used for infection 369 
at a multiplicity of infection (MOI) of 1. The virus was diluted in cell medium (FCS-free), and virus 370 
free cell culture medium was used for the mock infected cells. The cells were thereafter incubated 371 
for 2 h at the corresponding temperature. The inoculum was removed and the cells were gently 372 
washed with PBS (1X). Two mL per well of corresponding cell medium (culture medium 199 for 373 
Vero cells, and Leibovitz-15 for C6/36 cells) supplemented with 5 % FCS was added, followed by 374 
incubation at corresponding temperature. Samples, both supernatant and cells, were harvested daily 375 
throughout the week and used for viral RNA extraction and virus titration. 376 
PBMCs, monocytes and moDCs  were infected with DENV at an MOI of 1 or 10, or mock infected 377 
with FCS-free cell culture medium or heat-inactivated DENV (60°C, 30 min), and incubated at 378 
37°C in a 5 % CO2 humidified atmosphere for 2 h. Following incubation cells were centrifuged and 379 
inoculums discarded, and the cells were gently washed with DPBS (1X). Two hundred uL per well 380 
of cell culture medium (supplemented with 10 % FCS) was added and the cells were incubated at 381 
37°C, 5 % CO2 for 72 h. Following infection cells were centrifuged and supernatants were saved for 382 
further analysis. The cells were kept for immunofluorescence staining. 383 
 384 
Immunofluorescence with HB112 and J2 for detection of DENV infection and DENV titration by 385 
fluorescent focus assay (FFA) 386 
The infectious titer of DENVs in C6/36 cells was determined by FFA as described previously 387 
(Tuiskunen et al., 2011a). Briefly, 50 µL of diluted virus was inoculated in each well on a 96-well 388 
plate and incubated for 2h at 28˚C. Plaque-forming units (PFU) were counted in a light microscope 389 
72h post-infection (hpi). A primary panflavi anti-envelope monoclonal antibody (MAb) (HB112TM, 390 
ATCC) or a mAb staining for double-stranded RNA (J2, English and Scientific Consulting, 391 
Hungary) were used together with a goat anti-mouse IgG A488-conjugate (1:250 dilution, Gibco, 392 
Paisley, UK). In order to stain the eukaryotic nuclei, Dapi (4', 6-diamidino-2-phenylindole) binding 393 
(Sigma-Aldrich) was used in a 1:5000 dilution. 394 
 395 
Viral RNA extraction and real-time one-step quantitative RT-PCR 396 
Viral RNA was extracted from lysed cells and cell supernatant using the QIAmp Viral RNA Mini 397 
Kit. The RT-PCR reactions were set-up according to the manufacturer’s instruction (SuperScript III 398 
Platinium One-Step Quantitative RT-PCR system, Invitrogen Life Technologies) as described 399 
previously (Leparc-Goffart et al., 2009). 400 
 401 
Apoptosis TUNEL Assay 402 
Vero and C6/36 cells infected with DENV were grown on Lab-Tek Chamber slides (0.8 cm2 per 403 
well) in order to study apoptosis. The method has been described previously (Tuiskunen et al., 404 
2011a). Briefly explained, the cells were infected with a MOI of 1 and incubated for 24, 48, 72h, 405 
and six days, respectively. The cells were then stained for the presence of DENV antigen, using the 406 
HB112 and J2 MAbs, as well as for apoptotic cells using TUNEL-staining (terminal 407 
deoxynucleotidyl transferase mediated dUTP nick end labelling). Apoptosis was detected with the 408 
In Situ Cell Death Detection Kit Red (Roche), according to the manufacturers’ instructions and cells 409 
were stained for 1h at 37˚C. Staurosporin (Sigma-Aldrich) was used as positive control for 410 
apoptosis. 411 
 412 
Sequencing 413 
Genomic vRNAs were isolated from infectious supernatant from the first passage propagated in 414 
C6/36 cells, which is believed to confer the lowest possible level of selective pressure, using the 415 
QIAamp viral RNA mini kit (Qiagen, Hilden, Germany). RT was performed using the SuperScript 416 
First Strand Synthesis System for RT-PCR (Life Technologies) and random hexamer primers. 417 
Phusion Hot-Start High Fidelity DNA Polymerase (Finnzymes) was used to generate overlapping 418 
PCR fragments of approximately 1000 nucleotides, which were purified by gel electrophoresis 419 
followed by gel extraction using the MinElute Gel Extraction Kit (Qiagen, Hilden Germany), and 420 
eluted in 10µL water. DENV serotype specific primers were used for two-directional sequencing 421 
(supplementary tables 2a.-c.). Primers were designed to sequence both strands (by Sanger 422 
sequencing using ABI3739XL technology and the PhredPhrep program) of the PCR product, from 423 
which consensus sequences were assembled. 424 
 425 
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580 
Tables and Figures 581 
Table 1. Amino acid differences between DF, DHF and DSS isolates in the open reading frame of 582 
DENV-2 strains. (*) denotes that the amino acid is located in the MTase region of the NS5 protein, 583 
(±) is the NLS domain, and (#) the RdRp domain. Roman numbers indicate domain I/II/III in the 584 
viral E protein. Bold text indicates unique amino acid substitution among the three clinical isolates 585 
of the same serotype. 586 
 587 
Amino acid 
position in 
polyprotein 
Amino acid 
position in 
protein 
Gene or 
region 
Virus and amino acid 
DF DHF DSS 
266 61 M Val Ala Ala 
440 160I E Met Lys Lys 
483 203II  Asn Ser Ser 
508 228II  Glu Gly Gly 
904 129 NS1 Tyr His His 
1039 264   Ile Thr Thr 
1121 346  Ile Val Val 
1189 62 NS2A Ala Thr Thr 
1192 65  Ala Thr Thr 
1247 120  Val Ile Ile 
1266 139   Asn Asp Asp 
1457 112 NS2B Ile Val Val 
1821 346 NS3 Ser Thr Thr 
1827 352   Met Thr Thr 
2186 93 NS4A Ile Val Val 
2509 27* NS5 Ile Thr Thr 
2777 262*  Glu Gln Glu 
3128 613#  Val Ala Val 
3132 617#  Ala Val Ala 
  588 
Table 2. Amino acid differences between DF, DHF and DSS isolates in the open reading frame of 589 
DENV-3 strains. (*) denotes that the amino acid is located in the MTase region of the NS5 protein, 590 
(±) is the NLS domain, and (#) the RdRp domain. Roman numbers indicate domain I/II/III in the 591 
viral E protein. Bold text indicates unique amino acid substitution among the three clinical isolates 592 
of the same serotype. 593 
 594 
 595 
Amino acid 
position in 
polyprotein 
Amino acid 
position in 
protein 
Gene or region 
Virus and amino acid 
DF DHF DSS 
173 59 prM Val Val Ala 
412 132I E Tyr Tyr His 
626 346III   Asn Asn Ser 
643 363III  Val Ile Val 
763 483   Ile Val Ile 
790 17 NS1 Asn Asn Ser 
948 175  Tyr His Tyr 
1061 288  Ala Ala Thr 
1199 74  NS2A His Tyr Tyr 
1342 217   Arg Lys Arg 
1559 86 NS3 Ser Ser Asn 
2678 188* NS5 Thr Asn Thr 
2926 436#  Lys Lys Arg 
2972 482#   Tyr Phe Tyr 
3049 559#   Gly Glu Glu 
3120 630#   Lys Glu Lys 
3315 825#  Glu Gly Glu 
3385 895#   Thr Ser Ser 
 596 
 597 
  598 
Table 3. Amino acid differences between DF, DHF and DSS isolates in the open reading frame of 599 
DENV-4 strains. (*) denotes that the amino acid is located in the MTase region of the NS5 protein, 600 
(±) is the NLS domain, and (#) the RdRp domain. Roman numbers indicate domain I/II/III in the 601 
viral E protein. Bold text indicates unique amino acid substitution among the three clinical isolates 602 
of the same serotype. 603 
 604 
 605 
Amino acid 
position in 
polyprotein 
Amino acid 
position in 
protein 
Gene or 
region 
Virus and amino acid 
DF DHF DSS 
456 177I E Asp Glu Glu 
793 18 NS1 Ile Ile Val 
941 166  Pro Ser Ser 
1159 23 NS2A Met Met Ile 
2417 175 NS4B Ala Ala Val 
2429 187  Phe Phe Leu 
2441 199  Leu Leu Met 
2533 34* NS5 Lys Lys Arg 
2538 39*  Ile Ile Thr 
2540 41*  Tyr Tyr His 
2546 47*  Thr Thr Ser 
2558 59*  Val Val Ile 
2582 83*  Lys Lys Gln 
2892 393±  Ser Leu Ser 
3050 551 #  Ile Ile Val 
3313 814 #  Ile Ile Thr 
3368 869 #  Val Val Met 
3373 874 #  Ala Ala Val 
3375 876 #  Arg Arg Lys 
3380 881 #  His His Pro 
3381 882 #  Phe Phe Ser 
 606 
  607 
Table 4. Epidemiological and clinical characteristics associated with dengue virus serotype-2, -3 608 
and -4 isolates used in the study. I.D. indeterminable. 609 
 610 
ID Serotype 
Epidemic 
year 
Sex Age 
Type of 
antibody 
response 
Clinical 
outcome 
GenBank 
accession 
number 
R0712259 2 2007 M 7 Secondary DF GU131897 
R0802298 2 2007 F 4 Primary DHF FJ639717 
R0919234 2 2007 M 8 Secondary DSS JN368476 
R0627315 3 2007 M 3 I.D. DF JN368477 
R0711230 3 2007 M 5 Secondary DHF GU131913 
R0808265 3 2007 F 4 I.D. DSS GU131915 
S0702299 4 2008 F 3 I.D. DF JN638570 
R0818104 4 2007 F 12 Secondary DHF JN638571 
S0813047 4 2008 M 8 Secondary DSS JN638572 
 611 
 612 
Figure 1. Intracellular replication differences illustrated as ratio based on copy number of vRNA 613 
(top), or infectious titer (bottom) in Vero cells. Data are representative of three independent 614 
experiments. 615 
 616 
Figure 2. Replication differences illustrated as ratio based on copy number of vRNA (top), or 617 
infectious titer (bottom) in supernatant of Vero cell culture. Data are representative of three 618 
independent experiments. 619 
 620 
Figure 3. Clinical DENV isolates of serotype-1, -2, -3 and -4 were used to infect (a.) C6/36 cells, (b.) 621 
moDCs, (c.) PBMCs, and (d.) monocytes, with an MOI of 1 and 10. Infection was quantified by 622 
measuring vRNA day 3 pi. Data are representative of three replicates per sample, from five 623 
independent donors. HI = heat-inactivated. 624 
 625 
Figure 4. The DENV-3 isolate from a DSS patient induced syncytia, in C6/36 cells (MOI = 1). (a.) 626 
Mock infected cells (20X magnification), (b.) The multinuclear giant cells were clearly visible 627 
already at day 3 pi (40X magnification). (c.) day 6 pi (40X magnification). These data are the 628 
average of three individual experiments. 629 
 630 
Figure legend for supplemental figure: 631 
Figure 5. Clinical DENV isolates of serotype-2, -3 and -4 were used to infect C6/36 cells with an 632 
MOI of 1. Apoptosis on day 3 pi is expressed in percent of the total number of cells (in total, 250 633 
cell nuclei were counted per sample, corresponding to 100 %). Mock infected cells had naturally 634 
~5 % apoptosis and the positive control cells treated with staurosporin had approximately 50 % of 635 
apoptosis. Data are representative of three independent experiments. 636 
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Supplemental tables 
Table 1. The clinical DENV isolates of serotype-2, -3, and -4 differed at multiple sites 
throughout the genome. Certain genes particularly prone to amino acid substitutions were E, 
NS1, and NS5, and this was consistent between the three serotypes. 
 
Gene DENV-
2 
DENV-
3 
DENV-
4 
Total 
     
C 0 0 0 0 
prM/M 1 1 0 2 
E 3 4 1 8 
NS1 3 3 2 8 
NS2A 4 2 1 7 
NS2B 1 0 0 1 
NS3 2 1 0 3 
NS4A 1 0 0 1 
NS4B 0 0 3 3 
NS5 4 7 14 25 
Totalt 19 18 21 58 
 
  
Table 2 (a). Oligonucleotide primers for genomic sequencing of DENV serotype-2. 
 
 
* Primer names with F indicate forward direction and R indicate reverse direction. 
 
 
 
 
 
 
 
 
 
 
  
Name* Sequence (5’  3’) Position Length 
DV2F_16-39 GTG GAC CGA CAA AGA CAG ATT CTT 1 24 DV2R_983-1005 ATG TCA ACC CAR CTY CCT CCT GA 23 
DV2F_765-786 CAT GGA TGT CRT CAG AAG GGG C 2 22 DV2R_1868-1891 TCC ATG TTG YGT TTC TGC TAT TTC 24 
DV2F_1601-1620 CCC GGA GCR GAY ACA CAA GG 3 20 DV2R_2591-2613 TCC ART CTT GTT ACT GAG CGG AT 23 
DV2F_2514-2538 ATA YAA RTT CCA ACC AGA ATC CCC 4 24 DV2R_3468-3490 CTG YCC ATG TCC GGC TGT GAC CA 23 
DV2F_3380-3402 CRC TAA GRT ACA GAG GTG AGG A 5 22 DV2R_4490-4512 TTY ACT TCC CAC AGG TAC CAT GC 23 
DV2F_4403-4425 GAA GAR CAA ACA CTG ACC ATA CT 6 23 DV2R_5510-5532 CTT TCY TCR TCC ATG ATT GGT GC 23 
DV2F_5494-5418 CAG CAA GYA TAG CRG CTA RGG ATA 7 24 DV2R_6789-6812 CCT GGG AAT GTG YTG CAT AAT CAC 24 
DV2F_6622-6645 CCA CCA CTG TRA GGA TGG CTA TGA 8 24 DV2R_7880-7902 TCR TGT CCT GGT CCT CCT TTT GT 23 
DV2F_7678-7701 GGA YAG AAC CYT RGC AAA AGA AGG 9 24 DV2R_8645-8717 GGT TCT TGR GTT CTC GTG TCC AC 23 
DV2F_8502-8526 CAA ACA RAC TGG ATC AGC ATC ATC 10 24 DV2R_9536-9559 ATC TCC ACT GAT GGC CAT TCT TGA 24 
DV2F_9298-9318 GGT GGT GCG TGT GTG CAA AGA CC 11 23 DV2R_10198-10221 GGC ATG TAR TCT GTG TAT TCC TCA 24 
DV2F_10095-10117 GAG AAG ACC AAT GGT GCG GCT CA 12 23 DV2R_10697-10720 CTG TTG ATT CAA CAG CAC CAT TCC 24 
Table 2 (b). Oligonucleotide primers for genomic sequencing of DENV serotype-3. 
 
* Primer names with F indicate forward direction and R indicate reverse direction. 
 
 
 
 
 
 
 
 
 
  
Name* Sequence (5’  3’) Position Length 
DV3F_0-24 GTG GAC CGA CAA AGA CAG ATT CTT 1 24 DV3R_989-1011 TCR AGC ACC ACR TCA ACC CAC GT 23 
DV3F_927-950 CCA TGA CAA TGA GAT GYG TGG GAG 2 24 DV3R_1892-1915 TTC CCC TTT GTA CTC RGA CCT TAA T 25 
DV3F_1811-1833 AAG GGG ATG AGC TAT GCA ATG TG 3 23 DV3R_2854-2877 ACC TCC CAC ACR TTC CAT GCT CTT 24 
DV3F_2758-2781 GGC AAA AAT AGT GAC AGC TGA AAC 4 24 DV3R_3921-3945 GCA ACA GTC AAC GTG AAA ATT GTG 24 
DV3F_3836-3857 GCT CTG GGG CTC ATG ACT CTA A 5 22 DV3R_5194-5216 GGA GTC CTT TCA GTG CTT CTT CC 23 
DV3F_5115-5137 CAG CCA TCG TCA GAG AAG CCA CC 6 23 DV3R_6283-6305 AAT AAG TGC GGG CAT CAA GCC ACC 24 
DV3F_6220-6244 GAG GAG AAC ATG GAT GTG GAA ATC 7 24 DV3R_7317-7339 TGC ACA CAG AAC CAA GAG CAT GA 23 
DV3F_7238-7260 CCA ACG GTG GAC GGG ATA ATG AC 8 23 DV3R_8151-8174 GGG TTT CTC ACA AGC ATT CCT CC 23 
DV3F_7791-7813 CTR TTG TGT GAC ATT GGA GAA TC 9 23 DV3R_8776-8789 TTR TGG AGT TCA CGT TCT CTG TCC 24 
DV3F_8598-8620 TTY ACA GAG GAG AAC CAA TGG GA 10 23 DV3R_9482-9509 ATG AAA GTG GTG GGA GCA GAA AGG 24 
DV3F_9468-9491 GAT TGG CAA CAR GTY CCT TTC TGC 11 24 DV3R_10451-10473 CTG GCG TTC TGT GCC TGG AAT GA 23 
DV3F_9923-9943 CAC TTC CAG AGC AAC CTG GGC CC 12 23 DV3R_10451-10473 CTG GCG TTC TGT GCC TGG AAT GA 23 
Table 2 (c). Oligonucleotide primers for genomic sequencing of DENV serotype-4. 
 
* Primer names with F indicate forward direction and R indicate reverse direction. 
Name* Sequence (5’  3’) Position Length 
DV4F_1-21 AGT TGT TAG TCT GTG TGG ACC  1 21 DV4R_836-856 TCC TGG GTT TCT GAG TAT CCA 21 
DV4F_798-820 GGA AGG AGC CTG GAA ACA CGC CC 2 23 DV4R_1694-1716 TCA CAT CCT GTC TCT TGG CAT GAG 24 
DV4F_1631-1651 GAA TTA CAA AGA GAG AAT GGT 3 21 DV4R_2519-2538 GTA CTG TTC TGT CCA AGT GT 20 
DV4F_2479-2502 GGA AAG AGT TGA AAT GTG GAA GCG 4 24 DV4R_3482-3505 TAC CTG TGA TTT GAC CAT GTT CTC 24 
DV4F_3428-3451 GGG AGA AGA TGG ATG TTG GTA TGG 5 24 DV4R_4446-4469 AGT TTC ACC AGG AGG GTA ATC ATG 24 
DV4F_4376-4399 CAA GCC CAA TCA TAG AAG TGA AGC 6 24 DV4R_5504-5528 GTC GTT CCA GGA GGG GTT GCA GTC 24 
DV4F_5468-5488 CCA GGG TGG AAA TGG GAG AGG 7 21 DV4R_6186-6206 TAG CTC AGC CAC ACC GGA AGG 21 
DV4F_6138-6160 CAG AGG GGA GCA AAG GAA GAC CT 8 23 DV4R_7223-7245 GGC TTT GGC CTG CAA TCC TGG ACC 24 
DV4F_6975-6994 AGA CAC ACC ATA GAA AAC AC 9 20 DV4R_7905-7922 GAA TCG GTT CTT CAT GTC 18 
DV4F_7876-7898 GGC GAC ACT CAA GAA CGT GAC CG 10 23 DV4R_8872-8895 CGG CTG TCA TTC ACA GCT TCA CTG 24 
DV4F_8813-8835 GTT AGG TCA AAT GCA GCC ATA GG 11 23 DV4R_9987-10010 GAT GAG CGT GGA TTG ACC ATG TTG 24 
DV4F_9817-9839 AAG AGC CAG AAT CTC GCA GGG GG 12 23 DV4R_10662-10685 GAT CAA CAA CAC CAA TCC ATC TCG 24 

